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CHAPTER 1 INTRODUCTION AND SIGNIFICANCE
1a: Need for HDACs-Specific PET Imaging Agents
Over the past two decades, epigenetic regulation has become a rapidly growing, highly
innovative and influential field of biology and medicine. One of the key epigenetic regulatory
mechanisms involves the acetylation and deacetylation of lysine residues on histone core proteins
and other critical proteins involved regulation of gene expression and protein function. Protein
acetylation and deacetylation is mediated by histone acetylase transferases (HATs) and histone
deacetylases (HDACs), respectively. The important roles of some of the HDACs in normal cellular
physiology and the pathophysiology of different diseases have been recognized for more than a
decade. Several HDAC inhibitors have been developed by the pharmaceutical industry and
academia and some of them have been approved by the FDA for treatment of certain diseases (i.e.,
Vorinostat® for treatment of cutaneous T-cell lymphoma). However, many of the existing HDACs
inhibitors lack enzyme isoform specificity and/or are unable to pass through the BBB (Hendricks
et al., 2011a; Hooker et al., 2009) and are unsuitable for treatment of many CNS diseases.
The vast majority of studies on epigenetic regulation were conducted in cell cultures and
tissue samples using conventional methodologies of molecular and cellular biology. However,
these methods have several limitations for monitoring the efficacy of HDACs-targeted inhibitory
therapies, because they require invasive biopsies of tissues, which, except for cancer, are
prohibitive in most types of diseases involving vital organs (i.e., diseases of heart and brain).
Therefore, there is a growing need for novel, advanced methodologies that allow for non-invasive
detection and monitoring of HDAC–mediated epigenetic regulatory processes in different organs
and tissues, to improve our understanding of their roles in epigenetic pathophysiology of different
diseases and to aid the development and clinical translation of novel inhibitors of HDACs. One
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such methodology is molecular imaging with positron emission tomography (PET), which allows
for non-invasive visualization and quantification of spatial and temporal dynamics of expressionactivity of various receptors and enzymes in different organs and tissues in norm and disease.
The availability of selective substrates to individual classes and isoforms of HDACs would
enable the development of radiolabeled imaging agents for non-invasive in vivo PET imaging. The
advantages of enzyme substrate based vs. inhibitor based imaging agents include the ability to
measure enzyme expression-activity product rather than the presence and level of expression in
tissues, and provide the means for non-invasive monitoring of pharmacodynamics of HDACs
inhibitors at the target level. Therefore, the aim of this work was to develop class- and/or isoformselective radiolabeled substrates of HDACs, with particular emphasis on class III (sirtuins, SIRTs),
as will be discussed further.

1b: Overview of HDACs
The modification of DNA and corresponding histone core proteins to alter the transcriptional
availability of chromatin is referred to as epigenetic regulation. The primary methods of epigenetic
regulation include DNA methylation, nucleosomal remodeling and covalent histone modifications.
These epigenetic modifications, carried out by a variety of enzymes, act as either activators or
repressors of DNA transcription through alteration of surface charges on DNA or histone protein
and subsequent changes in interactions between the two. One of the primary epigenetic regulations,
includes the addition or subsequent removal of an acetyl moiety to a lysine residue in the tail of a
histone core protein (Wolffe, 1996). The addition of an acetyl moiety to a lysine amino acid on a
histone tail causes the tail to “loosen” its coil of the DNA thereby opening the core nucleosome
structure and allowing RNA polymerase to bind, thus forming the open reading frame structure.
The enzymes responsible for the transfer of an acetyl moiety to the lysine residue, and subsequent
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transcriptional activation, are so called histone acetyl transferases (HATs) (Nishina et al.)
(Brownell and Allis, 1996). Consequently, the enzymes responsible for the removal of the acetyl
groups from these lysine residues, and subsequent transcriptional silencing, are referred to as
histone deacetylases (HDACs) (Fig. 1). While, the processes of acetylation and deacetylation were
first discovered in 1968 , the first HAT and HDAC enzymes were not known until the mid-1990’s
(Yang and Seto, 2007).
Since the 1990’s the number and
type of distinct HDACs has grown
considerably.

To

date,

18

HDAC

enzymes have been identified in humans
and are typically divided into four major
classes (Haberland et al., 2009). To date,
18 HDAC enzymes have been identified
in humans and are typically divided into
four major classes (Haberland et al.,
2009). Class I HDACs includes: HDAC1,

Figure 1. Histone acetylation and deacetylation causing
transcriptional activation and repression of associated
DNA. Figure from (Chuang et al., 2009)

HDAC2, HDAC3, and HDAC8, which
have significant domain and sequence similarity. HDAC’s in this class have typically a nuclear
localization (Park et al., 2004) and are involved in the regulation of cellular proliferative activity
(de Ruijter et al., 2003; Khochbin et al., 2001). Class II HDACs, including HDAC4, HDAC5,
HDAC6, HDAC7, HDAC9, and HDAC10, shuttle between the cytoplasm and nucleus. Class II is
divided further into Class IIa (HDACs 4, 5, 7, 9) and Class IIb (HDACs 6, 10), with the primary
difference in the central domain of class IIb, containing a zinc finger motif, while class IIa contains
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a structural regulatory zinc-binding domain (Bottomley et al., 2008; Yang and Grégoire, 2005).
Class IIa is able to shuttle more readily between the nucleus and the cytoplasm, whereas class IIb
is primarily localized in the cytoplasm. In studying brain activity and pathophysiology, class IIa
HDACs are more relevant over class IIb due to their increased expression in certain structures of
the brain. HDAC enzymes in classes I, II, and IV are dependent on Zn2+ for enzymatic activity.
Class III is comprised of HDAC enzymes termed “silent information regulators” or “sirtuins”
(SIRTs), which represent a family of closely related deacetylases that are Zn2+-independent but
are dependent on NAD+. Seven sub-types of SIRTs (SIRT 1-7) have been identified in humans
(Haberland et al., 2009). SIRT enzymes are becoming increasingly scrutinized for their
involvement in cancer, mental illness, and lifespan regulation. Class IV HDACs is comprised of a
single HDAC protein, HDAC11, which is considered separate from classes I and II due to its
biological actions (Gao et al., 2002; Gregoretti et al., 2004). The mechanisms of catalytic activity
amongst different HDAC classes and unique structures of individual isoforms correspond to
peptide sequence-specificity and types of post-translational modifications of their client proteins
(i.e., acetylation, succinylation, myristoylation, etc.) (Yao and Yang, 2011). This allows for the
development of class and isoform-specific inhibitors for treatment of various pathological
conditions and diseases (Thomas, 2009).
HDACs class III is comprised of HDAC enzymes termed “silent information regulators”
(sirtuins, SIRTs), representing a family of closely related deacetylases that are Zn2+-independent
but NAD+-dependent. This family was first discovered as SIR2 (silent information regulator) gene
in the murine mode (Michan and Sinclair, 2007) and thus far seven sub-types of SIRTs (SIRT 17) have been identified in humans (Haberland et al., 2009). Sirtuins are implicated in a variety of
cellular processes including gene silencing, cell cycle regulation, metabolism, apoptosis, lifespan
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extension and the effects of calorie restriction, as well as circadian rhythms (Pan et al., 2011a).
Each of the SIRT isoforms plays a unique role in the regulation of cellular processes through SIRTmediated epigenetics. Accordingly, the SIRT isoforms vary in their cellular localization, with
SIRTs 1, 6, and 7 being primarily located in the nucleus, SIRTs 3, 4, and 5 located in mitochondria.
While SIRT enzymes cleave the acetyl moiety from a lysine residue, much like their other
HDAC counterparts, it has recently been recognized that the SIRT isoforms are capable of cleaving
many larger leaving groups than the acetyl (i.e., acetylation, succinylation, myristoylation, etc.)
(Yao and Yang, 2011). Furthermore, these enzymes are reported to act on other client proteins
outside of histone core proteins including TNF-a, FOXO, p53, a-tubulin and others (Jiang et al.,
2013; Solomon et al., 2006).
The HDAC enzymes are implicated in an increasing number of pathologies including cancers
and neurodegenerative disorders. A review on HDAC class IIa has been done very recently by
Volmar and Wahlestedt describing the expression of HDAC Class IIa enzymes in the brain and
their involvement with Alzheimer’s, stress related disorders, Autism and addiction (Volmar and
Wahlestedt, 2015). But these findings have not yet resulted in a substantial improvement to
treatment due to the complexity of these interactions. Likewise, HDAC1 was originally linked to
mSin3A expression in human cancers and a great rush ensued to produce inhibitors of HDAC1 for
cancer treatment (Dhordain et al., 1998; Laherty et al., 1997). However, as more research has
amassed and much data has been produced; the resulting evidence for either activating or inhibiting
HDACs in disease has been inconclusive and conflicting (Lakshmaiah et al., 2014; Taunton, 1996).
To confound this problem, many of the existing HDAC inhibitors lack selectivity to a single
isoform or class thereby limiting the understanding of the true biological effects of these enzymes.
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1C. HDAC Class III Biological Implications
Sirtuins play a variety of roles in the regulation of cellular metabolism and survival. Within
the cell, the SIRT enzymes are tagged for nuclear, cytoplasmic, or mitochondrial localization in
accordance with the primary function of the enzyme. SIRTs 1, 6 and 7 are primarily localized in
the nucleus while SIRT2 retains the ability to shuttle between the nucleus and the cytoplasm and
are believed to regulate histone core protein acetylation (North and Verdin, 2004). SIRTs 3, 4,
and 5 are located in the mitochondria and primarily regulate metabolic processes (North and
Verdin, 2004).
In particular, SIRT1 has been recognized for involvement in diabetes, cardiovascular disease
and neurodegeneration (Haigis, 2010) through cleavage of an acetyl moiety from lysine residues
of various proteins including PPARƔ, and NF-Kβ, and members of the p53 family. Through
regulation of these client proteins, SIRT1 acts as both a suppressor and activator of disease in
cancer and neurodegeneration.
Through deacetylation of lysine residues on histones H1, H3 and H4, namely H1K26, H3K9,
H4K16, H4K56, (Vaquero et al., 2004b) SIRT1 induces hypoacetylation thus causing the
formation of heterochromatin, which is generally associated with gene repression (Blander and
Guarente, 2004; Michan and Sinclair, 2007; Taylor et al., 2008) (Imai et al., 2000; Vaquero et al.,
2004a). Additionally, non-histone protein substrates, such as components of the core RNA
polymerase I transcriptional machinery and the HAT p300/CBP (Bouras et al., 2005), are
deacetylated by SIRT1 also contribute to the role of SIRT1 in reducing gene expression (Muth et
al., 2001). Through this gene regulation, SIRT1 may play a anti-apoptotic function and thus
promote cancer growth (Michan and Sinclair, 2007). SIRT1 can further promote cancer cell
survival by deacetylating the DNA repair protein Ku70 thereby blocking mitochondrial
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translocation of BAX to prevent apoptosis (Cohen et al., 2004). Additional key client proteins of
SIRT1 include tumor suppressors p53 and p73, as well as other enzymes of the p53 family, PPARγ,
and NF-Kβ (Rahman and Islam, 2011). SIRT1-mediated p53 deacetylation prevents p53
transcriptional activity preventing the usual apoptotic triggers in response to oxidative stress and
DNA damage (Dai et al., 2007; Di Giovanni et al., 2006; Luo et al., 2001; Vaziri et al., 2001).
SIRT1-mediated deacetylation of FOXO family transcription factors may also contribute a role to
the anti-apoptotic nature of SIRT1 pathways (Michan and Sinclair, 2007; Wang et al., 2007; Wang
and Tong, 2009).
However, SIRT1 has also been reported in some cases to act as a tumor suppressor through
indirect regulation of cell cycle progression (Brooks and Gu, 2009). For example, SIRT1
deficiency in mice actually impairs the DNA damage response and leads to genomic instability
(Wang et al., 2008). Whereas under in wild-type SIRT1 models, the introduction of doublestranded breaks causes SIRT1 to relocate as part of the transcription complex from more
housekeeping gene promoters to the site of DNA damage and begin facilitating repair
(Oberdoerffer et al., 2008).
SIRT1 catalytic activity is regulated by phosphorylation of key functional site residues (i.e.
threonine, serine, tyrosine residues) on the enzyme surface. In SIRT1, the primary sites of
regulation include S27, S47, T530, T540, T522, S434 and S682 (Protein Data Bank). One example
of this regulation begins with the JNK1 mediated pathway. JNK1 phosphorylates S47 on hSIRT1
to increase SIRT1 activity upon increase in cellular glucose levels, which subsequently targets
SIRT1 for ubiquination and degradation in response to increase in insulin levels (Gao et al., 2011).
JNK2 also phosphorylates SIRT1 at S27 to stabilize SIRT1 and allow the enzyme to activate
apoptotic pathways in cancer cells under damaged DNA conditions (Ford et al., 2008). Similarly,
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DYRK1A and DYRK3 phosphorylate SIRT1 at T522 to prevent apoptotic pathways from
occurring under conditions of damaged DNA, thereby acting as pro-survival enzymes through
direct SIRT1 modulation (Guo et al., 2010). Other factors influencing the activity of SIRT1 include
AMPK and cAMP/PKA. These enzymes primarily regulate SIRT1 activity in response to cellular
glucose levels, especially in the liver. For example, cAMP regulates PKA which in turn
phosphorylates S434 of SIRT1 to enhance deacetylase activity and promote fatty acid oxidation
under conditions of glucagon receptor stimulation in the liver (Gerhart-Hines et al., 2011). The
same pathway is also stimulated by oleic acid to activate SIRT1-PGC1α complex in skeletal
muscles to increase rates of fatty acid oxidation (Lim et al., 2013).
Other measurements of cellular energy stores may influence SIRT1 catalytic activity.
Because SIRT1 is dependent on NAD+ for catalytic activity, the ratio of NAD+ to NADH within
a cell plays a part in the ability of SIRT1 to effectively deacetylate client proteins. Under energy
depravation conditions, the ratio of NAD+ to NADH will increase, thus increasing the ability of
SIRT1 to be active. This theory is supported by studies demonstrating activation of a C. elegans
SIRT1 homologue as a result of calorie restriction, which may contribute to an increase in lifespan
and longevity (Bordone and Guarente, 2005). This pathway is of particular interest for the
treatment of obesity and Diabetes Type II resulting in exploratory clinical trials with SIRT1
activators for therapy (NCT01677611, NCT01031108, NCT01938521). Other hypotheses have
included the use of Resveratrol (a small molecule SIRT1-activator) for therapeutic use in humans
to increase lifespan (NCT01150955). Other clinical trials ongoing involve EX-527 (Selisistat,
SEN0014196) a SIRT1 selective inhibitor, for tolerability and treatment of Huntington ’s disease
(NCT01521585, NCT01485965). While these hold great promise for pharmacologic intervention
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of these diseases through SIRT1-targeted therapies, conclusive results have not yet been
determined.
Other indirect pathways for metabolic regulation include the SIRT1-mediated deacetylation
of PPARGC1α and forkhead box o1 (FoXo1) to increase gluconeogenesis in low energy states
under stimulation from glucagon and epinephrine (Schwer and Verdin, 2008). To promote fat
mobilization from white adipocytes in the fasted state, SIRT1 interacts with SMRT to inhibit the
transcription of PPARγ target genes (Picard et al., 2004). Additionally, SIRT1 is involved in
regulation of cholesterol metabolism in the liver through deacetylation and activation of liver X
receptor (LXR) causing the LXR to regulate the ATP-binding cassette transporter A1 (aBCa1)
promoter (Li et al., 2007) dictating cholesterol efflux rate from peripheral tissues and subsequent
formation of high-density lipoprotein particles (HDL).
In addition to the role SIRT1 plays in cancers and all of cellular metabolism on a larger scale,
SIRT1 is implicated in the outcome of many neurodegenerative diseases. Both SIRT1 and SIRT2
have been implicated in many types of neuronal degeneration including amyotrophic lateral
sclerosis (ALS), Parkinson's, Huntington's and Alzheimer's disease and models of induced axonal
degeneration (i.e. Wallerian degeneration) (Dillin and Kelly, 2007; Outeiro et al., 2008; Tang and
Chua, 2008; Taylor et al., 2008). Through SIRT1 interactions with p53 and p73, SIRT1 may
indirectly influence neuronal cell migration, nerve fiber outgrowth, growth cone motility and
axonal regeneration (Di Giovanni et al., 2006; Tedeschi and Di Giovanni, 2009; Zhang and Chen,
2007). For this reason, SIRT1 has generally been assigned neuroprotective functions, while SIRT2
has been implicated in more neurodegenerative functions. For instance, blocking SIRT2 function
resulted in rescue of alpha synuclein toxicity in Parkinson's disease models (Outeiro et al., 2007)
while the overexpression of SIRT2 prevented resistance of Wallerian axonal degeneration in a
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mouse model (Suzuki and Koike, 2007). Other studies demonstrate that elevated SIRT2 level
down-regulates neuronal motility (Pandithage et al., 2008).
The role of SIRT2 in the cell is primarily centered on cell cycle regulation through
deacetylation of H4K16 and α-tubulin (Inoue et al., 2007a; Inoue et al., 2007c; Inoue et al., 2009).
Through regulation of α-tubulin, SIRT2 is considered a primary mitotic exit regulator for the cell
(Dryden et al., 2003) and relative expression of SIRT2 can be correlated with cell cycle
progression. Therefore, the catalytic activity and expression of SIRT2 during cell cycle is also
highly regulated. SIRT2 is regulated by phosphorylation at different site-specific residues on the
surface of the enzyme. One example is inhibition of SIRT2 by CDK1-mediated phosphorylation
on S368 to delay cell cycle progression during G1/M phase transition (North and Verdin, 2007b)
(Pandithage et al., 2008). Similarly, phosphorylation of SIRT2 by CDC14B late in M/G2 transition
(Dryden et al., 2003) may provoke mitotic exit through increasing SIRT2 targeted ubiquination
and degradation. E-Cdk2 is another member of the cyclin family that may target SIRT2 for
phosphorylation on S331 to inhibit SIRT2 function (Pandithage et al., 2008).
The role of SIRT2 in various cancers been explored in limited detail. Thus far, SIRT2 has
been reported to act as to suppress glioma growth and colony formation in culture through
inhibiting mitotic exit (Hiratsuka et al., 2003). The mitotic exit regulatory mechanisms of SIRT2
through deacetylation of α-tubulin may be particularly dependent on stress-induction within the
cell, i.e. under normal, non-stressed conditions SIRT2 plays a much less significant role in cell
cycle control (Pandithage et al., 2008). Whereas, under imposed stress conditions in vitro due to a
microtubule poison, such as nocodazole, SIRT2 is overexpressed and delays mitotic exit (Dryden
et al., 2003; Inoue et al., 2007c; Inoue et al., 2009).
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Due to the pivotal role SIRT2 plays in cell cycle progression through its regulation of αtubulin and ability to shuttle between the nucleus and cytoplasm, it follows that SIRT2 would be
a key regulator cancer cell growth. In vitro studies have indicated an inverse relationship between
colony colony growth in glioma (Claes et al., 2007) cell lines and SIRT2 expression, indicating
that a decrease in SIRT2 expression may lead to a more severe grade of glioma . Furthermore,
genomic analysis has confirmed that mutations causing deletion of the SIRT2 gene arise in many
glioma cells as the cancer advances (Hiratsuka et al., 2003).
However, in some cases, the overexpression of SIRT2 is associated with an increase in cancer
growth and progression. Through immunohistological staining, it has been demonstrated that
SIRT2 is highly up regulated in breast cancer tissue (McGlynn et al., 2014). Previous studies
demonstrated downregulation of SIRT2 expression in about 70% of gliomas (Hiratsuka et al.,
2003; Inoue et al., 2007b). In contrast, studies that are more recent demonstrated that the labeling
index of nuclear-localized SIRT2 is significantly higher in glioblastomas (grade IV), as compared
to astrocytomas (grade II) and normal brain tissue and strongly correlated with malignant
progression and the overall survival of patients with glioblastomas (Imaoka et al., 2012). Higher
levels of expression and higher labeling index for SIRT2 is also associated with progression and
poor prognosis in patients with non-small cell lung cancer (NSCLC) (Grbesa et al., 2015) and
cervical carcinoma (Singh et al., 2015). Some tumors (i.e., melanomas), may harbor mutations in
SIRT2 gene resulting in reduction of enzymatic activity by 80–90% compared to the wild-type
protein, however consequences to tumor progression and overall prognosis are yet unknown
(Lennerz et al., 2005).
The role of SIRT2 in tumor progression is attributed to the stabilization and lack of
degradation of the Myc proteins, namely, C-Myc and N-Myc in pancreatic cancer and
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neuroblastoma cells, respectively (Liu et al., 2013). Therefore, the use of SIRT2-selective
inhibitors may provide therapy for Myc-induced malignancies. But, for most cancer strains it
remains yet unknown, whether a patient’s treatment would benefit most from inhibition or
activation of SIRT2.
Unlike SIRTs 1 and 2, SIRT3 is localized in the mitochondria and acts primarily as a
metabolic protein deacetylase rather than a true histone core protein deacetylase. SIRT3 is directly
involved in regulation of TCA cycle and fatty acid synthesis through increasing pools of acetylcoA molecules by deacetylation and subsequent activation of acetyl-CoA synthetase Lys-642
(ACS) (Jin et al., 2009). It is interesting to note that ACS may (has only been reported in yeast
thus far) also facilitate the transfer of acetyl groups to the lysine residues of histone core protein
tails, activating DNA transcription in a similar to the manner to HATs. Additionally, SIRT3
influences fatty acid oxidation and breakdown through regulation of the long-chain acyl-coA
dehydrogenase (Bharathi et al., 2013). Due to the metabolic implications of SIRT3, clinical trials
on undergoing intermittent fasting to affect aging and oxidative stress, as well as studies of
vitamins C and E on SIRT activity are currently in progress with specific focus on SIRT3 and
interactions with SIRT5 (NCT02132091, NCT02011906).
SIRT3 further plays a part in control of the TCA cycle through for deacetylation of alpha
subunit of E1 on pyruvate dehydrogenase (PDH) and ICDH2 K75 and K241 (Mathias et al., 2014;
Ozden et al., 2014; Schlicker et al., 2008b); while working in conjunction with SIRT4 to regulate
the activity of PDH complex. In most cases, deacetylation of E1 by SIRT3 activates PDH and
may contribute to the increase in metabolic activity of cancer cells. This may contribute to some
of the metabolic reprogramming that occurs during the cancer cell transition phase, often referred
to as the Warburg effect. SIRT3’s integral role in cellular metabolism and glycolysis-
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gluconeogenesis transition are still widely unknown and require further research to better
understand the consequences of this enzyme in pathological conditions.
SIRT4 is also located in the mitochondria and functions primarily as a lipoamidase rather
than a deacetylase (Mathias et al., 2014) and retains very little deacetylase activity. Primarily
SIRT4 is responsible for catalyzing the removal of lipoyl and biotinyl moieties from lysine
residues on metabolic client proteins (Mathias et al., 2014). Through delipoylation of pyruvate
dehydrogenase E2 subunit, SIRT4 works in conjunction with SIRT3 to regulate PDH activity
(Mathias et al., 2014) suggesting that PDH is regulated by other cofactors outside of E1
phosphorylation, as previously understood. Additionally, SIRT4 aids in cellular metabolism
regulation by decreasing reactive oxygen production and increasing ATP production (Haigis et al.,
2006). In cases of a SIRT4 knockout, the concentration of free fatty acids in the blood go to
unhealthy levels indicating a direct link between SIRT4 regulation and regulation of FFA.
Furthermore, circulating levels of SIRT4 may act as a biomarker for coronary artery disease due
to its role of FFA regulation (Tarantino et al., 2014). SIRT4 may play pivotal roles in mitochondrial
disease and aging though more research is currently needed to understand the cellular mechanisms
at play.
SIRT5 is the third of the mitochondrial localized sirtuins and regulates proteins involved in
oxidation/reduction reactions, fatty acid metabolism, aerobic respiration and TCA cycle (Tan et
al., 2014). Similar to SIRT4, SIRT5 contains very little deacetylase activity and primarily cleaves
succinyl and glutaryl moieties from lysine residues (Du et al., 2011). The cleavage of succinyl
moiety from a lysine residue of client proteins by SIRT5 may play a role in directly regulating the
succinyl-coA pool available for TCA cycle. SIRT5 also plays a critical role in mitochondrial and
cellular health by controlling reactive oxygen species (ROS) through desuccinylation and
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activation of superoxide disumutase 1 (SOD1) (Lin et al., 2013). Additionally, SIRT5 may work
synergistically with SIRT1 to increase lifespan under conditions of calorie restriction (Geng et al.,
2011). SIRT5 regulates the activity of carbamoyl phosphate synthetase I (CPSI) by desuccinylating
specific lysine substrates (Du et al., 2011; Peng et al., 2011).
Through regulation of ROS, apoptosis and cellular metabolism, SIRT5 may alter the
neuronal growth neuropathologies. In the rat model, immunohistochemical staining indicates
SIRT5 is present in the neurons of the cerebral cortex and the cerebral medullary substance (Geng
et al., 2011). Reportedly, SIRT5 knockout mice (KO) have minimal phenotypic differences from
the WT under normal, non-pathological conditions, however when they are given a Parkinson’s
Disease-like state the KO become more severely affected than the WT with PD. Through this study
the researchers believe that SIRT5 may be an important player in the protection of motor neurons
in the brain after pathological state sets in (Lei Liu, 2015). These findings support the
understanding that SIRT5 is a major player in the ROS pathway and neuronal mitochondria.
SIRT5 may also play a role in apoptosis and electron transport chain function through
regulation of other mitochondrial client proteins, such as cytochrome C (Schlicker et al., 2008a).
Reports have indicated that SIRT5 may be responsible for regulation, possible activation, of
cytochrome C through deacetylation in the inner mitochondrial space (IMS) (Schlicker et al.,
2008b). While the role of SIRT5 in many diseases has not been fully elucidated, the SIRT5mediated regulation of many critical client proteins indicate that targeting SIRT5 for treatment of
various pathologies may be beneficial. This work will need to be aided by the development of a
non-invasive imaging agent that is specific for SIRT5. Development of this agent will allow for
study of neuronal degenerative diseases such as ALS, Parkinson’s, and Alzheimer’s diseases to be
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investigated further under the lens of SIRT5 activity. These findings will be important for the
further discovery of treatments for these diseases.
SIRT6 is recognized for regulating cell cycle and cellular functions through control of client
proteins, such as NF-KB, HIF-1α, and other genes involved in metabolism and ageing
(Beauharnois et al., 2013). While SIRT6 does act as a deacetylase in vivo on endogenous client
proteins, reports have demonstrated that this enzyme may contain demyristoylase activity as well.
Though experimentally the ability of SIRT6 to cleave a myristoyl lysine from H3K9 or TNF-α
K19-20 it has not been validated that these activities occur in vivo (Kokkonen et al., 2012).
Pathologically, SIRT6 has been implicated in diseases such as type II diabetes (Huhtiniemi et al.,
2011). SIRT6 has also demonstrated a protective role for the cell during ageing. It follows then,
that using SIRT-6 targeted inhibitors or activators may be therapeutic for various pathological
conditions (Kokkonen et al., 2014).
SIRT7, the most recently discovered sirtuin, is implicated in the cellular transformation from
benign to malignant within cancer cells. SIRT7 localized to the nucleus and deacetylates both
histones and other non-histone client proteins, though the primary target for SIRT7-mediated
deacetylation is H3K18 (Paredes et al., 2014). SIRT7 plays a vital role to DNA transcription and
protein translation through deacetylation of H3K18 and interactions with non-coding RNA’s to
regulate rRNA and tRNA synthesis. Additionally, SIRT7 has been found to deacetylate and play
a role in regulation of p53 to aid in cellular regulation of DNA damage from oxidative stress
(Paredes et al., 2014). Another role SIRT7 plays in cells under stress includes regulating MYC
protein to facilitate the unfolded protein response (Paredes et al., 2014).
In cancer, the role of SIRT7 is likely both cancer suppressive and cancer supportive as its
functionality may change with the phenotype of the cell. Reports have indicated inactivation of
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SIRT7 in progressive cancers may halt the progression of cancer and even reverse the phenotype
of the cancer cells to reduce tumor expression, in vivo (Barber et al., 2012; Paredes et al., 2014).
However, it is also noted that SIRT7 plays a tumor suppressive and cellular protective role in premalignant, early stage cancer cells. One hypothesis for the change in cellular roles of SIRT7 is that
enzyme regulation may come from free fatty acids in the cell, indicating a link between SIRT7 and
cellular metabolic status (Paredes et al., 2014). While SIRT7 remains a promising target for
therapy of cancers, more work is needed to understand the correct pharmacomodulation (i.e.
activation or inhibition) most beneficial for a patient.
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CHAPTER 2 HDAC CLASS III SUBSTRATE SPECIFICITY
The catalytic mechanism and active site structure varies slightly between each class of
HDAC’s. HDAC classes I and IV are very similar in both structure and function and have only
very slight variations in the amino acid residues within their catalytic sites (Lombardi et al., 2011).
These two classes vary more in their biological activity than their catalytic activity. HDAC class
IIa has differences in the primary residues needed for catalysis within the active site, thereby
altering the mechanism of action, which will be discussed further in chapter three.
Lastly, class III HDACs, the sirtuins, have the most unique catalytic structure and mechanism
among the HDACs. These enzymes bind NAD+, (generally prior to binding the substrate) which
alters the state of the enzyme active site. Ultimately, the NAD+ will be cleaved into two parts, the
ADP-ribose ring and the nicotinamide during the catalyzed cleavage of a leaving group from a
lysine residue on a client protein. During this cleavage reaction, the leaving group moiety will be
transiently attached to the ADP-ribose ring (Sauve, 2010). Within the SIRT class, there are
subclasses based on the mechanistic differences within this group. There are two primary catalytic
functions among the sirtuins, which are defined as mono-ADP ribosyl transferase (ART) and
NAD+ dependent deacetylase (DAC) (Michan and Sinclair, 2007). Sirtuins can be subdivided into
four classes, class I includes sirtuins 1, 2, and 3, which are able to do both ART and DAC and bind
the substrate prior to the NAD+ (Pan et al., 2011a). Classes II and III encompass sirtuins 4 and 5.
While class IV includes sirtuins 6 and 7, which act as NAD+ dependent allosteric activator
enzymes, and act only as a DAC; this indicates that they rely on the binding of NAD+ prior to the
the substrate binding and are unable to act as an ART alone (Pan et al., 2011a). Unlike the rest of
the HDACs, which primarily localize to the nucleus or cytoplasm, the sirtuins can also localize to
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Figure 2. An illustration for deacetylation by SIRT of a lysine residue on a client protein using
NAD+ as a cofactor.
the mitochondria. Sirtuins, even more-so than other HDACs, deacetylate not only histone proteins
but also many other client proteins with acetylated lysines. SIRTs also have the unique ability to
cleave lysine moieties other than the typical acetyl susbtrate.
SIRT enzymes vary in cellular localization and core catalytic domain (Michan and Sinclair,
2007). As research continues, it becomes increasingly evident that sirtuins are capable of cleaving
much larger leaving groups from lysine residues than the acetyl moiety. Recently, reports have
indicated SIRT enzymes are responsible for acting as a desuccinylase, deglutarylase,
delipoamidase or demirostoylase within the cell (Du et al., 2011; He et al., 2014; Hu et al., 2013;
Tan et al., 2014). The SIRT substrates are wide ranging across many proteins outside of the histone
core proteins and the even the nucleus. Due to this great variation in enzyme activity the catalytic
residues and active site differ greatly in size and hydrophobicity within class III enzymes. HDAC
class III is the most unique among the 18 HDAC proteins and has wide ranging impacts on norm
and pathological states in the cell.
The primary mechanism for SIRT-mediated cleavage of lysine residue moieties using NAD+
was published (Sauve, 2010) and is represented in Fig. 2, though there are distinct differences
between the seven active sites allowing substrate specificity to be achieved. Towards an
understanding of substrate specificity for each sirtuin enzyme and structure activity relationships
(SAR) for these enzymes, an evaluation and comparison of the active site residues for each of the
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seven sirtuins was performed. Another review of sirtuin substrate specificity has recently been
published demonstrating some of the differences in pocket structure by molecular modeling
(Bheda et al., 2016). All sirtuins contain a large Rossman fold (7 mostly parallel beta sheets
connected by an alpha helix) encompassing the NAD+ binding domain and a smaller, more
variable, zinc ion binding domain. While SIRT enzymes have retained the Zn2+ binding domain
from the other classes of HDACs this domain is not utilized as the primary coordination site for
catalytic cleavage as it is in the other HDAC classes.
Activation of an acetylated lysine residue for SIRT-mediated amide bond cleavage occurs
through interactions with water molecule and NAD+. First, the acetylated lysine chain enters the
active site from a channel opposite to the NAD+, allowing for correct interaction between the two
substrates at the active site. The overall mechanism for sirtuin deacetylation relies on the
attachment of the lysine-leaving group to the adenine (Sauve et al., 2006). The nicotinamide leaves
when the oxygen of the carbonyl carbon from the lysine acetyl group attacks the adenine sugar at
the 1’ position and this position has been activated by a histidine or tyrosine residue (Zhao et al.,
2004). The 2’OH group is deprotonated by the histidine or tyrosine residue that is correctly
positioned for this reaction to occur (Sauve, 2010). As the nicotinamide leaves, the lysine-acetyl
moiety is transiently connected to the 1’ position through an ester linkage. An oxocarbenium ring
forms when the 2’ hydroxyl oxygen attacks the double nitrogen amide bond. This oxocarbenium
intermediate is stabilized by the presence of a highly conserved asparagine residue in all sirtuins
(Zhao et al., 2004). As the oxocarbenium is opened the lysine leaves as –NH2 while the acetyl (or
other leaving group) moiety is transferred to the 2’ position of adenine dinucleotide and connected
via ester linkage. Two histidine residues facilitate this leaving group transition from the 1’ position
to the 2’ position on the adenine ribose ring (Zhao et al., 2004). Therefore, the proof of a successful
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synthetic sirtuin substrate composition comes through evidence of the leaving group attached to
the adenine sugar ring.
This attachment of the leaving group to the 2’ O-ADPR portion of NAD is instrumental in
developing an imaging agent (Fig. 3), because the entire molecule will be trapped inside the cell
as it is too polar and large to be
transferred back across the cell
membrane. The ester linkage
of the leaving group to the
ADPR has been observed in
cases of the long acyl chain
leaving group as well as the
small acetyl moiety (Feldman

Figure 3. The entrapment mechanism of a sample sirtuin
substrate leaving group within a cell through attachment of the
et al., 2013). The hydrophobic leaving group to the adenine dinucleotide. From Gelovani et al.
binding pocket containing the
nicotinamide end of NAD+ and the substrate leaving group is comprised of different residues in
each of the sirtuins, thereby altering the substrate specificity.
Among sirtuins 1,2, and 5 there are a considerable number of conserved and semi-conserved
residues surrounding the active site region (Cosgrove et al., 2006). Sirtuins have 4 active site loops
within the large and small domains of the protein (Finnin et al., 2001). Finnin et al. gives an
excellent description of each of the loops in the sirtuin enzyme structure and their functions for the
enzymatic activity (Finnin et al., 2001). Due to such similarity, the ability to develop specific
substrates for each sirtuin becomes increasingly difficult. The large groove residues, which include
the NAD+ binding site, remain identical across Sirt1, 2, 3, 4, 5, and 6 (Finnin et al., 2001). The
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small domain, including alpha helices 5, 6, and 9, and loops 3 and 4 have some variations among
the sirtuins. These helicies consist of primarily hydrophobic residues, containing both zinc binding
sites and the substrate-binding site (Finnin et al., 2001). A number of these residues also
encompass the catalytic site for the sirtuin, and in many cases amino acid mutations in this region
will result in a complete loss of deacetylation activity.
To construct an isoform specific substrate, it is necessary to look closely at the residues
within the two primary loops, L3 and L4, which contain the substrate binding and activating
pocket. L3 is the active site containing the deprotonating residue for all sirtuins. This residue,
generally a histidine, is responsible for activating the substrate allowing deacetylation to occur.
SIRT1 contains regions distinct from other sirtuins at both amino and carboxyl terminals;
however, the catalytic core is highly conserved in all of the class III sirtuins. SIRT1 is an unordered
protein due to a flexible loop involved in the active, C site, residues and forming about half of the
total sequence (Autiero et al., 2009). While the core in all sirtuins is made from a Rossman fold,
containing a channel terminating near the NAD+ ribose ring; SIRT1 active site contains five
aromatic residues, Trp176, Tyr185, Phe187, Trp221 and Trp624 which contribute to pi-stacking
interactions (Autiero et al., 2009). These aromatic residues line the hydrophobic pocket where the
acetylated (or other moiety) lysine binds and could indicate that aromatic ring leaving groups with
hydrophobic features would bind well in the pocket and contribute to the pi-pi stacking (Autiero
et al., 2009). Therefore, it is understandable that an aromatic ring would work well as a leaving
group on a substrate type radiotracer. Interesting to note, SIRT1 is unable to effectively cleave
propionyl or butyryl groups, and functions at only ~28% and ~2%, respectively, of its deacetylase
efficacy in these cases (Heltweg et al., 2004; Hirsch and Zheng, 2011). However, this study showed
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that dephenylacetylation by SIRT1 had a catalytic reaction rate of about 56% of the deacetylation
rate.
The distance between the alpha carbon and the side chain acetamido group plays a large role
in the catalytic efficiency of SIRT1, thus the full lysine chain is necessary for activity (Hirsch and
Zheng, 2011). The orientation of the lysine’s center carbon (L-conformation) is also extremely
important, as all catalytic activity is lost from the enzyme with the D-lysine isomer (Jamonnak et
al., 2010).
Multiple X-ray crystal structures have been identified for SIRT2, allowing analysis of its
substrates and catalytic site interaction (Finnin et al., 2001; Moniot et al., 2013). SIRT2 primarily
regulate lysine residues on the tails of H3 (H3K9) and H4 (H4K16) (Imai et al., 2000). In contrast
to Sir2-Af1 (the murine homologue of SIRT1) SIRT2 has a lower degree of flexibility in the
binding loop leading to a very high level of substrate specificity even though it has a much wider
channel than some of the other sirtuin homologues in other species (Finnin et al., 2001).
Specifically, there are two residues that are necessary for deacetylase activity, Asn168 and
Asp170, which activate the ribose ring to allow for a quicker enzymatic transfer (Finnin et al.,
2001). It has also been proposed that it is Ser88 in SIRT2 performing the initial glycosidic attack
on the NAD+, thereby allowing the nucleophilic attack on the carbonyl (Finnin et al., 2001).
SIRT2 has a deeper catalytic pocket, though not wide enough to accommodate a benzene ring like
SIRT1, SIRT2 has the ability to fit much longer chains. He et al. provide proof of SIRT2 cleaving
the myristoyl moiety on a lysine chain of H3K9 and TNF-αK19-20 (He et al., 2014).
SIRT2 and SIRT3 share multiple residues in key positions, many of which are generally not
conserved between all sirtuins. For example, the amino acid at the -2 position from the protonating
residue is not conserved across all sirtuins, but both SIRT2 and SIRT3 share a tyrosine here.
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Similarly, the two key residues in the L4 active site loop are shared between SIRT 2 and SIRT3 as
they contain a valine at the +7 position from their respective FGEXL loops. Notably, the -1, -3
and -4 positions from this loop are also conserved between these two enzymes, yet not between
any of the other sirtuins. This information is important to understand how to construct a substrate
specific to one or the other.
Examining the surface residues for SIRT3 through in silico modeling demonstrates the cap
residues more preferred by SIRT3. Investigation of many of the natural client proteins for SIRT3,
the side chain and cap residues will provide valuable information for unique substrate synthesis
for SIRT3 (Smith et al., 2011). According to this model study, SIRT3 prefers the positively
charged and aromatic residues on both sides of the modulated lysine, namely, tyrosine,
phenylalanine and tryptophan (Smith et al., 2011). This will explain why so many of the positive
SIRT3 synthetic substrates are successful with the fluorescent compound amino-methylcoumarin
(AMC) on one side of the lysine. Much of SIRT3’s activity relies on the substrate’s cap and its
ability to fit well into SIRT3. Di-lysine cap groups also enhance SIRT3 catalytic activity regardless
of changes in leaving group. However, the most selective leaving group for SIRT3 is the crotonyl
moiety, as this sirtuin is the only one capable of successfully cleaving a crotonylated lysine moiety.
SIRT5 uses a histidine as the deprotonating residue, His158, which is common amongst the
sirtuins, however SIRT5 has a unique arginine in the catalytic pocket (Du et al., 2011). The Tyr102
and Arg105 in the active site allow SIRT5 to cleave succinylated substrates (Du et al., 2011).
SIRT5 has a further differentiated substrate-docking site due to its two arginine residues in the
bottom of the binding pocket. Du et al., demonstrated effectively that these two arginine residues
form hydrogen bonding with the carboxylic acid present on the end of the succinyl moiety (Du et
al., 2011). Because of this alteration in the active site, the substrate specification for SIRT5 is very
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straightforward; this is the only enzyme that will easily cleave these terminal carboxylic acid
chains. Tan et al. have also observed that SIRT5 is able to act as a deglutarylase on specific proteins
with lysine-glutarylated residues (Tan et al., 2014). Literature reports have suggested that SIRT5
is the only sirtuin with the ability to act as a deglutarylase (Tan et al., 2014).
An interesting study demonstrated the corresponding changes in SIRT5 Km and Kcat after the
addition of various groups at the beta carbon of the succinyl and glutaryl substituents. The
conclusion that the large changes in km did not necessarily reflect changes in kcat demonstrates a
fundamental difference in kinetic measurements of enzymatic activity (Roessler et al., 2014). It
appears that for SIRT5 a lowered affinity to a substrate is not necessarily reflected in a decreased
catalytic activity. In the development of synthetic substrates it is necessary to identify both strong
Km and Kcat values, but the Kcat is more indicative of the effectiveness for a particular substrate to
be cleaved. Furthermore, they identified multiple different dicarbonic acyl groups, which are
likely used as covalent lysine modifications for carbamoyl phosphate synthetase 1 (CPSI). Thus,
it has been found that SIRT5 acts on many dicarbonic acyl chains of lengh 2 carbons to 8 carbons
(Roessler et al., 2014). This finding was supported by the identification that Arg105 in SIRT5 is
able to adopt different conformations allowing larger acyl residues to interact with the Tyr102 and
Arg105 residues. This study also confirms the previous findings that SIRT5 is not an active
deacetylase, as the Kcat and Km for the deacetylase activity is extremely low. These findings are
instrumental in our design of radiolabeled substrates for imaging of SIRT5 in vivo.
While all other sirtuins contain the FGE loop, named for the conserved FGEXL residues,
SIRT6 contains instead a loop with WEDSL residues. Along with this, SIRT6 lacks the salt bridge
that normally constrains the two loops used in binding NAD and substrate, in the Rossman fold.
It has been documented in most sirtuins that the conserved FGEXL loop forms the hydrogen
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bonding interactions with the substrate in the pocket (Jin et al., 2009). However, SIRT6 is the only
enzyme without these conserved residues; instead it has a large gap in the protein sequence and
corresponding cleft in the quaternary structure, followed by a WEDSL loop. These changes make
the selectivity of the cap in SIRT6 much more important. This gives the enzyme more flexibility
in its binding mechanism. It is implied in Hu et al. that the cap of the substrate plays a large role
in the ability of an enzyme to cleave the lysine substrate (Hu et al., 2013). In their study they have
tested three compounds with a myristoyl-lysine contained within. The H3K9 (myr)-AMC did not
work at all while the TNF-alpha shortened analog works very well and SIRT6 is able to cleave the
myristoylated lysine.

Furthermore, the full chain length TNF-alpha protein with K20

myristoylated cuts the shortened peptide’s Km in half (Hu et al., 2013). It has been shown that
SIRT6 can catalyze demyristoylation in vitro for the TNF-α but it does not effectively cleave this
moiety from the myristoylated lysine 9 in H3K9 (Hu et al., 2013). However, the same group has
also published findings that SIRT2 can also cleave the myristoyl leaving group, but on H3K9, not
TNF-α (He et al., 2014). Looking at the structures of the two amino acid sequences in the TNF
protein and the histone protein there is one major difference. The TNF protein contains lysinelysine moiety where the lysine is myristoylated, however the H3 protein contains only one lysine
in the peptidic sequence. This leads us to believe that SIRT6 needs to have the Lys-Lys structure
for cleavage to occur, which may be the reason for SIRT6’s higher activity with a Lys-Lys
substrate. These studies are important for differentiation of possibly substrates between SIRT2 and
SIRT6 as they both fit many of the same leaving groups.
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CHAPTER 3 DEVELOPMENT OF NOVEL HDAC CLASS IIa
IMAGING AGENTS
Histone deacetylases (HDAC’s) became increasingly important targets for therapy of various
diseases, resulting in a pressing need to develop HDAC class- and isoform-selective inhibitors.
Class IIa deacetylases possess only minimal deacetylase activity against acetylated histones, but
have several other client proteins as substrates through which they participate in epigenetic
regulation. Herein, we report the radiosyntheses of the second generation of HDAC class IIa–
specific

radiotracers:

6-(di-fluoroacetamido)-1-hexanoicanilide

(DFAHA)

and

6-(tri-

fluoroacetamido)-1-hexanoicanilide ([18F]-TFAHA). The selectivity of these radiotracer substrates
to HDAC class IIa enzymes was assessed in vitro, in a panel of recombinant HDACs, and in vivo
using PET/CT imaging in rats. [18F]TFAHA showed significantly higher selectivity for HDAC
class IIa enzymes, as compared to [18F]DFAHA and previously reported [18F]FAHA. PET imaging
with [18F]TFAHA can be used to visualize and quantify spatial distribution and magnitude of
HDAC class IIa expression-activity in different organs and tissues in vivo. Furthermore, PET
imaging with [18F]TFAHA may advance the understanding of HDACs class IIa mediated
epigenetic regulation of normal and pathophysiological processes, and facilitate the development
of novel HDAC class IIa-specific inhibitors for therapy of different diseases.

3a: Novel Histone Deacetylase Class IIa Selective Substrate Radiotracer
for PET Imaging of Epigenetic Regulation in the Brain
Portions of this chapter have been published by PLOS One (Bonomi et al., 2015)
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Introduction:
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There is an increasing demand for understanding the molecular pathophysiology of
epigenetic regulation by histone deacetylases (HDACs). Longitudinal studies in experimental
animal models and in humans, aimed to investigate different HDACs-mediated epigenetic
mechanisms, could be greatly facilitated by the availability of agents for non-invasive, repetitive,
and quantitative imaging of enzyme expression-activity in vivo. Previously, we demonstrated that
Boc-Lys-trifluoroacetate (BLT) could be used for 19F-NMR spectroscopic monitoring of HDAC
activity in vivo (Sankaranarayanapillai et al., 2006; Sankaranarayanapillai et al., 2008). Also, our
group developed the first radiotracer for PET imaging of HDAC expression and activity, the 6([18F]fluoroacetamido)-1-hexanoicanilide, termed [18F]FAHA (Mukhopadhyay U, 2006a). We
demonstrated that after intravenous injection, [18F]FAHA rapidly accumulates in the brain in rats
and in rhesus macaques, and that the rate of [18F]FAHA accumulation in the brain is inhibited in a
dose-dependent manner by HDAC inhibitor SAHA (vorinostat) (Nishii R, 2007; Sanabria S, 2008;
Yeh et al., 2013a). Other investigators confirmed the results of our initial studies using PET
imaging with [18F]FAHA in mice (Tang et al., 2014) and baboons (Reid et al., 2009b; Seo et al.,
2013) . These studies reproducibly demonstrated accumulation of [18F]FAHA-derived
radioactivity in the n. accumbens, amygdala, hippocampus, periaqueductal grey matter and in the
cerebellum. These structures of the brain have selective upregulation of HDACs class IIa
expression, as demonstrated by immunohistochemical staining methods in rhesus macaque (Nishii
R, 2007; Sanabria S, 2008; Yeh et al., 2013a) and human brain (Yeh et al., 2013b). Furthermore,
the importance of HDAC IIa enzymes in n. accumbens, such as HDAC4 and HDAC5, has been
demonstrated in addiction, specifically in the development of drug-seeking behavior (Renthal et
al., 2007) . Evidence from different laboratories using cell culture and in vivo model systems
indicates that HDAC4 plays an essential role in the development of central nervous system (Morris
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and Monteggia, 2013) and in maintenance of neuronal survival (Chen and Cepko, 2009;
Majdzadeh et al., 2008). The HDAC4 null knockout mice, which die within 2 weeks of birth,
display cerebellar degeneration (Price et al., 2013). Also, selective deletion of HDAC4 in the brain
resulted in loss of learning and memory function (Kim, 2012), and haploinsufficiency
of HDAC4 in humans is associated with brachydactyly mental retardation syndrome (Williams,
2010).
Considering the importance of HDAC class IIa in epigenetic regulatory mechanisms
involved in brain development and function, we developed the second generation of HDAC class
IIa–specific radiotracers: 6-(di-fluoroacetamido)-1-hexanoicanilide (DFAHA) and 6-(trifluoroacetamido)-1-hexanoicanilide ([18F]-TFAHA) with improved selectivity and substrate
efficiency to HDACs class IIa. The rationale for development of these radiotracers was based on
previous reports that HDACs class IIa enzymes exhibit higher catalytic efficiency for Boc-LLys(ɛ-trifluoroacetyl)-AMC, as compared to Boc-L-Lys(ɛ-acetyl)- AMC. This is attributed to
much higher electrophilicity of carbonyl carbon atom of the trifluoroacetyl moiety, as compared
to acetyl moiety, despite the similarities in Van der Waals radii of acetyl and trifuloroacetyl
moieties (28-30). However, Boc-L-Lys(ɛ-trifluoroacetyl)- AMC has demonstrated high substrate
affinity also to HDAC8 (class I), which was discouraging in terms of its selectivity to HDACs
class IIa. It is well established that the rim region in the active site of individual HDACs mediates
the contact with capping groups of substrates (or inhibitors) and influences their affinity to
individual HDACs (Riester et al., 2007). Therefore, in this study we tested the hypothesis that a
smaller sized capping group, such as an aniline moiety, may preserve high substrate affinity of 6(trifluoroacetamido)-1-hexanoicanilide to HDACs class IIa, while reducing its substrate affinity to
HDAC8 and other HDACs class I enzymes. Also, we assessed whether the number of fluorine

29

atom substitutions in the acetyl moiety influences the substrate affinity and selectivity of mono-,
di-, and tri- fluoroacetyl-hexanoicanilides to different HDACs.
Herein, we report the synthesis of DFAHA and TFAHA, as well as the radiosynthesis of
[18F]DFAHA and [18F]TFAHA. We demonstrate that TFAHA exhibits significantly higher
substrate affinity and selectivity to HDACs class IIa, especially to HDACs 4 and 5, as compared
to FAHA and DFAHA. Although we have previously reported the results of 18F-FAHA PET/MRI
imaging studies in rhesus macaques (Yeh et al., 2013a), the results of PET imaging studies in rats
comparing [18F]FAHA, [18F]DFAHA, and [18F]TFAHA head-to-head are reported here for the first
time.
Results and Discussion:
Several previously studied radiolabeled hydroxamite HDAC inhibitors, including [125/131I]-SAHA

Figure 4. Synthesis of DFAHA and TFAHA. Reaction conditions are as follows: a) RT overnight;
b) 2mL DCM, stirred overnight.
(Haberkorn U, 2007), [11C]MS-275 (Hooker et al., 2009), [18F]SAHA (Zeglis et al., 2011),
[18F]FESAHA (Hendricks et al., 2011b), and [64Cu]CUDC-101 (Meng et al., 2013) demonstrated
poor accumulation in the brain due to inability to efficiently cross the BBB. Other hydroxamitebased HDAC inhibitors containing more lipophilic capping groups, such as the adamantyl in
[11C]martinostat, demonstrated efficient cellular membrane and BBB penetration of this
radiotracer, as well as efficient visualization and quantification of HDACs class I expression levels
in the brain and other organs in non-human primates (Wang et al., 2014). Thus, PET imaging has
been proven as an effective tool for image-guided optimization of potent BBB-permeable HDAC
inhibitors (19, 35-37).
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We focused on the development of class- and isoform- selective radiolabeled substrates
instead of radiolabeled inhibitors, because of their ability to visualize not only the localization and
magnitude of HDACs expression, but more importantly, their expression-activity product. In this
paper, we report two novel radiolabeled substrate-based radiotracers [18F]DFAHA and
[18F]TFAHA with enhanced enzyme selectivity for HDAC Class IIa, as compared to [ 18F]FAHA
(Nishii R, 2007; Yeh et al., 2013a). We demonstrate that increasing the number of fluorine atoms
in the acetyl moiety from [18F]FAHA to [18F]DFAHA to [18F]TFAHA increases not only the
selectivity and catalytic
efficiency

of

these

substrates for HDACs
class

IIa,

but

also

improves the metabolic
entrapment
radiolabeled

of
leaving

groups
([18F]difluoroacetate

Figure 5. Synthesis of DFAHA and TFAHA precursors. Reaction
conditions are as follows: c) pyridine, acetyl chloride added dropwise at 0°C, stirred overnight at RT d) 0.9 eq. SOCl2, 12 hr. stirred
under argon at 40°C, catalytic DMF; e) DCM, triethylamine added
drop-wise at 0°C, stirred 24 hr. under argon at RT.

and [18F]trifluoroacetate) in the brain. In contrast, previously reported studies with [11C]6acetamido-1-hexanoicanilide (11C-AHA) demonstrated significantly lower uptake and more
uniform distribution in the brain, as compared to 18F-FAHA (Seo et al., 2013).
The syntheses of DFAHA (3a) and TFAHA (3b) are shown in Fig. 4. Compound 1 was
synthesized following a previously published method in 80% yield (Mukhopadhyay U, 2006b).
Compound 1 was the key intermediate for the synthesis of the precursor compounds for both
DFAHA (3a) and TFAHA (3b). Reaction of 1 with bromofluoro acetyl chloride (freshly prepared
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by

reacting

bromofluoro acetic acid
with thionyl chloride),
and triethylamine in
DCM at 0°C, produced

Figure 6. Synthesis of [18F]DFAHA and [18F]TFAHA. Reaction
conditions are as follows: f) [18F]KF, K2,2,2; 0.4mL ACN, 105°C 25
min.; g)[18F]KF, K2,2,2; 0.4mL ACN, 105°C 25 min.

compound 2a in 15%
yield. Due to the low boiling point of bromofluoro acetyl chloride, it was not possible to evaporate
excess thionyl chloride prior to adding the compound 1; for this reason, less than 1 equivalent of
thionyl chloride was used in the reaction. Compound 2a was obtained as a diastereoisomeric
mixture and characterized by 1H,

13

C and

19

F NMR spectroscopy and high-resolution mass

spectroscopy. The 1H NMR spectrum of compound 2a showed 2 doublets corresponding to the
fluorobromomethyl proton at 7.03 and 6.74 ppm with coupling constants of 49.45 Hz (typical for
F-H coupling). Based on the relative integration of these two doublets the, diasteromeric mixture
was obtained in an 80:20 ratio. The corresponding 19F-NMR spectrum showed 2 doublet peaks at
-147.34 and -143.52 ppm with coupling constants 50.35 Hz and 48.83 Hz respectively, and the
same diasteromeric ratio of 80:20. Resolving the diastereomeric mixture was unnecessary, because
the subsequent reaction (radio-fluorination) led to the formation of difluroacetyl amide, which is
optically inactive. The yield of this reaction is quite low, only 15%. As an alternative, we
performed this reaction using the isobutyl chloroformate as intermediary step to aid the coupling.
Also, we tested N,N'-dicyclohexylcarbodiimide (DCC) as an alternative coupling agent with 4dimethylaminopyridine (DMAP) as a catalyst. Although not yet tested, other alternative coupling
agents such as hydroxybenzotriazole (HOBT) or (1-[Bis(dimethylamino)methylene]-1H-1,2,3triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) (HATU) can be explored with N,N-
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diisopropylethylamine (DIPEA) as catalyst. One possible reason for the consistently low yield is
the bromine atoms ability to couple with the amine of compound 1. The competition for coupling
site between the bromine and the chlorine will inherently lower the correct product formation.
Reaction of compound 1 with difluorobromo acetyl chloride in DCM in the presence of
triethylamine (Mathias et al.) produced the precursor, compound 2b, in 50% yield. Consistent with
the structure of 2b, a singlet at -60.07 ppm was observed in the 19F NMR spectrum.
Compound 3a was synthesized from 1 by reacting with difluoroacetic anhydride with no
additional solvents in 42% yield. The 1H NMR spectrum of 3a in DMSO-d6 was consistent with
the structure and the geminal proton observed at 6.16 ppm as a doublet with a coupling constant
of 53.8 Hz. The 19F NMR spectrum showed a doublet at -125.65 ppm with coupling constant 54.93
Hz, matching the coupling seen in the 1H NMR spectrum. Compound 3b was obtained in 51%
yield by reacting compound 1 with trifluoroacetic anhydride with only a small amount of DCM
(~2 ml). A singlet fluorine peak was observed at -74.32 ppm in the 19F NMR spectrum of 3b, which
is consistent with the structure of three fluorines in the trifluoroacetyl moiety. Compounds 3a and
3b were used as non-radioactive standards for HPLC analysis and biochemical assays (Fig. 5).
Compounds 4a and 4b were synthesized in radiochemical yields of 25% and 22%, respectively
(Fig. 6). The identity of the radioactive product was confirmed by co-elution with nonradioactive
standard as it is not possible to test the purity of radiochemical compounds by NMR. The purity
of the compounds was greater than 95%, as assessed by analytical radio-HPLC, and specific
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activities ranging between 60 and 80 GBq/µmole. The quality control HPLC chromatograms taken
for compounds 3a and 3b are shown in Figs. 7a and 7b respectively.
Evaluation of substrate affinity of FAHA, DFAHA, and TFAHA in a panel of recombinant
HDACs demonstrated the selectivity of these compounds for HDACs class IIa (HDACs 4, 5, 7,
and 9), especially for HDACs 4 and 5. The kcat values in HDACs class IIa were two orders of

Figure 7. Quality control chromatograms for 4a and 4b. A) Shows Compound 4a in
blue co-injected with compound 3a, the cold standard, in red. B) Compound 4b shown
in blue with compound 3b, the cold standard, shown in red. The blue shows the clean
radioactive spectrum, of the pure compound. UV detection was done at 254nm.
magnitude higher than those for other classes of HDACs (Fig. 8a). The higher kcat values of
TFAHA, as compared to DFAHA and FAHA demonstrates the increasing ability of HDACs class
IIa to cleave the trifluoro acetyl moiety, as compared to both difluoroacetyl and fluoroacetyl
moieties. The HDAC class IIa enzymes also have lower km values and higher vmax values for
TFAHA than the other HDACs enzymes (Fig. 8b, 8c). There is a significant change in the vmax
value of TFAHA from those of FAHA or DFAHA for HDAC8, demonstrating the decreased
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A

B

C

Figure 8. A) Substrate affinity of FAHA, DFAHA, and TFAHA to different recombinant
HDACs in vitro. The substrate affinity is expressed as Kcat. B) Maximum catalytic rate of
FAHA, DFAHA, and TFAHA for different recombinant HDACs in vitro, expressed as vmax.
C) The concentration required for half of the maximal catalytic activity for all recombinant
HDACs expressed as km.
cleavage efficiency of HDAC class I with the addition of fluorine atoms (Fig. 8b). Also, these
results are consistent with previous reports demonstrating that HDACs class IIa enzymes exhibit
higher catalytic efficiency for Boc-L-Lys(ɛ-trifluoroacetyl)- AMC, as compared to Boc-L-Lys(ɛacetyl)- AMC, which is not an efficient substrate to class IIa HDACs (Lahm et al., 2007). This
explains, at least in part, why [11C]6-acetamido-1-hexanoicanilide (11C-AHA) demonstrated
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significantly lower uptake and more uniform distribution in the brain in the regions of high
accumulation of 18F-FAHA (Seo et al., 2013).
It is important to
note,

that

the

entire

structure of the substrate
molecule plays a role in
the selectivity for HDACs
class IIa. The structure of

Fig 9. The three parts of a HDAC substrate, the cap (red), the linker
(green), and the leaving group (blue).

HDAC substrates can be subdivided into three regions, which individually contribute to HDAC
class and isoform selectivity: 1) the leaving group; 2) the linker; and 3) the capping moiety (Fig.
9). Previous studies demonstrated that trifluoroacetyl group can be cleaved by HDAC 8 when it is
attached to a lysine residue flanked by Boc and AMC (Boc-Lys(TFA)- AMC) (Riester et al., 2004).
In contrast, the phenyl capping group and lysine linker in DFAHA and TFAHA confer selectivity
of these compounds only to HDAC Class IIa, with no significant affinity to HDAC8.

Figure 10. The structures of compounds and docking scores with HDAC8, a
HDAC Class I enzyme. A lower docking score indicates higher affinity.
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Structural comparison of active sites of HDACs class I and IIa enzymes may explain the
mechanism of selectivity of FAHA, DFAHA and TFAHA for HDACs class IIa. The major
differences between HDACs class I (1, 2, 3 and 8) and HDACs class IIa (4, 5, 7 and 9) is the
substitution of His976 (class IIa) for Tyr306 (class I) in the catalytic site. This change in amino
acid residues in the catalytic site results in negligible intrinsic deacetylase activity but has two
important structural consequences: the change in size of the active site, and the removal of a
hydrogen bond donor site. Class I HDACs have a smaller catalytic cavity than class IIa enzymes,
which explains why larger leaving groups do not fit in the catalytic site and are not cleaved by
these enzymes. The docking results for HDAC 8 (class I) shown in Fig. 10, demonstrate that
increasing the size of the leaving group (acetyl < trifluoroacetyl) increases the docking score,
reflecting reduced ability of a molecule to fit inside the catalytic site of an enzyme. Indeed,
previous studies
have reported that
larger

leaving

groups, such as
propionyl,
butyryl, (Z)-but2-enyl,
isobutyryl,

3-

hydroxypropanyl,
3-methylbutanyl,
4-amino-4-

Figure 11. Mechanism of deactylation of AHA by HDAC8. In HDAC8
and other HDACs class I enzymes, the hydrogen bond forming between
Tyr306 and the carbonyl oxygen of the acetyl moiety increases the
electrophilicity of the carbonyl carbon, rendering it more susceptible to the
nucleophilic attack by the activated water molecule, bound to His142 and
His143. This leads to the formation of a tetrahedral oxyanion intermediate
stabilized by Zn2+ ion and the hydroxyl group of Tyr306. Subsequently,
the amide bond is cleaved and the acetyl moiety is released.
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oxobutanyl, and several other similar compounds are poor substrates for class I HDACs (Jones et
al., 2008).
HDAC class
IIa enzymes lack a
hydrogen

bond

donor

that

can

bind

to

the

carbonyl oxygen
of

the

leaving

acetyl group as a
result

of

the

substitution
His976 (class IIa)

Figure 12. The mechanism of action of HDAC4. As compared to HDAC
class I, HDAC class IIa enzymes exhibit significantly reduced ability to
deacetylate. In class IIa enzymes the His976 located in the same position
in the catalytic site as Tyr306 in class I HDACs does not serve as a
hydrogen bond donor to bind to the carbonyl oxygen of the leaving acetyl
group and thus reduces the susceptibility of carbonyl carbon to
nucleophilic attack by the water, as in HDAC class I.

for Tyr306 (class I), which renders the acetyl group inactive (Figs. 11, 12). In HDAC class I, this
hydrogen bond increases the electrophilicity of the carbonyl carbon in the acetyl group, which
renders it more susceptible to the nucleophilic attack by the activated water molecule, bound to
His142 and His143. This leads to the formation of a tetrahedral oxyanion intermediate stabilized
by the Zn2+ ion and by the hydroxyl group of Tyr306 of HDAC8. Consecutive replacement of the
hydrogen atoms in the methyl moiety of the leaving acetyl group by fluorine atoms reduces the
enzymatic activity in HDACs class I. This suggests that increasing the electronegativity of the
leaving group is not sufficient to overcome the size increase, which may force the carbonyl carbon
to rotate away from the activated water molecule, adding additional distortion to the hydrogen
bonding with Tyr306. Increasing the electronegativity should increase the reactivity of carbonyl
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carbon, but since this is not the case, it is reasonable to assume that the relative increase in the
effective size of the leaving group in TFAHA > DFAHA > FAHA may be a determining factor in
the decreasing enzymatic activity. In contrast, increasing the number of fluorine atom substitutions
in the methyl moiety of the acetyl leaving group increases the electrophilicity of the carbonyl
carbon and restores the catalytic activity of HDACs class IIa by facilitating the nucleophilic attack
on the carbonyl carbon of the acetyl moiety by activated water molecule bound to His802 and
His803. As a result, the formation of the tetrahedral oxyanion is irreversible and releases
trifluoroacetate as shown in Fig. 13.
The uptake, accumulation, and clearance of [18F]FAHA, [18F]DFAHA, and [18F]TFAHA in
various regions of the rat brain were studied using dynamic PET/CT imaging. Higher levels of
accumulation of all three radiotracers were observed primarily in n. accumbens, hippocampus,
amygdala, periaqueductal grey, and cerebellum (Fig. 14), where the HDACs 4 and 5 are
abundantly
expressed (Yeh et
al., 2013a). The
alignment of the
PET/CT

images

with the digital rat
brain

atlas

(Paxinos,
was

used

2006)
to

identify regions of
interest (Fig. 15).

Figure 13. Proposed mechanism of de-trifluoroacetylation by HDAC4.
Increased electronegativity of trifluoromethyl moiety of the trifluoroacetyl
leaving group increases the susceptibility of the carbonyl carbon to the
nucleophilic attack by the water molecule bound to His802 and His803 and
enables the catalytic activity of HDACs class IIa. This results in formation of the
tetrahedral oxyanion, which is irreversible, thereby releasing the trifluoroacetate.
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Highly selective accumulation of [18F]TFAHA-derived radioactivity was observed in the
cerebellum, n. accumbens, periaqueductal gray, and hippocampus (dentate gyrus-CA1, CA3
region). The levels of [18F]TFAHA-derived radioactivity accumulation in these brain structures
were higher than those from either [18F]DFAHA or [18F]FAHA. While [18F]FAHA exhibited
moderate levels of radioactivity accumulation throughout the brain, including brain cortex, which
is consistent with its higher substrate affinity to other HDAC classes, both [18F]DFAHA and,
especially [18F]TFAHA, exhibited much lower accumulation in the cortex (Fig. 16). Logan
graphical analysis of [18F]FAHA, [18F]DFAHA and [18F]TFAHA accumulation in cerebellum
using cortex as the reference tissue demonstrated that [18F]TFAHA was more actively accumulated
(had a steeper slope of the Logan plot) in the cerebellar nuclei than either [ 18F]FAHA or
[18F]DFAHA (Fig. 17). Following PET/CT in vivo imaging with [18F]TFAHA, quantitative
autoradiography (QAR) was performed in selected animals to verify the results at higher resolution
of images. Fig. 18 demonstrates a high degree of correlation between the areas of

18

F-TFAHA-

derived accumulation displayed by autoradiography and the PET images shown in Fig. 18. Higher
levels of accumulation of [18F]TFAHA were observed using QAR in n. accumbens, hippocampus,
periaqueductal grey, and in cerebellar nuclei.
Furthermore, our preliminary imaging studies demonstrated the feasibility of PET/CT with
[18F]TFAHA for monitoring pharmacologic inhibition of HDACs class IIa with SAHA. A
significant inhibition of [18F]TFAHA-derived radioactivity accumulation in the brain was
observed when SAHA (100 mg/kg) was administered i.p. 30 min prior to i.v. administration of
[18F]TFAHA (Fig. 19). These results demonstrate that [18F]TFAHA is a much more selective and
more efficient radiotracer for imaging expression-activity of HDAC class IIa enzymes in the brain,
as compared to either [18F]DFAHA or [18F]FAHA.
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In summary, current studies demonstrated that that [18F]TFAHA is a more selective and
effective substrate-based radiotracer for non-invasive PET imaging of class IIa HDACs
expression-activity in the brain. This novel PET imaging radiotracer can be readily translated into
the clinic and may aid in the fundamental understanding of epigenetic regulation by HDACs class
IIa involved in brain development and function, as well as in the mechanisms of different diseases,
including traumatic brain injury and post-traumatic stress disorders, depression, drug addiction,
Alzheimer’s, Huntington’s, brain tumors and other diseases of the brain. Furthermore, PET
imaging with [18F]TFAHA should facilitate the development and clinical translation of novel
HDACs class IIa selective inhibitors by enabling non-invasive quantification of their
pharmacodynamics at the drug target level.
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Figure 14. PET/CT images (A) of the spatial and temporal dynamics of influx, distribution, clearance and
retention of each of the three radiotracers at different time intervals after intravenous administration:
[18F]FAHA (top panel), [18F]DFAHA (middle panel), and [18F]TFAHA (bottom panel). In each panel,
PET/CT images are provided in three different planes: top row - axial images through the middle of the
brain; middle row – coronal images through the middle of the brain; bottom row – coronal images through
the cerebellum area. Images are color-coded to range of standard uptake values (SUV) shown in the color
bar and cross-normalized to facilitate direct comparison of radioactivity distribution. Corresponding timeactivity plots (B) of each radiotracer are provided on the right hand side for: cerebellum (blue diamonds),
muscle (green triangles), cortex (red squares), and heart (grey crosshairs).
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Materials and Methods:
All reagents and solvents were purchased from Aldrich Chemical Co. (Milwaukee, WI), and
used without further purification. Preparation of 6-amino-1-hexanoicanilide (Mukhopadhyay et
al., 2006) was done following a previously published method (Mukhopadhyay U, 2006b). Thin layer
chromatography (TLC) was performed on pre-coated Dynamic Absorbance F-254 (Norcross,
Georgia) silica gel, aluminum backed, plates. 1H,

13

C and

19

F NMR spectra were recorded on

Mercury and Varian 400 MHz spectrometers at Wayne State University. High-resolution mass
spectra (HRMS) were obtained from a Waters LCT Premier/XE mass spectrometer at the Lumigen
Imaging Center in the Department of Chemistry at Wayne State University using electrospray
ionization (ESI) technique. High performance liquid chromatography (HPLC) was performed
with an 1100 series pump from Agilent Technologies (Stuttgart, Germany), with a built-in UV
detector operated at 254 nm and a radioactivity detector with a single channel analyzer model
FC3200 (NaI/PMT) detector from Eckert and Ziegler Radiopharma, Inc. (Germany) with an
Ascentis RP-Amide column (Supelco, 4.4x150mm) for analytical and quality control
chromatography. Semi-preparative HPLC was conducted on a Knauer P4.1S pump 10ml/Ti, with
a Azura UVD 2.1S Detector using Clarity Software (Berlin, Germany) pump with an Alltima C18
(Fisher Scientific, 250x10mm) column with a UV detector at 254 nm and a radio detector model
FC-3500 from Eckert and Ziegler AG (Berlin, Germany).
Preparation of 6-(bromofluoroacetamido)-1-hexanoicanilide (2a): Bromofluoro acetic
acid (530mg, 3.3 mmol) was added to a reaction flask with 0.9 equivalents of thionyl chloride (210
μl, 2.9 mmol). The reaction was stirred for 4 hours at 60°C. Subsequently, the reaction mixture
was cooled to room temperature and a solution of compound 1 (280 mg, 1.37 mmol) in 12 mL of
anhydrous dichloromethane was added and followed by trimethylamine (2 ml, 15 mmol). The
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reaction was stirred under argon for 24 hours, after which, all of the solvent was evaporated and
the compound was re-dissolved in dichloromethane and washed with aqueous saturated sodium
bicarbonate solution. The organic layer was dried over sodium sulfate and evaporated. Flash
column chromatography was used for purification of the compound with a gradient of solvent from
10% ethyl acetate in hexane to 50% ethyl acetate in hexane. Product 2a (25 mg) was obtained in a
15% yield as an off-white solid.
Diastereomer 1: 1H NMR (DMSO-d6) : 9.83 (s, 1H, NH), 8.62 (s, 1H, NH), 7.56 (d, 2H,
aromatic, J = 8.11 Hz), 7.26 (t, 2H, aromatic, J = 7.30 Hz), 6.99 (t, 1H, aromatic, J = 7.30 Hz),
7.03 (d, 1H, -CHFBr, Jgem = 49.45 Hz) 3.12 (q, 2H, CH2, J = 6.49 Hz), 2.27 (t, 2H, CH2, J = 7.34
Hz), 1.57 (m, 2H, CH2), 1.46 (m, 2H, CH2), 1.28 (m, 2H, CH2). 13C NMR (DMSO-d6) δ: 189.88,
171.63, 164.66 (d, -C=O-CF, J = 22.13 Hz), 139.70, 128.97, 123.34, 119.58, 85.93 (d, -CHFBr, J
= 262.46 Hz), 36.67, 28.89, 26.21, 25.13 ppm.

19

F NMR (DMSO-d6) : -147.34 (d, J = 50.35 Hz),

-143.52 (d, J = 48.83). HRMS (m / z): [M + H]+ calculated for C14H20FBrN2O2, 367.0445; found
367.0433 (M+H).
Diastereomer 2: 1H NMR (DMSO-d6) : 9.83 (s, 1H, NH), 8.62 (s, 1H, NH), 7.56 (d, 2H,
aromatic, J = 8.11 Hz), 7.26 (t, 2H, aromatic, J = 7.30 Hz), 6.99 (t, 1H, aromatic, J = 7.30 Hz),
7.03 6.74 (d, 1H, -CHFBr, Jgem = 49.45 Hz), 3.12 (q, 2H, CH2, J = 6.49 Hz), 2.27 (t, 2H, CH2, J =
7.34 Hz), 1.57 (m, 2H, CH2), 1.46 (m, 2H, CH2), 1.28 (m, 2H, CH2). 13C NMR (DMSO-d6) δ:
189.88, 171.63, 164.66 (d, -C=O-CF, J = 22.13 Hz), 139.70, 128.97, 123.34, 119.58, 85.93 (d, CHFBr, J = 262.46 Hz), 36.67, 28.89, 26.21, 25.13 ppm.

19

F NMR (DMSO-d6) : -147.34 (d, J =

50.35 Hz), -143.52 (d, J = 48.83). HRMS (m / z): [M + H]+ calculated for C14H19FBrN2O2,
367.0445; found 367.0433 (M+H).
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Preparation of 6-(bromodifluoroacetamido)-1-hexanoicanilide (2b): Comound 1 (200
mg, 0.97 mmol) was dissolved in dimethylformamide (7.0 mL) with two equivalents of
diisopropylethylamine and stirred at 0 °C. 2-bromodifluoro acetyl chloride (0.2 mL, 2.2 mmol)
was added drop-wise to the mixture. The mixture was subsequently stirred at 0 °C for 1 hour then
warmed to room temperature and stirred for an additional 3 hours under argon. After evaporation
of solvent, the compound was purified using flash column chromatography with a gradient of 1050% ethyl acetate/hexane as the eluent. Product 2b (150 mg) was obtained after evaporation as a
white solid with 50% yield. 1H NMR (DMSO-d6) δ: 9.83 (s, 1H, NH), 9.17 (s, 1H, NH), 7.54 (d,
2H, aromatic, J = 7.34 Hz), 7.34 (t, 2H, aromatic, J = 7.34 Hz), 6.99 (t, 1H, aromatic, J = 7.83 Hz),
3.15 (q, 2H, CH2, J = 6.36 Hz), 2.27 (t, 2H, CH2, J = 7.34 Hz), 1.58 (m, 2H, CH2), 1.49 (m, 2H,
CH2), 1.28 (m, 2H, CH2). 13C NMR (DMSO-d6) δ: 171.42, 159.95 (t, -CO-CF2Br, J = 27.47 Hz),
139.71, 129.03, 123.21, 119.33, 112.21 (t, -CF2Br, J = 315.10 Hz), 36.70, 28.58, 26.40, 25.21 ppm.
19

F NMR (DMSO-d6) δ: -60.07 (s). HRMS (m/z): [M +H]+ calculated for C14H17N2O2F2Br

363.0520, found 363.0515.
Preparation of 6-(difluoroacetamido)-1-hexanoicanilide (DFAHA 3a): Compound 1
(200 mg, 0.97mmol) was stirred in difluoroacetic anhydride at room temperature until fully
dissolved. And then triethylamine (1 mL, 7.2 mmol) was added gradually until the pH of the
solution reached a value close to 8. The reaction mixture stirred at room temperature overnight.
The anhydride was removed under reduced pressure and the residue was purified by flash
chromatography using 50% ethyl acetate in hexane. Product 3a was obtained as a white powder
in a 42% yield. 1H NMR (DMSO-d6) : 9.82 (s, 1H, NH), 8.75 (s, 1H, NH), 7.56 (d, 2H, aromatic,
J = 7.83 Hz), 7.26 (t, 2H, aromatic, J = 7.34 Hz), 6.99 (t, 1H, aromatic, J = 7.34 Hz), 6.16 (t, 1H,
-CHF2, Jgem = 53.8 Hz), 3.12 (q, 2H, CH2, J = 13.1, 6.7 Hz), 2.28 (t, 2H, CH2, J = 7.34 Hz), 1.57
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(m, 2H, CH2), 1.46 (m, 2H, CH2), 1.27 (m, 2H, CH2). 13C NMR (DMSO-d6) δ: 171.42, 162.48 (t,
-CO-CF2, J = 24.41 Hz), 139.71, 129.03, 123.21, 119.33, 108.98 (t, -CHF2, J = 246.44 Hz), 36.83,
28.74, 26.47, 25.18 ppm.

19

F NMR (DMSO-d6) : -125.65 (d, J = 54.93 Hz). HRMS (m / z): [M

+ H]+ calculated for C14H19F2N2O2, 307.1234; found 307.1226 (M+H).
Preparation of 6-(trifluoroacetamido)-1-hexanoicanilide (TFAHA 3b): Compound 1
(100 mg, 0.48 mmol) was dissolved in trifluoacetic anhydride (1.0 g, 4.76 mmol) and 2mL of
dichloromethane at 0°C. The reaction mixture was stirred under argon for 20 min and then 2 hours
at room temperature overnight. The solvent was evaporated and the crude compound was purified
by flash column chromatography using 30% ethyl acetate in hexane. After evaporation of the
solvent, the product 3b was obtained as white solid in 51 % yield. 1H NMR (DMSO-d6) : 9.83 (s,
1H, NH), 9.4 (s, 1H, NH), 7.57 (d, 2H, aromatic, J = 8.8 Hz), 7.25 (t, 2H, aromatic, J = 7.83 Hz),
6.99 (t, 1H, aromatic, J = 6.85 Hz ), 3.16 (q, 2H, CH2, J = 13.1 Hz, J = 6.7), 2.28 (t, 2H, CH2, J =
7.5 Hz), 1.57 (m, 2H, CH2), 1.49 (m, 2H, CH2), 1.27 (m, 2H, CH2).

13

C NMR (DMSO-d6) δ:

171.61, 156.51(q, -CO-CF3, J = 71.6, 35.86 Hz), 139.83, 129.18, 123.52, 119.42, 116.45 (q, -CF3,
J = 576.6, 288.40 Hz), 36.69, 28.47, 26.30, 25.09 ppm. 19F NMR (DMSO-d6) : -74.32 (s). HRMS
(m / z): [M + H]+ calculated for C14H18F3N2O2 , 303.1320; found 303.1312 (M+H).
Radiosynthesis of 6-([18F]difluoroacetamido)-1-hexanoicanilide ([18F]DFAHA 4a): A
solution of K[18F]/kryptofix in acetonitrile (1 ml) was received and transferred into a crimped Vvial. The acetonitrile removed under a stream of argon at 105°C. A solution of 2a (6-7 mg) in dry
acetonitrile (0.4 mL) was added to previously dried K18F/kryptofix and the mixture was heated at
100°C for 20 minutes. The reaction was cooled and the mixture was passed through a silica gel
cartridge (Alltech, 900 mg) and eluted with 30% methanol in dichloromethane (2.5 mL). After
evaporation of the solvent under a stream of argon at 80°C, the mixture was re-dissolved in HPLC
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solvent and purified by semi-preparative HPLC using 40% ACN/buffer solution. The compound
eluted at 9.7 minutes. The solvent was evaporated under reduced pressure and the final product
was re-dissolved in saline for animal injection. The product purity and identity was confirmed by
co-injection with an authentic non-radiolabeled (4a) using an analytical HPLC. The compound
was obtained in 25% decay corrected yield, with > 95% purity, and specific activity of 60-70
GBq/µmole.
Radiosynthesis of 6-([18F]trifluoroacetamido)-1-hexanoicanilide ([18F]TFAHA 4b): A
solution of kryptofix/ K[18F] in acetonitrile (1 ml) was received and transferred into a crimped Vvial. The acetonitrile removed under a stream of argon at 105°C. A solution of 2b (6-7 mg) in dry
acetonitrile (0.4 mL) was added to previously dried K18F/kryptofix and the mixture was heated at
100°C for 20 minutes. The mixture was heated and stirred at 110°C for 25 minutes. The reaction
was cooled and the mixture was passed through a silica gel cartridge (Alltech, 900 mg) and eluted
with 30% methanol in dichloromethane (2.5 mL). After evaporation of the solvent under a stream
of argon at 80°C, the mixture was re-dissolved in HPLC solvent and purified by semi-preparative
HPLC using 40% ACN/buffer solution. The compound was eluted at 20 minutes. The solvent was
evaporated on a high vacuum pump and the desired product was re-dissolved in saline for animal
injection. The solvent was evaporated under reduced pressure and the final product was redissolved in saline for animal injection. The product purity and identity was confirmed by coinjection with an authentic non-radiolabeled (4b) using an analytical HPLC. The product was
obtained in a 22% decay corrected yield, with > 95% purity, and specific activity of 70-80
GBq/µmole.
In vitro HDAC enzyme affinity assay: In vitro enzyme assays were performed for a panel
of Class I, II, III, and IV HDACs. 10 nmol solution of each test compound or 2 nmol of control
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substrate 2A (BPS Bioscience, San Diego, CA) was incubated in 100 μl of the HDAC assay buffer
(25 mM Tris-HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2) in the presence or absence
of 1μg/ 100 μl of different HDAC enzymes (BPS Bioscience, San Diego, CA) at 37°C for 60 min.
The reaction was quenched by heating the assay at 95°C for 3 min. Subsequently, 25 ul of the
reaction mixture was analyzed by analytical HPLC (Agilent, Santa Clara, CA) equipped with
Econosil C18 column (Altech Associates, Deefield, IL) using a mobile phase: 50% acetonitrile /
20 mM ammonium acetate, pH=8.5. Detection of reaction products was detected via UV detection
at 240 nm. The area under the peak corresponding to hexanoic anilide reaction product were
integrated and expressed as percent of the area under the peak of the parent compound and
converted into mass (moles). The Kcat parameters were determined as described elsewhere
(Leskovac, 2003) using software GraphPad Prism 4 (GraphPad Software, La Jolla, CA).
In silico modeling: The crystal structures 1T69 and 2VQJ were used for the docking studies
of HDAC8 and HDAC4 respectively. For HDAC8 the missing residues 1-13 and 85-90 were added
using MODELLER (UCSF, San Francisco, CA) (Sali and Blundell, 1993). The residues 85-90 are
involved in the formation of a loop that is in close proximity to the inhibitor binding region of
HDAC8. Due to this potential importance, the loop formed by these MODELLER-added residues
was further refined using Chimera (UCSF, San Francisco, CA) (Pettersen et al., 2004). The two
crystal structures were hydrogenated using MolProbity software (Duke University, Durham, NC)
(Chen et al., 2009). Docking calculations were performed using the FlexX algorithm (Rarey et al.,
1996) as implemented in the LeadIT software package (BioSolveIT GmbH, Germany)
(BioSolveIT et al.). For both HDAC8 and HDAC4, native ligands in the crystal structure (namely
SHH for HDAC8 and TFG for HDAC4) were used as reference ligands for the docking
calculations. A grid volume that covered amino acids within 20Å from each reference ligand was
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used. All the waters within the grid volume were taken as freely rotatable and displaceable.
Pharmacophore rules based on the knowledge of ligand-receptor binding were used to guide the
ligands towards the binding site. For both HDAC8 and HDAC4 docking was performed with the
ligands AHA, FAHA, DFAHA, and TFAHA. Top 20 poses based on the docking score of each
docking run were saved and the top 10 poses were used for binding affinity calculations using
Hyde software (BioSolveIT GmbH, Germany) (Lange, 2010; Schneider et al., 2013).
PET Imaging Procedures in Animals: All studies involving animals were performed under
a protocol (A 6-13-13) approved by the Institutional Animal Care and Use Committee of Wayne
State University. Sprague-Dawley rats (200-250 g, N=3) were anesthetized with 3% isoflurane in
oxygen and maintained at 2% isoflurane in oxygen throughout the imaging studies. The body
temperature was maintained using electronically-controlled heating pad (M2M Imaging,
Cleveland, OH) set at 37oC. Anesthetized rats were placed in the microPET R4 scanner (Siemens,
Knoxville, TN) in the supine position with the long axis of the animal parallel to the long axis of
the scanner with the brain positioned in the center of the field of view. Each radiotracer (300-500
µCi/animal) was administered in saline via the tail-vein injection in a total volume ≤1.25 ml.
Dynamic PET images were obtained over 60 minutes, followed by 2 overlapping frames (5 min
each) acquired to obtain a whole body images of radiotracer biodistribution in other organs and
tissues. After PET imaging, the positioning bed with the affixed anesthetized animal was
transferred to the Inveon SPECT/CT scanner (Siemens, Knoxville, TN) and CT images and 4
overlapping frames (2 min each) were acquired covering the whole body using X-ray tube settings
of 80 kV and 500 uA.
Quantitative Autoradiography: After PET imaging (or at certain time point after 300-500
µCi radiotracer injection i.v.), the animals were sacrificed, the brain was rapidly extracted, frozen,
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and embedded in the mounting medium M1 (Shandon-Lipshaw, Pittsburg, PA). Serial 20 µm thick
coronal sections of frozen brain tissue were obtained at -13°C using a cryomicrotome CM3050S
(Leica, Germany). Tissue sections were thaw-mounted on poly-A lysine coated glass slides and
heat-fixed for 5 min at 65°C on a slide warmer (Fischer Scientific, PA). For QAR, tissue sections
were exposed to the phosphor plate (Fujifilm Life Science, Woodbridge, CT) along with set of 20
µm autoradiographic standards of known 18F radioactivity concentration, freshly prepared using
calf liver homogenate. Knowing the radioactivity concentration in standards, the injected dose,
and optical densities of each reference standard, a standard curve was developed, based on which
the autoradiographic images were converted to color-coded parametric images of percent injected
dose/g tissue (%ID/g) and/or standard uptake values (SUV) using software MCID 7.0 (Interfocus
Imaging Ltd., Cambridge, UK).
Image Analysis and Quantification: PET images were reconstructed using ordered subset
expectation–maximization (Guo et al.) method. PET image analysis was accomplished using the
AMIDE software. Digital Rat Brain Atlas was used for alignment and identification of specific
anatomical markers in the brain (Watson, 2006). GraphPad Prism 6 (Graph Pad Software La Jolla,
CA) and Excel 2010 (Microsoft, Redmond, WA) were used for image data analysis. Levels of
accumulation of individual radiotracers in tissues were expressed as standard uptake values (SUV)
that were calculated for the regions of interest (Ron S. Broide and Floyd E. Bloom) using the
AMIDE software. The SUV is defined as the ratio of the tissue radioactivity concentration C (e.g.
expressed as Bq/g tissue) at given time point post injection T, and the injected dose (e.g. in Bq,
decay-corrected to the same time T), and normalized by the body weight in grams. Formulas for
calculations for Logan plot analysis are provided in the supplemental materials (Logan J, 1996).
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Supporting Information
Quantification of dynamic PET imaging by multi-graphical analysis
To locate the exact ROI’s the Rat Brain Atlas was referenced and the corresponding maps to
PET images are shown in Fig. 15. While exact co-localization was difficult because the animal
was not perfectly planar, these images show a very close representation of the sites for metabolite
accumulation of the radiotracer. While the primary ROI of this paper is the cerebellum, the other
regions of specific uptake are quantified and shown in Fig. 16.
We used the heart-derived blood time-activity curve
(TAC) as an input function between 0 and 30 min,
because a previous study showed that blood radioactivity
BP=DVR-1
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during the first 30 min
post-i.v.
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[18F]FAHA

of
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the parent un-metabolized
compound.
The dynamic PET
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Logan
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whether
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could
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in

ROIs

Figure 15. The corresponding map and brain image for colocalization and ROI identification.

over time normalized by
the radioactivity concentration at a given time point in tumor radioactivity concentration was set
as the y-axis. The ratio of integrated reference tissue radioactivity concentration over time
normalized by tumor radioactivity concentration was set as the x-axis of a Logan plot. The cortex
was used as reference tissue, because relatively it has low HDAC4 and 5 activity or expression in
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Figure 16. The average calculated SUV quantification for each
of the ROI’s and reference tissues for all three compounds. The
error bars represent the standard deviation of the data. The stars
indicate statistical significance obtained by two-way ANOVA
with P < 0.01.

accommodate for differences in the immediate tracer uptake by tissue.
18

F-FAHA has non-specific interactions to many other HDAC enzymes in the brain.

Therefore, it shows a higher level of accumulation. The specific interaction, however, is actually
much higher for TFAHA and DFAHA because these have a very similar uptake but act on far
fewer enzymes. These conclusions are supported by the biochemical results showing that FAHA
is a substrate for many of the HDAC enzymes in all four classes. The plot in Fig. 17 is the Logan
plot given by Eq. 2 show the uptake for [18F]FAHA is very similar to that of [18F]DFAHA, while
[18F]TFAHA uptake has a steeper slope and therefore higher levels of metabolite accumulation in
the cerebellum.
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18

F-

Figure 17. The Logan plot for the primary ROI, cerebellum, with
the cortex used as a reference tissue. The stars represent statistical
significance as determined by comparison of linear regression fit
with a P < 0.01.

TFAHA-derived
accumulation displayed by autoradiography and the PET images in Fig. 15. Higher levels of
accumulation of [18F]TFAHA were observed in n. accumbens, hippocampus, periaqueductal grey,
and cerebellar nuclei.

Figure 18. Quantitative autoradiagraphy for 18F-TFAHA in the rat brain following in vivo i.v.
injection of the radiotracer and PET imaging. The rat brain atlas maps are shown with the images
for co-registration.
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Furthermore, our preliminary imaging studies in a
rat demonstrated the feasibility of PET/CT with
[18F]TFAHA for monitoring pharmacologic inhibition of
HDACs class IIa with SAHA. Significant inhibition of
[18F]TFAHA-derived radioactivity accumulation in the
brain was observed when SAHA (100 mg/kg) was
administered i.p. 30 min prior to i.v. administration of
[18F]TFAHA (Fig. 19). Additionally, we are currently
conducting expanded studies in rats to determine the IC50
values for SAHA for different regions of the brain.

Figure 19. A normal rat imaged
with 18F-TFAHA before (left) and
after (right) 100mg/kg injection of
HDAC inhibitor, SAHA.

3b. Continuing work
Due to the prevalence of HDACs 4 and 5 in the n. accumbens, hippocampus, amygdala,
periaqueductal grey, and cerebellum in the brain and immunohistochemistry data suggesting that
HDACs class IIa enzymes are overexpressed in cases of brain trauma and stress, the disease model
proposed for study is post-traumatic stress disorder (PTSD) (Kwapis and Wood, 2014; Zovkic et
al., 2013). The rat model for PTSD has been well established by Dr. Perrine’s group using a
method termed single-prolonged stress (SPS) (Eagle et al., 2013a; Eagle et al., 2013b; Knox et al.,
2010). In conjunction with Dr. Perrine’s group, the efficacy of 18F-TFAHA as an imaging agent
for PTSD will be studied in rats. The aim is to understand the changes in relative expression of
HDAC class IIa enzymes in the brain at varying time points after a traumatic event. Quantification
of

18

F-TFAHA-derived radioactivity accumulation in areas of the brain known to express high

levels of HDAC class IIa (primarily HDACs 4, 5 and 9) will be used as a method for a noninvasively monitoring changes enzymatic activity. These PET/CT images will also be compared
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against IHC stained sections from sacrificed animals at each time point (24hrs, 7d, 14d post SPS)
to verify imaging results. Furthermore, autoradiography will be done on some of these animals to
gain higher resolution images of the radioactivity distribution within the brain. These may also be
done with dual labeling to allow for comparison between C14-C6H12O6 and

18

F-TFAHA

distribution. Preliminary work in this project has demonstrated significant differences as compared
to baseline in 18F-TFAHA-derived accumulation in areas of the brain known to have high HDAC
class IIa expression-activity, especially at 24h post SPS. As this has evolved into a very large
project due to promising results, the majority of the work will be presented in a separate PhD thesis
of another student in BME.
Additionally, HDACs class IIa has demonstrated promise for treatment of cancers, There are
many HDAC targeted drugs (HDACs class I and II) currently in clinical or pre-clinical use for
treatment of lymphomas and leukemias, in particular. Recently, HDACs class IIa targeted
inhibitors have also arisen and shown promise in preclinical work for inhibiting melanoma cell
growth and proliferation (Venza et al., 2013). Furthermore, in identifying HDAC regulatory
enzymes with upregulation in a very aggressive form of brain cancer, gliomas, HDACs 4 and 5
demonstrated significant increase in expression via immunohistochemical (IHC) staining in patient
derived tissues (Protein Data Bank). Therefore, PET imaging of glioma tumor models using 18FTFAHA as an HDACs class IIa-selective imaging agent may lead to furthering the understanding
of HDAC-mediated epigenetic regulation in pathophysiology of disease.
18

F-TFAHA has shown great promise as an imaging agent for detection of glioma cancer in

the brain. In studies of both U87 and 9L rat glioma models clear detection of the tumor is
differentiable from the rest of the brain and demonstrates significantly different uptake between
structures in the brain and the tumor. This will be expanded upon in chapter 5. An example image
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for 18F-TFAHA characterization in 9L an U87 tumor models are demonstrated below in Fig. 2021. Within the tumor images, large amounts of intratumoral heterogeneity is visible as
demonstrated by the distribution of

18

F-TFAHA-derived radioactivity within the areas of tumor

tissue, i.e. areas of high and low expression activity of HDACs class IIa. Also, many differences
in HDACs class IIa expression between 9L and U87 tumors, both in degree of expression as well
as localization, are visible within these images. The localization and expression-activity of HDACs
class IIa will be compared and contrasted with SIRT1 heterogeneity in chapter 5. In summary,
HDACs class IIa are upregulated within tumor tissue as demonstrated by increases in 18F-TFAHAderived radioactivity accumulation as observed via in vivo PET/CT imaging. This finding provides
a promising opportunity for identifying treatments to slow or reverse tumor progression in this
aggressive form of cancer.

Figure 20. Dynamic PET/CT images using 18F-TFAHA in a 9L tumor-bearing rat, with
PET/CT images overlaid on MR. These images demonstrate increased accumulation of
the radiotracer in areas of the tumor lesions with relatively higher levels of HDAC activity.
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Figure 21. Dynamic PET/CT images using 18F-TFAHA in a U87 tumor-bearing rat, with
PET/CT images overlaid on MR. These images demonstrate increased accumulation of the
radiotracer in areas of the tumor lesions with relatively higher levels of HDAC activity.
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CHAPTER 4 DEVELOPMENT OF NOVEL PET IMAGING
SUBSTRATES FOR SIRT2
This work has been submitted as a provisional U.S. Patent.
Towards the development of a novel radiotracer for quantitative imaging of SIRT2
expression activity with PET, a focused library of potential substrates of SIRT2 has been
synthesized with tert-butyloxycarbonyl-lysine-aminomethylcoumarin (Boc-Lys-AMC) backbone
derivatized on the free amino terminus of lysine with a fluoroalkyl chain varying between 3 and
16 carbons in length. Enzyme kinetic studies with recombinant SIRT2 demonstrated most efficient
cleavage of the myristoyl group, followed by 12-fluorododecanoic and 10-fluorodecanoic groups
(kcat/km equals 716.5 ± 72.8, 615.4 ± 50.5, 269.5 ± 52.1 s-1M-1, respectively). Subsequently, an
aminohexanoicanilide (AHA) backbone was derivatized with 12-bromo- and 12-iododecanoic
groups

to

generate

precursors

for

radiosynthesis

of

12-[18F]fluorododecanoic

aminohexanoicanilide (12-[18F]DDAHA). In vitro uptake studies demonstrated a three-fold higher
accumulation of 12-[18F]DDAHA in U87 glioma cells with high SIRT2 activity, as compared to
MiaPaCa, MDA-MB-231, and MCF10A cells with relatively lower SIRT2 activity. Non-invasive
PET imaging with 12-[18F]DDAHA should enable in vivo studies of SIRT2-mediated epigenetic
regulation in normal physiology and in different diseases, and to facilitate the development of
novel SIRT2-targeted therapies.

4a. A novel substrate radiotracer for molecular imaging of SIRT2
expression and activity with positron emission tomography
Robin E. Bonomi, Vadim Popov, Aleksandr Shavrin, Philip Alther, Nashaat Turkman,
Thomas Mangner, Juri G. Gelovani
Introduction
SIRT2 is primarily localized in the cytoplasm, but can translocate into the nucleus (North
and Verdin, 2007a) and deacetylase of cytoplasmic alpha-tubulin and nuclear H4K16 proteins,
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thereby acting as a mitotic exit and cell cycle regulator (Hiratsuka et al., 2003; Inoue et al., 2007a;
Inoue et al., 2007c; Inoue et al., 2009; North and Verdin, 2007a; North and Verdin, 2007b). Several
studies have revealed important roles of SIRT2 in the pathogenesis of various diseases. SIRT2 can
play a neuroprotective role in neuorodegenerative diseases, such as Parkinson’s, Alzheimer’s
(Wang et al., 2013), and Huntington’s (Donmez and Outeiro, 2013). SIRT2 has been identified as
having both cancer-promoting functions (i.e., through stabilization of Myc oncoproteins in breast
cancer (Liu et al., 2013),(McGlynn et al., 2014)), as well as cancer suppressing functions (i.e.,
through tubulin regulation (Hiratsuka et al., 2003)). Therefore, SIRT2 has been identified as a
potential drug target for treatment of various neurodengenerative and inflammatory diseases, and
cancer. However, it is important to assess its activity during pharmacomodulation (i.e., activation
or inhibition) due to pleiotropic roles of SIRT2 under normal and pathologic conditions. The
development of non-invasive molecular imaging approaches for monitoring SIRT2 expression and
activity in vivo using PET with SIRT2-selective substrate radiotracer may aid in the development
of therapies targeting SIRT2.
Understanding structure-activity relationships (SAR) of SIRT2 and its endogenous substrates
is important for the development of SIRT2-specific substrate-type radiotracers. The best studied
endogenous substrates of SIRT2 are acetyl-α-tubulin and acetyl-H4K16. SIRT2, similar to other
SIRT isoforms namely 4, 5, and 6, is able to cleave larger moieties outside of the acetyl. In
particular, it has been demonstrated that SIRT2 can cleave a myristoyl group from the myristoyl(K19 and K20)TNFα (Yao and Yang, 2011).
To explore the efficiency with which SIRT2 cleaves larger leaving groups, a focused library
of potential substrates was synthesized with tert-butyloxycarbonyl-lysine-aminomethylcoumarin
(Boc-Lys-AMC) backbone derivatized on the free amino terminus of lysine with a fluoroalkyl
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chain varying between 3 and 16 carbons in length. Additionally, the influence of fluorine
substitution on the ω-carbon in the alkyl chain on substrate affinity and specificity for SIRT2 was
evaluated as well. The library of compounds was studied using a fluorogenic enzyme assay with
recombinant SIRT2 to determine trends in catalytic efficiency. Furthermore, the SAR of these
compounds with SIRT2 was investigated using in silico modeling to better understand the
observed trends (Fig. 22). Based on these studies, the lead compound, the Boc-Lys(12fluorododecanoyl)-AMC, was identified and its analogue with an aminohexanoicanilide (AHA)
backbone was synthesized (12-fluorododecanoic-AHA; 12-FDDAHA). The AHA backbone has
been used previously to generate effective HDAC class IIa specific radiotracers: [ 18F]FAHA and
[18F]TFAHA(Bonomi et al., 2015; Yeh et al., 2013a)a,19b. Additionally, the radiolabeled analogue

Figure 22. The structure of SIRT2 docked with the Boc-Lys(12F-dodecanoyl)-AMC and NAD+
adapted from crystal structure 4RMG. The SIRT2 sites of phosphorylation and binding highlighted
on the residue chart. The SIRT2 client proteins are also listed in the table and the mechanism for
NAD-dependent SIRT2 mediated cleavage of long acyl chains is depicted here.
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of the lead compound, 12-[18F]DDAHA, was synthesized from 12-iodododecanoic and 12bromododecanoic precursors. Finally, the uptake of 12-[18F]DDAHA was studied in vitro to
determine the magnitude of radiotracer accumulation in cells with high versus low SIRT2
expression.
Results:
The library of compounds with terminally fluorinated acyl chains was synthesized through
traditional coupling methods of the fluorinated carboxylic acid chain with the lysine amino
derivative via in-situ formation of an acetyl chloride in moderate yields of 20-55%. Synthesis of
the fluorinated carboxylic acid chains employed a novel approach: diethylaminosulfur trifluoride
was used for non-selective fluorination of the n-hydroxycarboxylic acid forming the acetyl fluoride
and fluorination of the terminal carbon. Selective hydrolysis of the acetyl fluoride was achieved
using flash chromatography over silica gel to form a mono-ω-fluorinated chain due to the abrupt
change

in

purity
compounds

Figure 23. The focused library of compounds synthesized with
fluroalkyl chain derivatized lysines. A) The backbone used tertbutyloxycarbonyl-L-lysine-7-amino-3-methylcoumarin (Boc-LysAMC) was coupled to fluoroalkyl chains, varying in length from 3
carbons to 16 carbons using acetyl chloride coupling.

pH.
of

The
final

in

the
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library was >95%, as determined by 1H-NMR, 13C-NMR, 19F-NMR, and HRMS (Fig. 23).
Compound 11 was synthesized from Cbz-Lys-OH (Bachem) and Boc-Lys-AMC (Bachem),
which was derivatized to Boc-Lys(myr)-AMC. Following myristoylation, the Boc protecting
group was removed and the resulting free lysine amino terminus was coupled with the Cbz-LysOH group. The four-step synthesis yielded 11 in a yield of 12% with >95% purity as determined
by 1H NMR, 13C NMR, and HRMS (Fig. 24).
Results from in vitro characterization of this library of compounds using fluorogenic assay
demonstrated a positive correlation between the substrate efficiency for SIRT2 and the increasing
length of the leaving alkyl chain. Compound 9 containing the myristoyl group was the most
efficient substrate of SIRT2 with Kcat/Km = 715.6±72.8 s-1M-1followed by compound 8
(fluorododecanoyl) and compound 7 (fluorodecanoyl) with Kcat/Km of 615.4±50.5 s-1M-1 and

Figure 24. To experimentally determine the effect of the cap on the selectivity of
a substrate for SIRT2 we developed a di-lysine substrate, with a more peptidic
backbone, Cbz-lys-lys(myr)-AMC (11). This allows for head to head comparison
between the Boc-lys(myr)-AMC (9).
269.5±52.1 s-1M-1, respectively. In contrast, compound 10 containing the fluoropalmitoyl leaving

63

1000

-1

M

-1

)

800

K c a t/ K m ( s

600

400

200

S

1

C
P

y

B

r)

-A

-A

M

M

C

C
M
y

(m

o
it
y

s

lm

-L

a

s

(p

y

s

L

y
C

b

z-

-L
c
B

o

l)

l)
y
to

s
ri
y
(m

s
y
-L
c

o
B

(1

B

o

c

B

o

-L

c

y

s

-A

M
-A
l)
y

o
n
a
c
e

d
o
-d

2

F

(1
s
y

C

C
M
-A
l)

y
o
n
a
c

F
0

F
(6
s
y
-L

-L
c
o
B

-d

e
-h

ro
-p
F
(3
s
y
-L
c
o
B

e

x

p

a

a

n

n

o

o

y

y

l)

l)

-A

-A

M

M

C

C

0

Compound
Boc-Lys(3F-propanoyl)-AMC (5)
Boc-Lys(6F-hexanoyl)-AMC (6)
Boc-Lys(10F-decanoyl)-AMC (7)
Boc-Lys(12F-dodecanoyl)-AMC (8)
Boc-Lys(myristoyl)-AMC (9)
Boc-Lys(fluoropalmitoyl)-AMC (10)
Cbz-Lys-Lys(myr)-AMC (11)
BPS1

Km
(μM)
53.53
44.89
18.03
8.07
2.36
51.15
10.36
31.73

Stand. Vmax
Stand.
Stand. Kcat/km Stand.
Kcat (s-1)
Dev. (uM/sec) Dev.
Dev. (s-1, M-1) Dev.
11.44
4.56
4.07
0.79
0.22
6.91
1.30
5.57

0.15
0.28
0.52
0.54
0.26
0.33
0.60
0.95

0.016
0.013
0.041
0.014
0.010
0.022
0.022
0.022

1.41E-03
2.58E-03
4.86E-03
4.97E-03
2.38E-03
3.09E-03
5.51E-03
8.78E-03

5.00E-04
4.11E-04
1.29E-03
4.25E-04
3.03E-04
6.83E-04
6.88E-04
6.98E-04

26.3
57.4
269.5
615.4
716.5
60.4
532.3
275.0

5.07
5.22
52.2
50.5
72.9
7.31
56.2
42.6

Fig. 25. Biochemical assay data from fluorogenic (Fluor de Lys®) assay. A) The catalytic
efficiency (kcat/km) for SIRT2 against different length fluoroalkyl chain leaving groups to assess
the structure activity relationship between these compounds and SIRT2. The error bars represent
the standard deviation of N=6 experiments. B) The table details the effect on km (amount of
substrate necessary for half of vmax), vmax (the maximal turnover velocity for a given substrate in
SIRT2), and kcat (the catalytic efficiency for a given substrate with SIRT2).
group exhibited a significant decrease in substrate efficiency for SIRT2 (30.4±7.3 s-1M-1), as
compared to compounds containing shorter fluoroalkyl chains. The reference substrate, p53(379382)K382ac-AMC (BPS1) exhibited Kcat/Km = 275±42 s-1M-1 (Fig. 25).
To assess the influence of a “cap” modification on SIRT2 selectivity, compounds 4, 5 and 7
were evaluated against a panel of recombinant sirtuins (SIRT1-7). 7 was cleaved efficiently by
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SIRT2, SIRT3 and, to a lesser
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extent, by SIRT6. In contrast, 8

validate the catalytic efficiency
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an IC50 of 28.21µM (Fig. 27).
In silico modeling studies
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and 9 were cleaved efficiently

)

*

S ir t u in E n z y m e Is o f o r m

Figure 26. Compound 11 is not selective for SIRT2 whereas
compounds 8 and 9 are selective for SIRT2. These results
were taken from 40-minute incubation of substrate with
enzyme. The error bars represent the standard deviations of
the means with significance of P<0.05 denoted by *, as
determined by two-way ANOVA.

demonstrated that positioning
of compounds 8 and 9 in the SIRT2 active site resulted in a smaller distance between the carbonyl
carbon and the nicotinamide-ribose ester linkage (Fig. 28). This may contribute to enhanced
substrate efficiency of these compounds.
12-fluorododecanoyl-AHA

(12-FDDAHA)

and

12-[18F]-dodecanoylAHA

(12-

[18F]DDAHA) were synthesized as non100

8 (Fig. 29-30). The initial radio-synthesis
18

of 12-[ F]DDAHA (15) was performed
using a brominated precursor, 12Br-

% a c t iv it y

radiolabeled and radiolabeled analogues of
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0
-1 0

DDAHA (13), however due to low
radiochemical

yield,

the

iodinated

precursor, 12I-DDAHA (14), was used for
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A G K 2 c o n c e n t r a t io n ( u M )

Figure 27. Boc-Lys(12F-dodecanoyl)-AMC (8)
was used to experimentally determine the IC50
value for a known inhibitor AGK2.
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optimization of the radiolabeling procedure and improve radio-synthetic yield. The iodinated
precursor (14) was synthesized from the brominated precursor in a high yield of 73% using
literature procedure(Belanger et al., 2011). The radiochemical yield achieved with precursor 14
was 5-fold higher than that with precursor 13. The highest radiofluorination yields were achieved

A

B

Figure 28. A) The 2D representation of the interactions between SIRT2 and the substrate, BocLys(12F-dodecanyl)-AMC. The 12-fluoro dodecanyl leaving group has similar interactions to
those in literature, evidence that the leaving group is fitting in the correct position. B) The table
of results from our compound docking study. The compound name, MW, docking score (where
more negative is a better fit), and most importantly, the distance between the 1’ postion of the
ADP ring and the carbonyl of the leaving group. This distance is also shown after the 1.7Å
correction for catalytic conformational change.
using precursor 14 in acetonitrile at 85-90°C. 12-[18F]DDAHA was obtained with purity of >95%
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(Fig. 30) and a decay corrected radiochemical
yield of 12% (total preparation time: 66 min)
with specific activity of 259 Gbq/mmol.
The level of uptake of 12-[18F]DDAHA
in cell cultures after 30 minutes of incubation
in vitro was significantly above the cells-toFigure 29. A) The backbone used for
enzymatic in vitro biochemical assays- BocLys-AMC. B) The backbone developed for
improved systemic viability of a small
molecule radiotracer.

culture medium equilibrium and was 3-fold
higher in U87-NesTG cells, expressing higher
levels of SIRT2, as compared to MiaPaCa,

MDA231, MCF10A, expressing relatively lower levels of SIRT2 (Fig. 31).

Figure 30. A) The synthesis of both the cold (non-radiolabeled) analogue (13) and B)
precursors for 12-[18F]DDAHA, 12-BrDDAHA (13) and 12-IDDAHA (14). The 12[18F]DDAHA (15) radiotracer was synthesized from the iodinated precursor and the in dry
acetonitrile in 85°C for 15 minutes.
Discussion
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Understanding structure-activity relationships of SIRT2 with various natural and synthetic
substrates to develop novel
18

F-labeled radiotracers for

quantitative

molecular

imaging of SIRT2 expression
and activity, it is important to.
Previously it has been reported
that in addition to an acetyl
group, SIRT2 can also cleave
long acyl chains from lysine
residues, including a myristoyl
moiety (He et al., 2014). Other

Figure 31. The quality control chromatogram of the 12[18F]DDAHA (15) radiotracer as analyzed by HPLC
demonstrates high radiochemical purity and very small
amount of UV impurities. A) The UV non-radiolabeled
standard chromatogram (12) B) The radio-HPLC
chromatogram for the labeled 12-[18F]DDAHA, (15).

HDAC class III enzymes, such
as SIRT3 and SIRT6, have also been reported to cleave a myristoylated lysines of the H3K9
peptide (Feldman et al., 2013; Feldman et al., 2015) and K19-20TNF-α (He et al., 2014). However,
there are no data on the effects of fluorine substitution on the ω-carbon in alkyl chains on different
lengths on SIRT2 catalytic efficiency.
Our current studies demonstrated that the catalytic efficiency of SIRT2 gradually increases
with the elongation of fluoroalkyl chain from 3 to 12 carbons. The catalytic efficiency of SIRT2
for fluorododecanoyl chain (Kcat/Km = 615.4±50.5 s-1M-1) is comparable (difference is not
statistically significant) with that of the non-fluorinated myristoyl chain (reference compound),
which is cleaved most efficiently (Kcat/Km = 716.5±72.8 s-1M-1). In contrast, the catalytic efficiency
of SIRT2 was significantly lower for the fluoropalmitoyl group (Kcat/Km = 60.4±7.3 s-1M-1) (Fig.
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25). These observations are in agreement with previous reports, demonstrating a similar trend in
SIRT2 catalytic efficiency for the H3K9 peptide backbone derivatized with hexanoyl, octanoyl,
decanoyl, dodecanoyl, and myristoyl groups, but significantly less efficiently the palmitoyl and
lipoyl-derivatized H3K9 peptide (Feldman et al., 2013; Feldman et al., 2015). Similarly, using
TNF-α peptide backbone with varying chain lengths to a fluorophore or quencher moiety the
longer chain length (11 carbons) resulted in much improved catalytic efficiency over the shorter
(6 or 8 carbons) or very long (13 carbons) chain lengths(Schuster et al., 2016). However, despite
the similarities in trends, the absolute Kcat/Km values obtained in the current study for different
alkyl chains with Boc-Lys-AMC backbone

U p t a k e C e lls /M e d ia
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are significantly lower than those reported
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Figure 32. The radiotracer 12-[18F]DDAHA (15)
was used in cellular uptake studies for four tumor
cell lines. The error bars represent the standard
deviation for N=4 for each cell line. Where ****
represents P<0.05 as determined by One-Way
ANOVA and Tukey’s multiple comparisons test
this value is significantly larger than the other
three values.

efficiency of a peptide “cap” group, as
compared to Boc-Lys-AMC. Similarly,
reports of a “cap” group containing either
p53 or TNF-α peptide residues on one side
and an AMC

group

on the other

demonstrate reduced Kcat/Km as compared
to compounds with a full peptide cap (Chiang and Lin, 2016; Feldman et al., 2015; Schuster et al.,
2016). Also, the observed differences may be due to the presence of electronegative ω–terminal
fluorine. In the current study, the Kcat/Km values were determined by measuring the rate of the
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AMC cleavage product formation, whereas in some of the previously reported data Kcat/Km values
were determined by measuring the rate of NAD+ consumption, which may also explain the
differences in absolute Kcat/Km values between studies.
Furthermore, results of current in silico modeling studies demonstrate that the distance
between the carbonyl-carbon to the ADPR-nicotinamide ester linkage is smaller for longer chain
leaving groups, such as the fluorododecanoyl derivatized Boc-Lys-AMC and AHA backbones
(Fig. 29). These in silico docking studies were conducted using currently available crystal
structures of SIRT2, which depict the enzyme in either the “closed” or “open” confirmation (i.e.
before or after enzymatic reaction with a substrate). Because there are no crystal structures
available for SIRT2 in the transition state with bound NAD+, we chose the structure of SIRT2 cocrystallized with SirReal2 (SIRT2 inhibitor) and NAD+(Rumpf et al., 2015) (PDB: 4RMG). This
crystal structure with full NAD+ intact, rather than post cleavage with only ADPR present (Moniot
et al., 2013), is indicative of an enzyme in the open confirmation when a substrate initially docks
inside the enzyme active site. This step is especially important for the SIRT enzymes, as the close
proximity and accurate positioning between nicotinamide and the substrate carbonyl moiety is
crucial for the reaction to occur. The root mean square deviation (r.m.s.d) for the central carbon
during the transition from the “open” to “closed” conformation has been characterized in the
literature (Rumpf et al., 2015), allowing estimation of the changes in key interaction distances.
The r.m.s.d of the open versus closed configuration is about 1.7Å in PDB 4RMG. Using this
correction factor, the distances between a leaving group carbonyl and a nicotinamide of NAD+
ring fall into an acceptable range for reaction to occur. Other studies have explored the structural
activity in 5 ns molecular dynamic simulations and noted similar findings for the structural changes
in the SIRT2 active site (Sakkiah et al., 2013). Therefore, we hypothesize that the distance between
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the amide bond carbonyl carbon and the nicotinamide cleavage site of NAD+ plays an important
role in substrate catalytic efficiency of SIRT enzymes. The mechanism of SIRT2 mediated
cleavage of acylated lysine moieties involves simultaneous cleavage of nicotinamide and
activation and subsequent cleavage of the acyl carbonyl carbon amide bond. Therefore, the
selection of site for with substitution fluorine atom (strongly electronegative and electron
withdrawing) is crucial for preservation of catalytic activity of SIRT2. For example, if a fluorine
atom (or another electron withdrawing group) were to be placed in close proximity to the α-carbon,
catalytic efficiency would decrease, as reported by us previously for fluro- and trifluoroacetamidohexanoicanilide (Bonomi et al., 2015; Yeh et al., 2013a).
To examine the selectivity of compounds for SIRT2 among all SIRT enzymes, three of the
most efficient substrates, 8, 9, and 11 were screened against a panel of recombinant SIRT enzymes
(SIRT 1-7). The aim was to elucidate the differences in SIRT selectivity that may occur as a result
of altering the cap (mono- vs. di-lysine cap), the leaving group (12- vs 14-carbon chain) and last
the terminal fluorine atom (12F-carbon vs 14-carbon). Our results indicate that compound 11, with
a di-lysine cap, was cleaved more effectively by SIRT3 and SIRT6 than compound 5, with a monolysine cap. Therefore, 9 is more selective to SIRT2 as it shows very little cleavage by other SIRT
enzymes. Both 8 (12F-carbon chain) and 9 (14-carbon chain) are cleaved effectively by SIRT2
and not by any other SIRT enzymes, indicating that both leaving groups are selective for SIRT2.
These findings are consistent with other reports in the literature (Feldman et al., 2013; He et al.,
2014; Pan et al., 2011b) and demonstrate that leaving group specificity may not entirely define the
selectivity of a substrate to a certain SIRT enzyme. Altering the cap group can have a significant
impact on the efficiency with which the SIRT enzyme cleaves a substrate.
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Also, we assessed the effectiveness of the lead substrate 8 against a potent selective SIRT2
inhibitor AGK2 (Cui et al., 2014). A competitive inhibition study (Cui et al., 2014) was performed
using increasing concentrations of AGK2 with 8 at its apparent km concentration (8 µM) for SIRT2.
The observed inhibition of SIRT2 by AGK2 at IC50 of 28.21 μM (Fig. 27) using 8 as substrate was
comparable to previously reported IC50 values of 3-5 µM obtained with myristoylated or acetylated
substrates of SIRT2(Hoffmann et al., 2014; Lain et al., 2008). As demonstrated by the comparable
catalytic efficiencies of 8 and BPS1 (p53 (379-382)K382ac-AMC) this data further confirm that 8
is an efficient substrate of SIRT2.
Based on the results of biochemical and in silico modeling studies, we have chosen the
dodecanoyl chain fluorinated on the ω-position for coupling to an AHA backbone to generate the
SIRT2-specific

18

F-labeled radiotracer termed 12-[18F]DDAHA. We did not study the 14-

fluoromyristoyl-Boc-Lys-AMC

and

14-[18F]fluoromyristoyl-AHA,

because

Boc-Lys(12-

fluorododecanoyl)-AMC exhibits 2/3 efficiency of Boc-Lys(myristoyl)-AMC as selective
substrate for SIRT2, and because radiotracers with smaller molecular weight have
pharmacokinetic advantages over radiotracers with larger molecular weight. Nevertheless, the
synthesis and evaluation of these compounds are currently underway and will be reported
separately. For synthesis of 12-[18F]DDAHA, we adapted methods for radiolabeling of ω[18F]substituted long chain fatty acids (Belanger et al., 2011), that are used for PET imaging of
cardiac metabolism (Pandey et al., 2012) (Fig. 30-31). Our studies confirmed previous reports that
ω-iodinated dodecanoyl precursor provides a 3-fold higher radiosynthetic yield than the ωbrominated precursor (Belanger et al., 2011). The radiosynthetic yield for 12-[18F]DDAHA could
be optimized further by using microwave assisted heating (Belanger et al., 2011).

72

The mechanism of substrate cleavage by SIRT enzymes allows for a radioactive leaving
group to be transiently entrapped in the cell in a similar manner to other radiotracers such as 18FFDG and 18F-FLT, by converting or coupling a tracer into a more polar molecule. In this case, an
ester linkage between a leaving group and O-ADPR (Fig. 22) forms, thereby preventing the
leaving group from crossing a cell membrane because 18F-fluoroalkyl-O-ADPR is quite large and
polar. Therefore, SIRT2-mediated cleavage of 18F-fluoroalkyl group from 12-[18F]DDAHA with
formation of

18

F-fluoroalkyl-O-ADPR complex represents the rate-limiting step in the cellular

entrapment of 12-[18F]DDAHA-derived radioactivity. The removal of the acetyl or longer acyl
chain moieties from O-ADPR group has been hypothesized to occur by way of ARH3 cleavage or
possible methanolysis to form 1’O-methyl’ADPR (Fahie et al., 2009; Mashimo et al., 2014).
Additionally, a nucleophilic attack from lysine side chains of other proteins in close proximity may
also de-acetylate the O-AADPR. Further studies are needed to fully characterize the half-life of O12-[18F]DD-ADPR and residence time for the 12-[18F]dodecanoyl moiety within the cell. Although
this entrapment may be transient, it should provide a long enough residence time within the cell
for adequate PET imaging and quantification of SIRT2 expression-activity product.
In vitro radiotracer uptake studies in cell lines with varying degrees of SIRT2 expression
provided initial evidence for the efficacy of 12-[18F]DDAHA as a radiotracer for quantification of
SIRT2 expression-activity. The level of 12-[18F]DDAHA derived radioactivity accumulation was
increased three fold in U87 glioma cells over other cells with relatively lower SIRT2 expression
(i.e. MiaPaCa, MDA-MB-231, and MCF10A) (Fig. 32). Previous studies demonstrated
downregulation of SIRT2 expression in about 70% of gliomas (Hiratsuka et al., 2003; Inoue et al.,
2007b). In contrast, more recent studies demonstrated that the labeling index of nuclear-localized
SIRT2 is significantly higher in glioblastomas (grade IV), as compared to astrocytomas (grade II)
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and normal brain tissue and strongly correlated with malignant progression and the overall survival
of patients with glioblastomas (Imaoka et al., 2012). The immunohistochemical staining of many
tissues in the Human Protein Atlas displays intense staining of SIRT2 protein in all glioma tissues
with greater magnitude than in breast or pancreatic cancer patient derived tissue samples
(http://www.proteinatlas.org/search/sirt2). Higher levels of expression and higher labeling index
for SIRT2 is also associated with progression and poor prognosis in patients with non-small cell
lung cancer (NSCLC) (Grbesa et al., 2015) and cervical carcinoma(Singh et al., 2015). Some
tumors (i.e., melanomas), may harbor mutations in SIRT2 gene resulting in reduction of enzymatic
activity by 80–90% compared to the wild-type protein, however consequences to tumor
progression and overall prognosis are yet unknown (Lennerz et al., 2005). Therefore, molecular
imaging with PET using SIRT2-specific radiotracers should provide information about the location
and magnitude of SIRT2 expression and activity in tumors non-invasively and in real time. This
may help to determine the mechanistic, therapeutic, and prognostic roles of SIRT2 in different
cancers. Also, SIRT2 is an emerging target for therapy of various neurologic diseases, including
neurodegeneration (Donmez and Outeiro, 2013), as well as cardiac (Matsushima and Sadoshima,
2015) and metabolic diseases (Houtkooper et al., 2012; Matsushima and Sadoshima, 2015).
The translation of 12-[18F]DDAHA to in vivo PET imaging may further the field of
epigenetic regulation in both norm and disease and facilitate development and clinical translation
of SIRT2-targeted drugs. PET imaging with a substrate type radiotracer such as 12-[18F]DDAHA,
will allow for in vivo visualization and quantification of the enzyme expression-activity product.
Accumulation of 12-[18F]DDAHA-derived radioactivity is directly proportional to the amount of
active enzyme in a tissue. The current approach to imaging SIRT2 activity using substrate-type
radiotracers complements other methodologies for PET imaging of enzymes, including
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radiolabeled inhibitors. PET imaging with radiolabeled enzyme inhibitors is essentially similar to
a receptor-ligand based imaging approach, where the amount of radiotracer-derived radioactivity
accumulation is proportional to the amount of free (unoccupied) receptor or enzyme in a given
tissue (J, 2000). Visualization of receptor or enzyme occupancy is especially important for
determining the pharmacokinetics and bio-distribution of an inhibitor (i.e. drug or therapeutic
agent). Successful inhibitor-type radiotracers have been developed specifically for HDAC class I,
in the form of 11C-Martinostat (Kim et al., 2013; Reid et al., 2009a; Wey et al., 2015). However,
imaging with an inhibitor does not provide information about the enzyme activity. In contrast,
substrate-type radiotracers allow for assessment of the enzyme expression-activity and monitoring
the pharmacodynamics of inhibitor at the target (enzyme) level.
Although several previous studies have reported significant defluorination of ω[18F]substituted fatty acids in rodents following intravenous injection (Pandey et al., 2012), it
occurs at a much lower magnitude in higher mammals (i.e. pigs and dogs) and in humans, due to
a decrease in level of expression of defluorinating enzymes (Pandey et al., 2012). The AHA
backbone was selected based on our previous success with the development of HDAC class IIa
specific radiotracers

18

F-FAHA and

18

F-TFAHA(Bonomi et al., 2015; Yeh et al., 2013a) and

because the use of peptide-based backbones will prevent (or significantly reduce) the ability of
radiotracers to cross cellular membranes by non-facilitated diffusion. Although it is still possible
that 12-[18F]DDAHA may exhibit unacceptable levels of defluorination in vivo, an alternative site
for radiofluorination may be explored in the ω-3 position of dodecanoyl chain. Alternatively,
carbon-11 labeling of the dodecanoyl chain could be accomplished similar to 11C-palmitate (Mock
et al., 2011; Runkle et al., 2011).
Conclusions
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In summary, guided by the results of biochemical and in silico modeling studies of structureactivity relationships between SIRT2 and a non-peptide type lysine mimicking substrate backbone
derivatized with fluoroalkyl chains of different length, we have developed and validated in vitro a
novel SIRT2-selective substrate-type radiotracer termed 12-[18F]DDAHA. 12-[18F]DDAHA is
suitable for assessment of SIRT2 expression-activity using in vitro radiotracer uptake assays in
cell cultures and potentially for in vivo PET imaging of SIRT2 expression-activity in normal and/or
diseased organs and tissues. Molecular imaging with PET using SIRT2-specific radiotracers, such
as 12-[18F]DDAHA, should provide information about the location and magnitude of SIRT2
expression and activity in tumors non-invasively and in real time, which should help to determine
the mechanistic, therapeutic, and prognostic roles of SIRT2 in different diseases.
Experimental Methods
All solvents were purchased from Sigma-Aldrich Chemicals (Milwaukee, WI) and used
without further purification. Boc-Lys(Ac)-AMC and Cbz-Lys-OH were purchased from Bachem
(Bubendorf, Switzerland) and used without further purification. Preparation of 6-amino-1hexanoicanilide (Mukhopadhyay et al., 2006) was synthesized using a previously published
procedure (Mukhopadhyay U, 2006b). Thin layer chromatography (TLC) was performed on precoated Dynamic Absorbance F-254 silica gel, aluminum backed plates (Norcross, Georgia); flash
chromatography was performed using silica gel pore size 60 Å, 230-400 mesh particle size
(Sigma-Aldrich, Milwaukee, WI).
NMR spectra including 1H, 13C and 19F were performed on Mercury 400 MHz, Varian 500
MHz or Agilent 600 MHz spectrometers. High-resolution mass spectra (HRMS) were obtained
using Waters LCT Premier/XE spectrometer (Milford, MA) with an electrospray ionization (ESI)
technique. The analytical high performance liquid chromatography (HPLC) system included:
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Ascentis RP-Amide 4.4x150 mm column (Supelco, Bellefonte, PA) connected to the 1100 series
pump and UV detector (Agilent Technologies, Stuttgart, Germany), operated at 254 nm, and a
radioactivity detector FC3200 (Eckert and Ziegler Radiopharma, Inc, Berlin, Germany). The semipreparative HPLC system included: the Alltima 250x10mm C18 column (Fisher Scientific,
Waltham, MA) connected to the P4.1S pump, Azura 2.1S UV detector (Knauer, Berlin, Germany),
operated at 254 nm, and a radioactivity detector FC-3500 (Eckert and Ziegler Radiopharma, Inc,
Berlin, Germany).
SIRT Enzyme Assay: Recombinant SIRT1-7 enzymes and BPS1 reference substrate for
SIRT2, an oligopeptide corresponding to 379-382 of p53 (Arg-His-Lys-Lys(Ac)-AMC)
(Huhtiniemi et al., 2011; Marcotte et al., 2004) were purchased from BPS Bioscience (San Diego,
CA). 10 mM solutions of all newly synthesized compounds were prepared in pure DMSO and then
diluted to 100 μM aliquots in DMSO for further use. Enzyme assay reactions were performed in
black, low binding 96-well microtiter plates (Nagle Nunc International, Rochester, NY). End point
assays were performed by incubation of the appropriate substrate, NAD, a SIRT enzyme, and
inhibitor (if applicable) in enzyme assay buffer (50 μL final volume). Control wells without
enzyme were included in each plate. After 40 min at 37 °C, a developer mixture (50 μL) containing
nicotinamide (2 mM) and trypsin (0.4 mg mL−1) was added, and the mixtures incubated for 30 min
at 22°C. The intensity of cleaved 7-amino-4-methylcoumarin (AMC) fluorescence was measured
using Synergy H1 microplate reader (Biotek, Winooski, VT) at 360 nm excitation and 450 nm
emission wave lengths. Experiments for determination of enzyme kinetic parameters were
performed by incubation of test compounds or BPS1 reference substrate at different concentrations
with NAD+ and individual SIRT enzymes in an assay buffer (100 μL final volume) at 37°C for
different periods of time (5, 10, 20, 30, and 60 min), followed by in situ fluorophore cleavage by
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addition of a developer mixture (50 μL) containing nicotinamide (2 mM) and trypsin (0.4 mg
mL−1). Fluorescence was measured as relative fluorescence units (RFU) at 22°C to determine the
initial linear rate V0 (RFU min−1) for each concentration. The data were analyzed using GraphPad
Prism v6.02 (GraphPad, La Jolla, CA) to afford km (μM) and Vmax (RFU min−1) values. The kcat
values were calculated based on the RFU vs AMC concentration standard curve and the enzyme
purities and concentrations provided by the manufacturer.
Computational Docking Studies: Schrodinger Suite (New York, NY) with the Glide(Zhu
et al., 2014) docking program was used for simulating ligand-protein interactions in silico. The
ligands were prepared using LigPrep (Sastry et al., 2013) in Maestro v10.3 and the lowest 5 energy
states were used for covalent docking interactions. Epik was used to generate the tautomeric states
and choosing the lowest Epic (Shelley et al., 2007) ionization state. The protein, SIRT2 (PDB:
4RMG) was prepared with the Protein Preparation Wizard (Sastry et al., 2013). A Cartesian
coordinate receptor grid was generated on SIRT2 by positioning the prereaction form of the ligand
in the binding site close to the NAD+. The affinity score is given as a Glide score based on the
binding mode of the ligand with the protein where the optimal interactions are represented by a
low Glide score (Friesner et al., 2004). The distance between the NAD+ and the carbonyl-carbon
of the leaving group cleavage site was calculated manually using the Measure Distance
functionality.
Cell cultures and in vitro Radiotracer Uptake Studies: The U87MG, MiaPaca, and MDAMB-231 cell lines were obtained from the American Type Tissue Culture Collection (ATCC); the
MCF10A cell line was obtained from the cell culture repository of the Karmanos Cancer Institute
(Detroit, MI). Tumor cells were propagated in DMEM supplemented with 10% fetal calf serum
(FCS), penicillin and streptomycin, at 37°C in a humidified atmosphere with 5% CO2. In vitro
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radiotracer uptake studies were performed as previously described (Yeh et al., 2013c). Briefly,
prior to in vitro radiotracer uptake experiment, the cells were inspected for confluency and
viability. Each of the four cell plates for a given cell line had the media removed by pipette
aspiration, and fresh media (15mL) containing the radiotracer (1-2uCi/mL) was added to cells in
the culture plates. The tumor cell monolayers were incubated with the radioactivity-containing
medium for 30 minutes. The cells were then harvested by gentle unidirectional scraping and the
suspensions of cells in the media were transferred into 15mL conical centrifuge tubes and pelleted
by centrifugation (3000 rpm for 2 min). 50uL samples of supernatant and cell pellets flash-frozen
on dry ice were placed in pre-weighed scintillation vials, weighed, and the radioactivity was
measured using Pakard 5500 gamma counter (Perkin Elmer, CA). The background-corrected and
decay-corrected radioactivity concentrations in individual cell pellets (cpm/g) was divided by
corresponding cell culture media samples (cpm/g) to determine the fold increase of radiotracer
accumulation in cells versus the cell culture media.
Chemical Synthesis:
Synthesis of ω-fluorinated acyl chains: 3-fluoropropionic acid was purchased from Santa
Cruz Biotechnology (Dallas, TX) and used without further purification. 10-hydroxydecanoic acid,
12-hydroxydodecanoic acid, and 16-hexadecanoichydroxyhexadecanoic acid were purchased
from Sigma Aldrich (Milwaukee, WI) and used for synthesis of ω-fluorinated carboxylic acid
chains. The n-hydroxycarboxylic acids were treated with molar excess of diethylaminosulfur
trifluoride (DAST) at 0°C for 5-10 minutes. Immediately following, the reaction mixture was
transferred dropwise to 5 ml of hexane resting on a small plug of silica gel primed with hexane to
selectively hydrolyze the acetyl fluoride formed during the DAST reaction. The compounds were
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eluted from the silica using 50:50 ethyl acetate/hexane and they were used without further
purification for formation of acetyl chloride and coupling to the lysine derivative.
tert-Butyl

(7-(3-fluoropropanamido)-1-((4-methyl-2-oxochroman-7-yl)amino)-1-

oxoheptan-2-yl)carbamate (5): 3-Fluoropropionic acid (61.7 mg, 0.66 mmol) was dissolved in
acetonitrile with 1 equivalent of N,N'-dicyclohexylcarbodiimide (DCC) (155 mg) and a catalyst
amount of 4-dimethylaminopyridine (DMAP) (few crystals). The mixture was stirred at 22°C
under argon for 10 minutes. Subsequently, Boc-Lys-AMC (188 mg, 0.46 mmol) was dissolved in
7 mL of dichloromethane (DCM) with 1 equivalent of triethylamine (TEA) and added dropwise
to the reaction mixture. The reaction was stirred continuously at 22°C, under argon, for 12 hours.
Following completion of the reaction, the solvent was evaporated and the compound was purified
by column chromatography using a gradient of 0.5-2% methanol/dichloromethane for elution. The
product was obtained in 85% yield as an off white powder. 1H NMR (400 MHz, CDCl3) δ 9.42 (s,
1H), 7.68 (s, 1H), 7.47 (s, 1H), 7.38 (s, 1H), 7.26 (s, 1H), 6.20 (s, 1H), 6.14 (s, 1H), 5.54 (s, 1H),
5.29 (s, 1H), 4.79 (t, J = 5.6 Hz, 1H), 4.67 (t, J = 5.6 Hz, 1H), 4.30 (s, 1H), 3.51 – 3.37 (m, 1H),
3.35 – 3.16 (m, 1H), 2.60 (dd, J = 15.3, 9.7 Hz, 1H), 2.54 (t, J = 5.6 Hz, 1H), 2.38 (s, 2H), 1.45 (s,
H), 1.94 – 1.88 (m, 2H), 1.82 – 1.62 (m, 2H), 1.57 (dd, J = 16.4, 11.8 Hz, 2H), 1.30 (dt, J = 17.4,
13.0 Hz, 2H), 1.20 – 0.99 (m, 2H). 19F NMR (376 MHz, CDCl3) δ -217.96 (tt, J = 47.0, 27.5 Hz).
HRMS (+ESI-TOF) m/z for C25H35N3O6 [M+Na]+ calculated: 493.5802; found: 493.2097
tert-Butyl

(7-(6-fluorohexanamido)-1-((4-methyl-2-oxochroman-7-yl)amino)-1-

oxoheptan-2-yl)carbamate (6): 6-Bromoethylhexanoate (1 g) was dissolved in 10 mL of TBAF
and stirred at 80°C for 3 hours. The resulting mixture was evaporated and purified by column
chromatography using 10% ethyl acetate in hexane as the eluent. The ethyl protecting group was
hydrolyzed by 100ul of 15wt% sodium methoxide in methanol. The following mixture was

80

evaporated and 2 mL of thionyl chloride (SOCl2) was added to the residue. The resulting mixture
was stirred at 60°C, under reflux, for 3 hours. Following the reaction, all SOCl2 was evaporated
and the product was washed with toluene before being evaporated once more. Boc-Lys-AMC
(Bachem (92 mg, 0.24 mmol) was dissolved in 10 mL of dichloromethane with 1 equivalent of
TEA. The mixture was added dropwise to the flask containing the acetyl chloride residue, and the
reaction was stirred continuously at 22°C, under argon, for 12 hours. Following completion of the
reaction, the solvent was evaporated and the compound was purified by column chromatography
using a gradient of 3-5% methanol/dichloromethane for elution. The product was obtained in 20%
yield as an off white powder. 1H NMR (600 MHz, CDCl3) δ 11.20 (s, 1H), 9.40 (s, 1H), 7.68 (s,
1H), 7.45 (s, 2H), 7.42 (s, 2H), 7.25 (d, 2H), 6.13 (s, 1H), 5.95 (s, 1H), 5.50 (s, 1H), 4.45 (t, J =
5.9 Hz, 1H), 4.37 (t, J = 5.7 Hz, 1H), 4.28, 3.33 – 3.26 (m, 1H), 3.23 (dd, J = 13.3, 6.7 Hz, 1H),
2.99 (d, J = 4.3 Hz, 1H), 2.55 (s, 2H), 2.37 (s, 2H), 2.18 (t, J = 7.4 Hz, 2H), 1.77 – 1.62 (m, 7H),
1.57 (dd, J = 13.8, 6.9 Hz, 3H), 1.50 – 1.40 (m, 14H), 0.95 (t, J = 7.1 Hz, 2H).

13

C NMR (151

MHz, CDCl3) δ 173.2, 171.4, 161.1, 154.5, 152.3, 141.5, 125.0, 123.6, 115.8, 115.6, 113.2, 107.1,
83.9 (d, J = 164.4 Hz), 80.4, 77.0 76.8, 60.0, 55.0, 52.2, 48.6, 38.3, 36.5, 31.2, 30.1 (d, J = 19.5
Hz), 28.8, 28.3, 25.3, 25.1, 25.0, 24.9, 22.5, 20.1, 18.5, 13.5.

19

F NMR (376 MHz, CDCl3) δ -

175.21 – -184.59 (m). HRMS (+ESI-TOF) m/z for C28H41N3O6 [M+Na]+ calculated: 535.66;
found: 535.2642
tert-Butyl

(7-(10-fluorodecanamido)-1-((4-methyl-2-oxochroman-7-yl)amino)-1-

oxoheptan-2-yl)carbamate (7): 10-Fluorodecanoic acid (45 mg, 0.24 mmol) was dissolved in
excess SOCl2 (1 mL, 1.3 mmol) and stirred at 60°C, under reflux, for 3 hours. Following the
reaction, all SOCl2 was evaporated and the product was washed with toluene before being
evaporated once more. Boc-Lys-AMC (96 mg, 0.24 mmol) was dissolved in 7 mL of
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dichloromethane with 1 equivalent of TEA. The mixture was added dropwise to the flask
containing the acetyl chloride residue, and the reaction was stirred continuously at 22°C, under
argon, for 12 hours. Following completion of the reaction, the solvent was evaporated and the
compound

purified

by

column

chromatography

using

a

gradient

of

3-5%

methanol/dichloromethane for elution. The product was obtained in 55% yield as an off white
powder. 1H NMR (499 MHz, CDCl3) δ: 9.55 (s, 1H), 7.70 (s, 1H), 7.45 (s, 2H), 7.33 (s, 1H), 6.13
(s, 1H), 5.94 (s, 1H), 5.59 (s, 1H), 4.47 (d, J = 12.1 Hz, 1H), 4.39 – 4.34 (m, 1H), 4.02 (s, 1H),
2.38 (s, 2H), 1.95 (s, 2H), 2.28 (t, J = 7.5 Hz, 1H), 2.16 (t, J = 7.6 Hz, 2H), 1.79 – 1.52 (m, 9H),
1.46 (s, 9H), 1.26 (s, 10H).

13

C NMR (126 MHz, CDCl3) δ 173.6, 171.6, 161.2, 156.5, 154.0,

152.5, 141.6, 125.0, 115.7, 115.6, 113.1, 107.1, 84.2 (d, J = 163.9 Hz), 80.4, 64.3, 55.1, 38.5, 36.7,
34.4, 31.6, 30.4, 30.3, 29.4, 29.31, 29.26, 29.2, 29.1, 29.0, 28.6, 28.4, 25.8, 25.7, 25.13, 25.08,
25.0, 22.7, 18.5. 19F NMR (376 MHz, CDCl3) δ -217.73 – -218.25 (m). HRMS (+ESI-TOF) m/z
for C32H49N3O6 [M+Na]+ calculated: 614.3519, found M+Na: 614.3581
tert-Butyl

(7-(12-fluorododecanamido)-1-((4-methyl-2-oxochroman-7-yl)amino)-1-

oxoheptan-2-yl)carbamate (8): 12-Fluorododecanoic acid (21 mg, 0.027 mmol) was dissolved
in excess SOCl2 (1 mL, 1.3 mmol) and stirred at 60°C, under reflux, for 3 hours. Following the
reaction, all SOCl2 was evaporated and the product was washed with toluene before being
evaporated once more. Boc-Lys-AMC (36 mg, 0.09mmol) was dissolved in 7 mL of
dichloromethane with 1 equivalent of triethylamine (TEA). The mixture was added dropwise to
the flask containing the acetyl chloride residue, and the reaction was stirred continuously at 22°C,
under argon, for 12 hours. Following completion of the reaction, the solvent was evaporated and
the compound was purified by column chromatography using a gradient of 3-8%
methanol/dichloromethane for elution. The product was obtained in 20% yield as an off white
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powder. 1H NMR (500 MHz, CDCl3) δ: 9.55 (s, 1H), 7.70 (s, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.32
(d, J = 7.5 Hz, 1H), 6.12 (s, 1H), 5.95 (s, 1H), 5.62 (d, J = 6.5 Hz, 1H), 4.41 (dt, J = 47.4, 6.2 Hz,
2H), 3.34 – 3.16 (m, 2H), 2.36 (s, 3H), 2.15 (t, J = 7.7 Hz, 2H), 1.99 – 1.88 (m, 2H), 1.81 – 1.71
(m, 2H), 1.72 – 1.51 (m, 8H), 1.44 (s, 9H), 1.39 – 1.32 (m, 4H), 1.23 (d, J = 5.6 Hz, 14H).

13

C

NMR (126 MHz, CDCl3) δ: 173.8, 171.8, 161.3, 156.6, 154.1, 152.6, 141.7, 125.1, 115.8, 115.7,
113.2, 107.2, 84.3 (d, J = 163.8 Hz). 80.5, 55.3, 38.7, 36.9, 31.7, 30.6, 30.4, 29.6, 29.4, 29.3, 29.1,
28.5, 25.9, 25.3, 25.2, 25.0, 22.8, 18.6. 19F NMR (376 MHz, CDCL3) δ -217.99 (dq, J = 47.4, 25.0
Hz). HRMS (+ESI-TOF) m/z for C34H53N3O6 [M+Na]+ calculated: 626.3415 found: 626.3395
tert-Butyl (7-(14-decanamido)-1-((4-methyl-2-oxochroman-7-yl)amino)-1-oxoheptan-2yl)carbamate (9): Boc-Lys-AMC (100 mg, 0.25 mmol) was dissolved in 5 mL of
dimethylformamide (DMF) with excess of N,N-diisopropylethylamine (DIPEA) (0.5 mL).
Myristoyl chloride (92 mg, 0.37 mmol Sigma-Aldrich, Milwaukee, WI) was added dropwise to
reaction at 0°C and subsequently stirred at 22°C under argon for 12 hours. The resulting mixture
was evaporated and the residue was dissolved into ethyl acetate (EtOAc) and was washed 2 times
with 2N aqueous hydrochloric acid solution. The organic layer was separated and dried for 2 hours
on sodium sulfate, evaporated, and purified by using flash chromatography in an Alltech 900 mg
silica cartridge (Fisher Scientific, Waltham, MA) with EtOAc as an eluent. The compound was
isolated as a white powder in 64% yield. 1H NMR (600 MHz, CDCl3) δ 9.62 (s, 1H), 7.71 (s, 1H),
7.42 (d, J = 8.3 Hz, 1H), 7.29 (d, J = 7.7 Hz, 1H), 6.14 (s, 1H), 6.10 (s, 1H), 5.67 (d, J = 7.0 Hz,
1H), 4.34 (d, J = 4.0 Hz, 1H), 3.33 – 3.15 (m, 2H), 2.35 (s, 3H), 2.16 (t, J = 7.6 Hz, 2H), 1.95 –
1.87 (m, 1H), 1.79 – 1.69 (m, 1H), 1.61 – 1.53 (m, 4H), 1.44 (s, 9H), 1.31 – 1.15 (m, 26H), 0.85
(t, J = 7.0 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 174.0, 171.8, 161.3, 156.6, 154.0, 152.7, 141.7,
125.1, 115.8, 115.7, 113.2, 107.2, 80.5, 55.3, 38.8, 36.8, 32.0, 31.8, 29.8, 29.8, 29.7, 29.6, 29.5,
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29.5, 29.1, 28.5, 26.0, 22.9, 22.8, 18.6, 14.2. HRMS (+ESI-TOF) m/z for C36H57N3O6 [MCH3+Na]+ calculated: 636.3890 found: 636.3795.
tert-Butyl

(7-(16-fluorohexadecanamido)-1-((4-methyl-2-oxochroman-7-yl)amino)-1-

oxoheptan-2-yl)carbamate (10): 16-Fluorohexadecanoic acid (100 mg, 0.38 mmol) was
dissolved in excess SOCl2 (1 mL, 1.3 mmol) and stirred at 60°C, under reflux, for 3 hours.
Following the reaction, all SOCl2 was evaporated and the product was washed with toluene before
being evaporated once more. Boc-Lys-AMC (100 mg, 0.25 mmol) was dissolved in 10 mL of
dichloromethane with 1 equivalent of triethylamine (TEA). The mixture was added dropwise to
the flask containing the acetyl chloride residue, and the reaction was stirred continuously at 22°C,
under argon, for 12 hours. Following completion of the reaction, the solvent was evaporated and
the compound was purified by column chromatography using a gradient of 3-8%
methanol/dichloromethane for elution and isolated as a white powder in 20% yield. 1H NMR (500
MHz, CDCl3) δ 9.27 (s, 1H), 7.69 (s, 1H), 7.50 (s, 2H), 6.19 (s, 1H), 5.76 – 5.67 (m, 1H), 5.40 (d,
J = 7.7 Hz, 1H), 5.31 (s, 1H), 4.49 (t, J = 6.2 Hz, 1H), 4.39 (t, J = 6.2 Hz, 1H), 4.06 (t, J = 6.7 Hz,
3H), 3.67 (d, J = 4.8 Hz, 3H), 3.65 (d, J = 4.7 Hz, 1H), 2.41 (s, 2H), 2.30 (dd, J = 15.0, 7.5 Hz,
5H), 2.21 – 2.17 (m, 1H), 1.66 – 1.60 (m, 9H), 1.47 (s, 9H), 1.28 (d, J = 16.1 Hz, 28H). 19F NMR
(376 MHz, CDCl3) δ -217.83 – -218.35 (m). HRMS (+ESI-TOF) m/z for C38H61N3O6 [M+Na]+
calculated: 698.4500, found: 698.4520
Benzyl

(6-amino-1-((1-((4-methyl-2-oxochroman-7-yl)amino)-1-oxo-6-

propionamidohexan-2-yl)amino)-1-oxohexan-2-yl)carbamate (11): Boc-Lys-AMC (232 mg,
0.45mmol) was dissolved in trifluoroacetic acid (TFA) to remove the boc protecting group. The
mixture was stirred for 30 minutes at 22°C and the TFA (2.5 mL) was evaporated. The resulting
residue was dissolved in dichloromethane (DCM) and 1eq of TEA was added to neutralize the

84

product. The mixture was evaporated and the product was washed with water and dried to remove
salts. The intermediate product was obtained as 138 mg of white powder. This product was
dissolved in DCM and 0.8 equivalents (85 mg) of Cbz-Lys-OH was added along with 1.5 eq. 1Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (67 mg) and Hydroxybenzotriazole
(HOBT) (50 mg) and 3 eq. of DIPEA (0.12 mL). The mixture was stirred for 12 hours at 22°C
under argon. The mixture was evaporated and dissolved in ethyl acetate and washed with saturated
sodium carbonate solution. The organic layer dried over magnesium sulfate and evaporated. The
residue was purified by column chromatography and the product was eluted with a gradient of 35% MeOH/DCM. The product was obtained as an off white powder in 12% yield (40 mg). 1H
NMR (600 MHz, DMSO-d6) δ 10.41 (s, 1H), 8.08 (d, J = 7.4 Hz, 1H), 7.75 (s, 1H), 7.68 (dd, J =
10.8, 7.3 Hz, 2H), 7.46 (d, J = 8.5 Hz, 1H), 7.37 (d, J = 7.7 Hz, 1H), 7.32(s, 3H), 7.28 (dd, J = 7.3,
2.8 Hz, 1H), 6.72 (t, J = 5.5 Hz, 1H), 6.24 (s, 1H), 5.00 (s, 2H), 4.34 (dd, J = 13.7, 7.7 Hz, 1H),
3.98 (dd, J = 12.8, 8.3 Hz, 1H), 3.02 – 2.95 (m, 2H), 2.84 (dt, J = 12.7, 6.5 Hz, 2H), 2.37 (s, 3H),
1.96 (t, J = 7.4 Hz, 2H), 1.75 – 1.65 (m, 1H), 1.65 – 1.53 (m, 2H), 1.48 (d, J = 9.4 Hz, 1H), 1.42 –
1.34 (m, 3H), 1.33 (12H), 1.18 (s, 22H), 0.81 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ:
174.2, 173.3, 170.9, 161.4, 157.0, 156.7, 154.1, 152.6, 141.7, 136.2, 128.6, 128.3, 128.1, 125.0,
116.0, 113.3, 107.4, 79.4, 67.2, 55.7, 54.1, 50.8, 38.5, 36.9, 32.0, 30.9, 29.8, 29.7, 29.6, 29.5, 29.4,
29.1, 28.5, 26.0, 25.4, 22.8, 22.6, 18.6, 14.2. HRMS (+ESI-TOF) m/z for C49H75N5O9 [M+Na]+
calculated: 776.3913, found: 776.3911
6-(12-Fluorododecanamido)-N-phenylhexanamide (12): 6-Amino-N-phenylhexanamide
(AHA(Mukhopadhyay et al., 2006)) (0.10 g, 0.48 mmol) was dissolved in acetonitrile with 12fluorododecanoic acid, a catalyst amount of DMAP (few crystals), and 1 equivalent of DCC (275
mg). The mixture was stirred under argon at 22°C for 12 hours. The solvent was evaporated and
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the residue was purified by column chromatography. The product was eluted with 3% MeOH in
DCM and subsequently purified by semi-preparative HPLC to improve the purity, eluted as a
single peak at 8 minutes with 50% acetonitrile/water. The final compound was isolated in 10%
yield. 1H NMR (400 MHz, DMSO-d6) δ 9.85 (s, 1H), 7.72 (s, 1H), 7.56 (d, J = 7.85Hz, 2H), 7.25
(d, J = 1.8 Hz, 2H), 6.99 (t, J = 7.3 Hz, 1H), 4.44 (dt, J = 47.6 Hz, 2H), 2.99 (s, 2H), 2.25 (m, 2H),
1.98 (m, 2H), 1.54 (m, 4H), 1.37 (m, 4H), 1.20 (s, 10H).19F NMR (376 MHz, DMSO-d6) δ -216.36
– -216.88 (m). HRMS (+ESI-TOF) m/z for C24H40FN2O2 [M+Na]+ calculated 407.3074, found
407.3083.
6-(12-Bromododecanamido)-N-phenylhexanamide (13): DIPEA (0.13 mL, 0.73 mmol)
was added to the mixture of 6-amino-N-phenylhexanamide (AHA) (prepared using previously
published method(Mukhopadhyay et al., 2006)) (0.10 g, 0.48 mmol) and bromoundecanoic acid
benzotriazole (0.21 g, 0.58 mmol) dissolved in DMF (5 mL), and left to stir at 22°C for 6 h. The
solvent was then evaporated under reduced pressure; the crude was dissolved in DCM and washed
with 2N hydrochloric acid. The organic layer was dried over sodium sulfate. Evaporation and
purification with column chromatography (eluent - EtOAc) gave the desired precursor in 62%
yield. 1H NMR (400 MHz, CDCl3) δ 8.25 (s, 1H), 7.55 (d, J = 7.9 Hz, 2H), 7.27 (t, J = 7.9 Hz,
2H), 7.06 (t, J = 7.4 Hz, 1H), 5.96 (t, J = 5.2 Hz, 1H), 3.38 (t, J = 6.9 Hz, 2H), 3.22 (dd, J = 13.2,
6.8 Hz, 2H), 2.35 (t, J = 7.4 Hz, 2H), 2.13 (t, J = 7.6 Hz, 2H), 1.88 – 1.77 (m, 2H), 1.76 – 1.66 (m,
2H), 1.61 – 1.45 (m, 4H), 1.43 – 1.31 (m, 4H), 1.24 (s, 10H). 13C NMR (101 MHz, CDCl3) δ 173.6,
171.8, 138.4, 128.9, 124.1, 119.9, 39.2, 37.3, 36.9, 34.2, 32.9, 29.6, 29.5, 29.5, 29.4, 29.4, 29.3,
28.8, 28.2, 26.4, 25.9, 25.0. HRMS (+ESI-TOF) m/z for C24H40BrN2O2 [M+Na]+ calculated
467.2273, found 467.2283.
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6-(12-Iodododecanamido)-N-phenylhexanamide (14): 6-(12-Bromododecanamido)-Nphenylhexanamide (100 mg) was dissolved in acetone and 4 equivalents of NaI was added at 22°C
and the mixture was stirred for 80 hours. The solution was evaporated and purified with column
chromatography (eluent – EtOAc) to give the desired product in 73% yield (80 mg). 1H NMR (600
MHz, CDCl3) δ 7.54 (d, J = 7.6 Hz, 3H), 7.31 (t, J = 7.8 Hz, 2H), 7.09 (t, J = 7.4 Hz, 1H), 5.63 (s,
1H), 3.26 (dd, J = 13.2, 6.7 Hz, 2H), 3.18 (t, J = 7.0 Hz, 2H), 2.37 (t, J = 7.3 Hz, 2H), 2.14 (t, J =
7.6, 2H), 1.85 – 1.72 (m, 4H), 1.63 – 1.57 (m, 2H), 1.57 – 1.51 (m, 2H), 1.44 – 1.34 (m, 4H), 1.26
(m, 12H). HRMS (+ESI-TOF) m/z for C24H40IN2O2 [M+Na]+ calculated 515.2135, found
515.2131.
6-18F-(12-fluorododecanamido)-N-phenylhexanamide (15): The F-18 was obtained in
kryptofix/K[18F] complex in acetonitrile/water (1 mL) from the PET/Cyclotron Facility, Wayne
State University (Detroit, MI) and transferred into a crimped 2 mL V-vial for azeotropic drying.
Acetonitrile (0.4 mL) was added to the mixture, which was dried under a stream of argon at 90100°C. A solution of 14 (2-3 mg) in dry acetonitrile (0.4 mL) was added to the dried kryptofix/
K[18F] and heated to 85-90°C under argon with stirring for 20 minutes. After cooling, the reaction
mixture was passed through a 900 mg Altech silica gel cartridge (Fisher Scientific, Waltham, MA)
and eluted with 2 mL of 10% methanol in dichloromethane (DCM). The solvent was evaporated
under a stream of argon to remove DCM and to reduce the volume to 0.5 mL. The 15 was purified
by semipreparative HPLC (40% ACN in water) by collecting the peak at 9 min. The decay
corrected radiochemical yield was 12% and the compound purity was >95%, as assessed by
analytical HPLC and co-elution with the non-radiolabeled reference standard 12.
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4b. Continuing work
Preliminary dynamic PET/CT images acquired after i.v. administration of 12-[18F]DDAHA in normal and 9L tumor bearing rats have been done however significant defluorination
is visible as soon as 5-10 minutes after injection of the radiotracer and increases with time post
injection (Fig. 33). This is indicated by the abnormally high uptake of

18

F into the bones of the

animal and is increasing with time. As noted previously, this has been hypothesized based on
studies performed with 16-[18F]-palmitic acid substrates, which demonstrated high rates of
SUV
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Figure 33. PET/CT images from a rat bearing a 9L brain tumor with 12[ 18F]-DDAHA
demonstrating significant defluorination, as indicated by F-18 accumulation in the bone
especially with increasing time post i.v. injection of the radiotracer.
defluorination in rodents. It is possible that this problem would not persist in higher mammals and
humans due to significantly lower circulating concentrations of enzymes, we have also begun work
on a second generation of compounds aimed at reducing the likelihood of defluorination.
It has been suggested that positioning the fluorine atom on the ω-3 position rather than on
the terminal, ω-carbon, may reduce defluorination (Pandey et al., 2012). We have hypothesized
that other midchain substitutions of a fluorine-18 atom may also prevent defluorination. From
preliminary in silico studies it is plausible that these compounds would retain SIRT2 selectivity.
In light of these observations, we have designed synthesis schemes for generating a second set of
SIRT2 selective radiotracers based upon mid-chain fluorination of dodecanoyl or myristoyl acyl
chains (Fig. 34). These synthesis schemes may provide means for constructing a more robust
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SIRT2-selective radiotracer to prevent against defluorination in rodents as well as higher
mammals.

These schemes cover the chains fluorinated at the Ɣ-position, generating 4-

fluorododecanoyl and 4-flurotetradecanoyl, as well as 5-position to make 5-fluorododecanoyl and
5-flurotetradecanoyl leaving groups which would be radiolabeled from the brominated-precursors.
While these compounds place the fluorine atom in closer proximity to the carbonyl carbon, it
should be far enough to limit interference with enzymatic activation and cleavage site.
Additionally, we have developed schemes for radiolabeling the more terminal fluorines at ω-3 and
ω-4 sites to generate 9-fluorododecanoyl or 11-fluorotetradecanoyl (ω-3) substituted chains and
8-fluorododecanoyl

or

10-fluorotetradecanoyl

radiofluorination from the brominated precursors.

(ω-4) substituted chains

with

possible
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Fig. 34. Possible schemes for synthesis of alternative SIRT2-selective radiotracers that may be less
susceptible to defluorination. A) Sample synthesis for 4-fluorododecanoyl or 4-fluorotetradecanoyl
compounds with radiofluorination from the brominated precursor. B) Sample synthesis scheme for
construction of 5-fluorododeconyl or 5-fluorotetradecanoyl compounds with radiofluorination
from the brominated precursor. C) Sample synthesis for the ω-3 compounds, 9-fluorododecanoyl
or 11-fluorotetradecanoyl substituted chains. D) Synthesis of ω-4 compounds 8-fluorododecanoyl
or 10-fluorotetradecanoyl substituted chains with possible radiofluorination from the brominated
precursors.
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CHAPTER 5 DEVELOPMENT OF NOVEL PET IMAGING
SUBSTRATES FOR SIRT1
5a. Development of a novel substrate-type radiotracer, 2-[18F]PhAHA, for
PET imaging of SIRT1-mediated epigenetic regulation
Robin Bonomi, Vadim Popov, Maxwell Laws, David Gelovani, Anjoy Majhi, Amer M.
Najjar, Aleksander Shavrin, Tong William Ping-Yiu, Nashaat Turkman, Xin Lu, Thomas
Mangner, Juri G. Gelovani*
Introduction
Seven sub-types of SIRTs (SIRT 1-7) have been identified in humans (Haberland et al., 2009)
and play a role in gene silencing, cell cycle regulation, metabolism, apoptosis, lifespan and
circadian rhythms (Pan et al., 2011a). In particular, SIRT1 has been recognized for involvement
in diabetes, cardiovascular disease and neurodegeneration (Haigis, 2010) through cleavage of an
acetyl moiety from lysine residues of various proteins including PPARƔ, and NF-Kβ, and
members of the p53 family. Furthermore, increased expression of SIRT1 has been correlated with
poor prognosis in a variety of cancers such as pancreatic (Wauters et al., 2013), non-small cell
lung carcinoma (Grbesa et al., 2015) and leukemias (Li et al., 2012)
Due to the biological importance of SIRT1 (further reviewed in chapter two), many targeted
therapies have been developed using small molecule therapeutics for activation or inhibition of
SIRT1. Because of the notable link between resveratrol and SIRT1, clinical trials were conducted
using resveratrol or a synthetic small molecule activator (i.e. SRT2104) to activate SIRT1mediated pathways for treatment of diabetes and obesity (Hoffmann et al., 2014; Poulsen et al.,
2013; Pulla et al., 2012). Additionally, the observation of SIRT1 overexpression in proliferative
cancer cells has prompted investigation of the effects of SIRT1 inhibitors on progression of various
cancers (Liu et al., 2009).
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Several SIRT1 selective inhibitors have been developed and reported in literature, such as
Selisistat (EX-527) (Napper et al., 2005; Solomon et al., 2006), Sirtinol (Grozinger et al., 2001),
and Tenovin-6 (Lain et al., 2008). These compounds are gaining recognition for treatment of
diseases through SIRT1-targeted pharmacomodulation. In vitro evidence has demonstrated a
reduction in growth and proliferation of colon cancer and uveal melanoma cancer stem cells after
treatment with SIRT1-selective inhibitors EX-527 and tenovin-6 (Dai et al., 2016; Suzuki et al.,
2009). Though these SIRT1 inhibitors have shown promise as anticancer drugs in vitro and in
preliminary in vivo studies, few have been evaluated or approved for clinical trials (Park et al.,
2004).
As noted, SIRT1 plays a pivotal role in many important cellular processes, however, the upand downstream effects of SIRT1 are not fully understood. Therefore, the development of noninvasive imaging approaches to monitoring SIRT1 expression and activity in vivo via PET imaging
with a SIRT1-selective substrate radiotracer may aid in understanding disease progression and the
development of novel SIRT1-targeted therapeutics.
Recently, studies have demonstrated that SIRT1 is able to cleave other leaving groups outside
of the acetyl moiety (Yao and Yang, 2011). In particular, Hirsch et al. demonstrated that SIRT1
can dephenylacetylate a lysine residue (Hirsch and Zheng, 2011) (Fig. 35). Additionally, it has
been implicated that other SIRT enzymes, namely SIRT2 and SIRT6, may contain the ability to
cleave long acyl chains but may not be able to cleave an aromatic ring (Yao and Yang, 2011).
Towards the development of a SIRT1-selective substrate radiotracer we developed a library of
compounds investigating the relationship of substituted aromatic rings as leaving groups on SIRT1
catalytic efficiency. In vitro assessment of these compounds using a fluorogenic assay indicated
that the fluorinated phenyl ring leaving groups were cleaved more efficiently by SIRT1 than the
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substituted benzyl ring leaving groups or aromatic rings with iodinated substitutions. For purposes
of high-throughput screening, this library was developed with the carbazol-lysineaminomethylcoumarin backbone, however, this peptide mimetic is not well suited for use as an in
vivo imaging agent, due to its high lipophilicity. Through fluoromeric screening, 2-fluorophenyl
(2FPh) was identified as the lead leaving group to use for further development into a systemically
viable radiotracer. Following this, 2-fluorophenylhexanoicanilide was developed using the
aminohexanoicanilide backbone to form an analogous compound to the tested one, CbzLys(2FPh)-AMC, using providing increased systemic viability as seen in [18F]-TFAHA (Bonomi
et al., 2015) and [18F]-FAHA (Yeh et al., 2013a). The resulting compound, 2fluorophenylaminohexanoicanilide (2-FPhAHA) was synthesized in the radiolabeled version
[18F]-2-fluorophenylaminohexanoicanilide ([18F]-2FPhAHA) from the 2-nitrophenyl precursor.
[18F]-2FPhAHA demonstrated efficacy as a viable imaging agent for SIRT1 expression-activity
through in vitro and in vivo assessment. PET/CT images with [18F]-2FPhAHA in the rat model
resulted in [18F]-2FPhAHA-derived accumulation in areas of the brain with higher SIRT1 activity
were validated by the IHC and ISH data in literature (Ramadori et al., 2008; Zakhary et al., 2010)
as well as by our own IHC and autoradiography data. Quantification of PET/CT images was
performed using Logan plot analysis for specific regions of the brain to validate the differential
washout of [18F]-2FPhAHA within the brain.
The development of [18F]-2FPhAHA as a BBB permeable SIRT1-selective substrate type
radiotracer with and subsequent characterization of SIRT1 expression-activity in vivo in the
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absence of disease may further the study of SIRT1-mediated epigenetic regulation in various
neuropathologies.

Figure 35. The unique SIRT1 mechanism for cleavage of a benzyl moiety (highlighted in red) from
a lysine residue of a protein using NAD+ as a cofactor.
Results:

Figure 36. Synthesis of control compound 17, Cbz-Lys(ac)-AMC.
The library of compounds developed for in vitro assessment of SIRT1 catalytic activity
utilized the carbazol-Lysine-aminomethylcoumarin backbone (Cbz-Lys-AMC) dervatized with
fluorinated and iodinated phenyl and benzyl substituents (Fig. 36-37). The compounds (17-27)
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Figure 37. Synthesis of the focused library of SIRT1 substrates
were primarily synthesized from variations of existing methodologies for peptide mimetic
synthesis, including acetyl-chloride coupling, in yields of 50-80% with >95% chemical purity as
assessed by TLC, 1H, 13C, and 19F NMR and HRMS.
The synthesis of 4-Fluorophenylaminohexanoicanilide (28) was accomplished through
DCC-catalyzed coupling of the 4-fluorobenzoic acid with compound 1 in a yield of 77% and >95%
purity (Fig. 38). The synthesis of small molecule compounds including, 2-[18F]ethyl benzoate (30),
2-[18F]benzoic acid (31), and 2-[18F]benzaldehyde (34) with decay corrected radiochemical yields
of 25% and 15%, respectively, was accomplished through radiofluorination of commercially
available ortho-nitro compounds (29, 32) with high radiochemical purity (>95%) (Fig. 39). These
compounds were assessed by analytical radio-HPLC for purity and verification of compound
identification.
Synthesis

of

non-radiolabeled

2-

fluorophenylaminohexanoicanilide (35) was performed using
in situ acetyl chloride formation to couple the commercially
available 2-fluorobenzoic acid with N-aminophenylhexamide
(prepared by previous methodology (Mukhopadhyay et al.,
2006)) in a 30% yield and high chemical purity, >95%, as

Figure 38. Synthesis of 4fluorophenylaminohexanoic
anilide (28).
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assessed

by TLC,

1

H,

13

C,

and

19

F

NMR

and

HRMS.

The

synthesis

of

2-

nitrophenylaminohexanoicanilide (36) was accomplished through coupling 2-nitrophenyl acetyl
chloride with N-phenylhexamide in 70% yield with >95% chemical purity, as assessed by TLC,
1

H, 13C, and 19F NMR and HRMS. This compound was used for subsequent radiofluorination to

produce [18F]-2FPhAHA (37) under novel radiofluorination conditions of 135°C in dry DMSO to
produce the compound with high radiochemical purity >99% and a decay corrected RCY of 15%
as assessed by radio-analytical HPLC (Fig. 40).
Fluorogenic assay results screening compounds 18-27 from library in Fig. 37 indicate
leaving groups containing a phenyl ring are cleaved more rapidly by SIRT1 than those with a
benzyl moiety (Fig. 41). The aromatic ring leaving groups containing fluorine atoms are cleaved
more rapidly than iodine-substituted rings. In particular, the fluorinated phenyl groups, especially
in ortho- or meta-position, are the most efficiently cleaved substrates, with kcat/km values of 26.02
(19) and 63.39 M-1, s-1 (20), respectively (Fig. 42). The ortho-fluorophenyl leaving group is
cleaved 5-fold more efficiently by SIRT1 than any other SIRT or HDAC enzyme (Fig. 43). A
reference, control, compound,

A

BPS1, a p53 fragment (Arg-HisLys-Lys(ac)-AMC) was also
analyzed

for

B

comparison

purposes.
The IC50 for the CbzLys(2FPh)-AMC is 12.60 uM as
assessed

by

competitive

Figure 39. A) Synthesis of 2-[18F]-ethylbenzoate (30) and
corresponding benzoic acid (31) from the commercially available 2nitro-ethylbenzoate (29). B) Synthesis of 2-[18F]benzaldehyde (34)
from 2-nitrobenzaldehyde (32).
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inhibition

assay

commercial

with
SIRT1

inhibitor, EX-527 (Fig.
44).
In vivo assessment
of

2-[18F]PhAHA

dynamic

via

PET/CT/MRI

imaging in the normal rat
displayed
accumulation

significant
of

2-

Figure 40. Synthesis of 2-nitrophenylaminohexanoicanilide (36) to
be used as a precursor for radiolabeling with F-18 to form 2[18F]phenylaminohexanoicanilide (37). The non-radiolabeled
standard
2-fluorophenylaminohexanoicanilide
(35)
was
synthesized using similar methodology.

[18F]PhAHA-derived radioactivity in specific areas of the brain, i.e. n.accumbens, dentate gyrus,
hippocampus, lateral septal nucleus, caudate putamen and amygdala (Fig. 45-46). These areas of
the brain correlate well with reported IHC data for SIRT1 expression within rodent brain (Fig. 47).
Autoradiography preformed from these images demonstrated accumulated radioactivity in these
areas of the brain as determined by alignment with brain atlas maps (Fig. 48).
In vivo inhibitor studies demonstrate significant decrease in accumulation of 2-[18F]PhAHAderived radioactivity in areas of the brain after i.p. administration of EX-527 (5mg/kg), SIRT1selective inhibitor, 30 min prior to PET/CT imaging (Fig. 49).
Assessment of radiolabeled 2-[18F]PhAHA metabolites by in vivo PET/CT imaging with i.v.
administered 2-[18F]Ethylbenzoate (further metabolized to 2-[18F]Benzoic acid) and 2[18F]benzaldehyde was conducted to establish the potential contribution of metabolites to regional
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uptake of 2-[18F]PhAHA (Fig. 50). Furthermore, it is interesting to analyze the differences in
radiotracer derived accumulation in each of these three compounds.
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Figure 41. The catalytic efficiencies (kcat) for the library of compounds synthesized assayed
against a panel of recombinant SIRT enzymes. A) Demonstrates the catalytic cleavage rat to be
greatest for the 4FPh leaving group and the 2FPh leaving group. Statistical significance is
denoted by stars as tested by ANOVA. B) Comparing the iodine vs fluorine substitutions on a
phenyl or benzyl ring, 4IPh is cleaved significantly faster than the iodinated compounds,
especially for SIRT1. C) Comparison of 2FBz vs 4FBz leaving groups, the 4FBz is cleaved more
efficiently by SIRT1.
Discussion:

3
IR

T

2
S

IR

T

1
S

S

IR

T

7
IR
S

IR

T

6
T

5
S

IR

T

4
S

IR

T

3
S

IR

T

2
S

IR

T

1
T
S

IR

IR

S

C

0 .0 0

7
T

6

0 .2 0

S

S

IR

IR

T

T

5

4

B

S

IR
S

IR
S

T

3
T

2
T
IR
S

S

IR

T

1

*

98

Towards the development of a novel substrate-type radiotracer for quantitative molecular
imaging of SIRT1 expression and activity, we developed a focused library of substrates
comprised of the Cbz-Lys-AMC backbone and various phenyl or benzyl leaving groups. This
cap group has been widely used for SIRT substrates and is especially useful for preliminary
screening due to the presence of a fluorescent moiety, 7-amino-4-methylcoumarin (AMC), with
which high throughput fluorogenic assays can be used. Previously, it has been reported that in
addition to the acetyl group, SIRT1 can also cleave a phenylacetylated lysine with 56% of the
natural catalytic efficiency (Hirsch and Zheng, 2011) (Fig. 29). Similarly, other class III HDAC
enzymes have been reported to cleave long acyl chains (myristoyl), glutaryl or succinyl moieties
(Du et al., 2011; He et al., 2014; Heltweg et al., 2004; Hirsch and Zheng, 2011). However, there
are no data on the effects of aromatic ring fluorine substitution or phenyl vs. benzyl moieties on
SIRT1 catalytic efficiency.
Current studies demonstrate that SIRT1 catalytic rate of cleavage (kcat) is greatest with either
the 2FPh (19) leaving group or the 4FPh (21) leaving group (Fig. 36). Furthermore, these
compounds display much greater rates of catalytic cleavage by SIRT1 than any of the other
sirtuins. In testing the catalytic rate of cleavage for other types of leaving groups, including
iodinated substrates (25, 26) and phenyl (18-21) and benzyl (22-24) moieties, it is clear that 2FPh
(19), 3FPh (20), and 4FPh (21) are the strongest candidates for SIRT1 (Fig. 42). However, the
rates of catalytic cleavage (kcat) are not always proportional to the catalytic efficiency (kcat/km),
therefore further analysis was done to ensure the most efficient substrate leaving group was used
for radiotracer development. Taking this into account, a full kinetic analysis was performed for a
subset of the original library of compounds, to include only compounds 18-24. These results
confirm that SIRT1 catalytic efficiency (kcat/km) is greatest with a phenyl ring leaving group as
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opposed to a benzyl (phenylacetyl) moiety (Fig. 42). Interestingly, 21 was cleaved with a greater

Figure 42. Evaluation of fluorine substituent positioning on both the phenyl and benzyl
leaving groups on SIRT1 catalytic efficiency, as determined by fluorogenic (Fluor de Lys®)
assay. The catalytic efficiency of SIRT1 is demonstrated by kcat/km and the error bars represent
the standard deviation of the mean from N=3 experiments. The full kinetic parameters for
SIRT1 with selected substrates are detailed in this table. The data represents the apparent
Michelis-Menton kinetics as derived from initial steady-state reaction velocity.
rate than 20 but is cleaved less efficiently when km is taken into account, making compounds 19
and 20 the most efficient substrates for SIRT1(kcat/km = 26.02 and 63.39 M-1, s-1) (Fig. 36).
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Figure 43. The catalytic efficiency for the lead compound
Cbz-Lys (2FPh)-AMC (19) was assessed in a panel of
recombinant HDACs for relative selectivity for SIRT1.
The data were analyzed by one way ANOVA; statistically
significant differences with P<0.05 were denoted by ****.

substitution on the benzyl leaving
group decreases the catalytic
efficiency. Whereas, with a phenyl
moiety,
actually

fluorine
increases

substitution
catalytic

efficiency. Compound 20, containing 3-fluorophenyl leaving group, is cleaved equally as
efficiently as the acetylated standard, p53Lys382(ac) analogue (Arg-His-Lys-Lys(ac)-AMC,
BPS1). (kcat/km = 65.29 M-1, s-1) and compound 19 cleaved at 25% of the rate.
Although, the 3-fluorophenyl (20) leaving group is cleaved moderately more efficiently by
SIRT1 than the 2-fluorophenyl leaving group, compound 19 was chosen as the lead substrate for
further development as an imaging agent. This decision was influenced by a significant increase
in difficulty for radiofluorination and opportunity for in vivo defluorination by various esterase
enzymes with a meta-fluorophenyl ring. However, current work is focused on development of 3[18F]fluorophenyl derived radiotracer for a SIRT1-selective imaging agent, as well.
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To establish selectivity of 19 for
SIRT1 among other SIRT and HDAC
proteins, compound 19 was screened
against a panel of recombinant proteins
including HDACs1-11 and SIRT1-7.
Compound 19 demonstrated at least 3fold increase in relative rates of cleavage
by SIRT1 over all HDACs based upon kcat
values. HDAC 6 expressed the closest

Figure 44. IC50 curve for SIRT1 with 19 at its
apparent km value obtained by competition assay
with known potent SIRT1 selective inhibitor, EX527 at increasing concentrations on the log scale.

catalytic activity to SIRT1 of any other HDAC enzymes, with a relative kcat of 30% of SIRT1 (Fig.
44 ), however HDAC6 has much lower expression in the brain, effectively increasing the SIRT1
selectivity within the brain (Ramadori et
al., 2008). Furthermore, to assess the
effectiveness of lead substrate 19 against a
potent,

SIRT1-selective

inhibitor,

a

competitive inhibition assay with EX-527
(Selisistat) (Cui et al., 2014; Napper et al.,
2005) was performed using increasing
concentrations of EX-527 and apparent km
concentration of 19 for SIRT1 (239 μM).
The

observed

inhibition

for

SIRT1

cleavage of compound 19 with increasing
concentrations of EX-527 can be used to

Figure 45. HPLC analysis for catalytic rates of cleavage
of 4-FPhAHA (28) with a panel of recombinant HDAC
enzymes (HDACs 1-11 and SIRT1-5) demonstrating
selective cleavage by SIRT1.
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calculate an IC50 value of
12.6 +/- 2.1 μM (Fig. 44).
This value is significantly
higher

than

previously

reported IC50 value of
0.098 μM obtained using
fluorogenic oligo peptideacylated substrates of p53Lys382 (BPS1) (Napper et
al.,

2005).

Using

our

system, we independently
found a comparable IC50 of

Figure 46. Dynamic PET/CT images acquired using 2[18F]PhAHA demonstrating differential washout over time
normalized to peak SUV values at 20 min.

0.0103 +/- 0.0025 μM for BPS1 and SIRT1 with inhibitor EX-527. While the experimental IC50
values for BPS1 and 19 vary significantly, the catalytic efficiency (kcat/km) differ much less and
may be explainable, at least in part, due to the differences in cap groups (peptide vs blocking
group).
To create a more pharmacologically viable substrate radiotracer, compound 19 has been
converted to an analogue using aminohexanoicanilide (AHA) backbone rather than the larger CbzLys-AMC group. The resulting radiotracer, 2-[18F]fluorophenylacetamidohexanoicanilide (2[18F]PhAHA, 37), was developed in both F-18 and F-19 versions (Fig. 40). Towards synthesis of
this radiolabeled compound, there are no established methods for radiofluorination on a phenyl
ring in the ortho position, thus we developed new methodology for radiosynthesis of 2[18F]PhAHA. Originally, both 2-nitrophenylaminohexanoicanilide (2-NO2PhAHA, 36) and 2-
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trimethylamoniumsalt-phenylaminohexanoicanilide precursors were developed, however after
testing radiofluorination conditions, only 2-NO2PhAHA proved to be successful. This finding
contradicts the data for para- radiofluorination on a phenyl ring where the trimethylammonium
salt precursor produces higher yields than the nitro leaving group.
In vitro HPLC analysis of 4-FPhAHA demonstrates comparable cleavage rates (kcat) as
compared to in vitro fluorogenic studies of 21 for SIRTs 1-5 (Fig. 45). This study confirms the

Figure 47. Representative PET/CT images using 2-[18F]PhAHA aligned with rat brain atlas maps
demonstrating the areas of high accumulation that align with areas of the brain such as
hippocampus (CA1, CA2, CA3), dentate gyrus(DG), n. accumbens (Acb), caudate putamen (Cpu),
and amygdala (amyg).
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AHA backbone is sufficiently recognized
and attached leaving group is cleaved by
SIRT1 without appreciable loss in efficacy.
The mechanism of substrate cleavage
by SIRT enzymes allows for the radioactive
leaving group to be transiently entrapped in
a cell in a similar manner to other
radiotracers such as

18

F-FDG and

18

F-FLT,

by conversion of a tracer into a more polar
molecule. Theoretically, as the result of ester
linkage between the leaving group with OADPR (Fig. 35), the leaving group is trapped
inside the cell in form of the

18

F-

Figure 48. IHC results demonstrating increased
SIRT1-expression in the rat. A) Rat prefrontal
cortex; B) Rat nucleus accumbens; C) Rat
striatum; D) rat hippocampus. Data is from
literature (Zakhary et al., 2010). The arrow
indicates nuclear localization of the stain within
neuronal fibers.

fluorophenyl-O-ADPR product. Therefore, SIRT1-mediated cleavage of

18

F-fluorophenyl group

from 2-[18F]PhAHA with formation of 2-18F-fluorophenyl-OADPR complex represents the rate-limiting step in the cellular
entrapment of 2-[18F]PhAHA -derived radioactivity. The removal
of an acetyl (or other) moiety from the O-ADPR group has been
investigated and hypothesized that enzymes such as ARH3 may
cleave an acetyl moiety from the O-AADPR (O-acetyl-ADPribose) ring or possible methanolysis of acetyl into 1’Omethyl’ADPR may occur. Additionally, a nucleophilic attack
from lysine side chains of other proteins in close proximity may

Figure
49.
Autoradiography
(left)
aligned
with
corresponding
PET/CT/MR image (right)
for 2-[18F]PhAHA.
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also de-acetylate the O-AADPR. However, little is known about the removal of a larger group
such as a phenyl ring from ADP moiety, therefore further studies are needed to fully characterize
the half-life of O-2-[18F]Ph-ADPR, and determine whether this intermediate is in fact stabile.
These factors will contribute to the residence time for the possible radiotracer-derived metabolite,
2-[18F]benzoic acid, within the cell. Characterizing the nature of this entrapment is important
because this represents k4 in the molecular imaging equation and determines whether the
circulating metabolite may contribute to radiotracer volume of distribution.
Additionally, altered SIRT1 expression levels have been noted in many neurodegenerative
diseases, such as Huntington’s, and have led to exploratory clinical trials with SIRT1 selective
inhibitors, such as Selisistat (EX-527) (Smith et al., 2014), for treatment of the disease (Sussmuth
et al., 2015). Though there is some debate in literature regarding the effectiveness of SIRT1
activators vs. inhibitors for treatment of neurodegeneration (Naia and Rego, 2015). In fact, both
SIRT1-activators and inhibitors are currently in clinical trials for treatments of different pathologic
conditions. Therefore, non-invasive molecular imaging with PET using SIRT1-specific substratetype radiotracers may provide information about both location and magnitude for SIRT1expression and activity, which could help to determine the mechanistic, therapeutic and prognostic
roles of SIRT1 in different pathological states. One area where this may be especially useful, is
within the brain, where biopsies are not possible and SIRT1 plays very pleiotropic roles in both
norm and neuropathological conditions.
Dynamic PET/CT images of the brain, acquired in normal rats, using 2-[18F]PhAHA, have
demonstrated significant differential tracer washout in areas of the brain with relatively higher
SIRT1 expression, as correlated with ISH and IHC results in literature (Ramadori et al., 2008;
Zakhary et al., 2010) (Fig. 46-48). The accumulation of 2-[18F]PhAHA- derived radioactivity in
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areas of the brain is most predominant at 15-30 minutes post administration of the tracer. This is
verified by both Logan plots and time activity curve quantification of PET/CT images with 2[18F]PhAHA (Fig. 46). Alignment of the brain regions to the corresponding brain atlas regions
demonstrates high activity in hippocampus, caudate putamen, dentate gyrus, amygdala and n.
accumbens (Fig. 47). While there is very little tracer-derived radioactivity accumulation in the
brainstem region or the cerebellum. This observation, coupled with literature findings of little
SIRT1 activity in these areas, allow us to use the brainstem as a reference tissue for quantification.

Figure 50. Fluorescent microscopy staining for SIRT1 with an alexa-fluor 488 primary conjugated
antibody (green), counter stained with DAPI as a nuclear marker (blue) at 10x magnification. The white
box is magnified at 20x on bottom.
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Figure 51. Fluorescent staining of SIRT1 expression in the hippocampus of a rat brain (green) counter
stained with DAPI nuclear marker (blue).
Furthermore, autoradiography was performed at 20 minutes post i.v. administration of 2[18F]PhAHA to capture the radioactivity
accumulated

at

this

time

point,

corresponding to the highest point of
differential washout on the time activity
curves (Fig. 49). The axial autoradiography
images

acquired

with

2-[18F]PhAHA

correlate well to the axial PET/CT images
of the corresponding brain region.
Fluorescent microscopy of brain
slices stained for SIRT1 with DAPI counter
stains

demonstrates

expression

in

increased

hippocampal

SIRT1
regions,
Figure 52. 20x magnification of hippocampal CA2
region with SIRT1 fluorescent stain in green and DAPI,
nuclear marker, in blue.
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specifically in the CA2 region and nucleus accumbens (Fig. 50-52). The ventral and ventral-medial
sides of the n. accumbens demonstrate the highest increase in SIRT1 expression. From the
magnified image, it is possible to depict both nuclear and cytoplasmic localization for SIRT1. The
hippocampal region also demonstrates significant increases in SIRT1 expression as seen on
fluorescent images of the CA1, CA2 and CA3 region (Fig. 51). This correlates well with what is
seen on PET/CT images with 2-[18F]PhAHA. It is evident from this image that the CA2 (lateral
aspect of hippocampus) region has higher SIRT1 expression than CA1 (medial aspect of
hippocampus). The magnified view of CA2 shows heterogenous localization for SIRT1, both
cytoplasmic as well as nuclear. Interestingly, the corpus collosum has no SIRT1 expression and
only shows nuclear stains. Another key factor to note is the strong axonal staining evident within
the hippocampus indicating strong SIRT1 localization and presence within the axonal cytoplasm.
Within some cells of the image, it is possible to define the distinct axon radiating from the nucleus.
The staining of SIRT1 in the hippocampus matches the more lateral accumulation of 2[18F]PhAHA within the hippocampus and lack of accumulation in the middle of the hippocampal
region on coronal sections. Furthermore, these data correspond well to the published IHC and ISH
data for SIRT1 in both mouse and rat brains (Ramadori et al., 2008; Zakhary et al., 2010).
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To further test the responsiveness of novel SIRT1-selective radiotracer 2-[18F]PhAHA to an
inhibitor in vivo, EX-527 was used at 5mg/kg dose i.p. 30 min prior to imaging to demonstrate
differences in 2-[18F]PhAHA-derived radioactivity accumulation before and after inhibitor
administration in the same animal, 24 hours apart. The significant decreases in 2-[18F]PhAHAderived radioactivity accumulation evident in dynamic PET/CT images after administration of
inhibitor, specifically in regions of the brain of previously high radioactivity accumulation,
validates the in vivo selectivity of this radiotracer for SIRT1. Quantitatively, these differences are
demonstrated as differences in SUV at 22 min post radiotracer injection, for many regions of the
brain, as well as muscle for reference (Fig. 53). As previously noted, the brainstem demonstrates
little SIRT1 activity and accumulation of 2-[18F]PhAHA-derived radioactivity product, this is
further validated through the lack of differences seen with and without inhibitor (Fig. 53).
However, it should be noted that EX-527 may have limited BBB penetrability, thereby dampening
the effects of the inhibitor within the brain. This is evidenced by other ongoing studies in rats
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Figure 53. A) PET/CT images acquired with 2-[18F]PhAHA (at 20 min post i.v. bolus injection)
and without administration of SIRT1 selective inhibitor EX-527 (5 mg/kg) given 30 min prior to
radiotracer i.p.. B) Quantification of dynamic PET/CT images demonstrating a decrease in uptake
of 2-[18F]PhAHA in areas of high SIRT1-specific accumulation within the brain.
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bearing brain tumors, with a broken BBB, where much greater differences in 2-[18F]PhAHAderived radioactivity accumulation are seen before and after inhibitor administration.
Additional PET/CT images were acquired using radiolabeled metabolites of 2-[18F]PhAHA
(37), including 2-[18F]Ethylbenzoate (30), 2-[18F]benzoic acid (31) and 2-[18F]benzaldehyde (34)
in both normal mice and rats (Fig. 54-55). It is possible that when 2-[18F]PhAHA is cleaved the
phenyl ring leaving group may be attached to the -OADPR ring only briefly due to increased steric
hindrance of a phenyl ring as compared to an acetyl moiety. While more in vitro studies are needed
to understand this mechanism in full, imaging animals with possible radiolabeled metabolites
provides information regarding the potential contribution of metabolites to the images acquired
with 2-[18F]PhAHA. This study also helps to identify whether SIRT1 mediated cleavage is the
primary source of cleavage for the parent compound or whether peripheral cleavage is occurring,
leading to an increased fraction of free metabolites.

Figure 54. A) PET/CT images of a mouse post i.v. administration of 2-[18F]Benzoic acid (31) B): PET/CT
images of a mouse post i.v. administration of 2-[18F]ethylbenzoate (30) C) Overlay of A and B D) PET/CT
images of a rat post i.v. administration of 2-[18F]Ethylbenzoate. All images taken at 25 min. post
radiotracer injection.
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2-[18F]Ethylbenzoate was chosen as an attempt to create a more BBB permeable metabolite
that would be cleaved to 2-[18F]benzoic acid (31) upon entering the brain by the abundant brain
esterases. However, PET/CT images in mice at 20 min. post i.v. administration of 30 and 31
demonstrated an increased BBB penetration of 31 over 30, which was surprising given the nature
of the compounds’ polarity (Fig. 54). Furthermore, once inside the brain both of these compounds
exhibited remarkable differences in accumulation patterns. Compound 31 accumulates
preferentially in the median reticular nucleus (-2.0- -4.0), where as compound 30 accumulates
much more in the hypothalamic and amygdala regions (-2.0) (Fig. 53-54). Also, interesting to note
that imaging with compound 30 in a rat (Fig. 54D, Fig 55) does not demonstrate the same patterns
as in a mouse and exhibits even lower BBB permeability. One possible reason for these differences
could be due to changes in esterase activity between species. The reasoning behind reduced BBB
penetrance with compound 30 is still
yet unknown and warrants further
investigation.
In a rat, compounds 30 and 34
were studied with the parent compound
37.

Compound

significantly

34

demonstrated

increased

BBB

permeability over compound 30 and
strong accumulation in the brainstem
(Fig. 54). 2-[18F]benzaldehyde exhibits
Figure 55. PET/CT images with compound 30
(bottom) and 31 (top) and corresponding brain
histology and maps.

remarkably

different

patterns

of

radioactivity accumulation within the
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brain as compared to the
parent

compound,

2-

[18F]PhAHA. The biggest
difference between the two
is a great increase in
accumulation

of

2-

[18F]benzaldehyde-derived
radioactivity
brainstem,

within

the

whereas

2-

[18F]PhAHA-derived
radioactivity accumulation
in this area is minimal.
There are some regions
within the brain of overlap,
such as nucleus accumbens.
The

large

patterns

of

accumulation
these

three

variation

in

radioactivity
between

Figure 56. Comparison between PET/CT images acquired 20
min. post i.v. administration of three tracers, the parent compound
2-[18F]PhAHA (37), and two possible metabolites: 2[18F]benzaldehyde (34) and 2-[18F]Ethylbenzoate (30)
metabolized to 2-[18F]benzoic acid (31).

radiotracers

within the brain highlights the results of using a substrate-type radiotracer. Within the brain,
SIRT1-mediated cleavage of the parent compound causes cellular entrapment of the radiolabeled
leaving group. Administration of the “pre-cleaved” metabolite (i.e. fluorobenzoic acid or
fluorobenzaldehyde) does not allow enzyme-mediated entrapment to occur.
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The pattern of accumulation of 2-[18F]-benzaldehyde (34) within specific regions of the brain
has not yet been fully explained. However, it is known that benzaldehyde acts as a potent inhibitor
of glutathione peroxidase (GSH-PX) (Tabatabaie and Floyd, 1996). Reportedly, 250 μM of
benzaldehyde is sufficient to completely remove all residual GSH-PX activity and 2bromobenzaldehyde or 2-hydroxybenzaldehyde reduce GSH-PX activity by 80% at 250 μM
(Tabatabaie and Floyd, 1996). These two compounds have similar chemical properties and size to
2-fluorobenzaldehyde. Furthermore, areas within the brain demonstrating high levels of GSH-PX
include structures within the brainstem (i.e. pons, medulla, mesencephalon) (Nisticò et al., 1992).
These structures have almost a 2 fold increase in levels of active GSH-PX over other structures
within the brain such as the cortex and hippocampus, particularly in adult rats (Nisticò et al., 1992).
These findings may provide an explanation to the perceived selectivity for 2-[18F]-benzaldehyde
(34) accumulation within structures of the brain, though more studies are needed for conclusive
results.
At this point, we can conclude that the metabolites may not be having a large influence on
the distribution of 2-[18F]PhAHA seen in the brain. Even more importantly, there is a difference
between SIRT1-mediated cleavage of 2-[18F]PhAHA and administering the pre-cleaved product,
thus indirectly supporting the theory to the degree of radiolabeled metabolite entrapment within
the cell. Further studies are also necessary to understand why the stark difference in BBB
permeability between 30 and 31.
The translation of 2-[18F]PhAHA to in vivo PET imaging may further the field of epigenetic
regulation in both norm and disease and facilitate the development and clinical translation of
SIRT1-targeted drugs. PET imaging with a substrate type radiotracer such as 2-[18F]PhAHA will
allow for in vivo visualization and quantification of the enzyme expression-activity product.
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Therefore, the accumulation of 2-[18F]PhAHA derived radioactivity is directly proportional to the
amount of active enzyme in a tissue. The current approach to imaging SIRT1 activity using
substrate-type radiotracers complements other methodologies for PET imaging of enzymes,
including radiolabeled inhibitors. PET imaging with radiolabeled enzyme inhibitors is essentially
similar to a receptor-ligand based imaging approach, where the amount of radiotracer-derived
radioactivity accumulation is proportional to the amount of free (unoccupied) receptor or enzyme
in a given tissue (J, 2000). The visualization of receptor or enzyme occupancy is especially
important for determining the pharmacokinetics and bio-distribution of an inhibitor (i.e. drug or
therapeutic agent). Successful inhibitor-type radiotracers have been developed specifically for
HDAC class I, in the form of

11

C-Martinostat (Hooker et al., 2009). However, imaging with an

inhibitor does not provide information about the enzyme activity. In contrast, substrate-type
radiotracers allow for assessment of the enzyme expression-activity and monitoring the
pharmacodynamics of inhibitor at the target (enzyme) level.
Conclusions
Visualization and quantification of SIRT1 expression-activity non-invasively in vivo via PET
imaging may help elucidate the role of SIRT1 in both norm and disease. This work includes the
first ever PET/CT imaging with and characterization of SIRT1-selective radiotracer, 2[18F]PhAHA, in the brain and can be applied to many future studies of larger animals and
pathologies such as cancers and neurodegenerative disorders. Additionally, this novel
understanding of SIRT1 structure activity relationships may help in development of BBB
permeable pharmacologic modulators. In summary, the development of a novel method for
imaging SIRT1 expression-activity in the brain should help further the field of epigenetics and
treatment of untreatable diseases.
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Experimental Section
All solvents were purchased from Sigma-Aldrich Chemicals (Milwaukee, WI) and used
without further purification. Boc-Lys(Ac)-AMC and Cbz-Lys-OH were purchased from Bachem
(Bubendorf, Switzerland) and used without further purification. Preparation of 6-amino1hexanoicanilide (Mukhopadhyay et al., 2006) was synthesized using a previously published
procedure (Yeh et al., 2013a). Thin layer chromatography (TLC) was performed on pre-coated
Dynamic Absorbance F-254 silica gel, aluminum backed plates (Norcross, Georgia); flash
chromatography was performed using silica gel pore size 60 Å, 230-400 mesh particle size (SigmaAldrich, Milwaukee, WI). NMR spectra including 1H,

13

C and

19

F were performed on Mercury

400 MHz, Varian 500 MHz or Agilent 600 MHz spectrometers. High-resolution mass spectra
(HRMS) were obtained using Waters LCT Premier/XE spectrometer (Milford, MA) with an
electrospray ionization (ESI) technique. The analytical high performance liquid chromatography
(HPLC) system included: Ascentis RP-Amide 4.4x150 mm column (Supelco, Bellefonte, PA)
connected to the 1100 series pump and UV detector (Agilent Technologies, Stuttgart, Germany),
operated at 254 nm, and a radioactivity detector FC3200 (Eckert and Ziegler Radiopharma, Inc,
Berlin, Germany). The semi-preparative HPLC system included: the Alltima 250x10mm C18
column (Fisher Scientific, Waltham, MA) connected to the P4.1S pump, Azura 2.1S UV detector
(Knauer, Berlin, Germany), operated at 254 nm, and a radioactivity detector FC-3500 (Eckert and
Ziegler Radiopharma, Inc, Berlin, Germany).
SIRT Enzyme Assay: Recombinant SIRT1-7 enzymes and BPS1 reference substrate for
SIRT2, an oligopeptide corresponding to 379-382 of p53 (Arg-His-Lys-Lys(Ac)-AMC) were
purchased from BPS Bioscience (San Diego, CA). 10 mM solutions of all newly synthesized
compounds were prepared in pure DMSO and then diluted to 100 µM aliquots in DMSO for further
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use. Enzyme assay reactions were performed in black, low binding 96-well microtiter plates (Nagle
Nunc International, Rochester, NY). Endpoint assays were performed by incubation of the
appropriate substrate, NAD, a SIRT enzyme, and inhibitor (if applicable) in enzyme assay buffer
(50 µL final volume). Control wells without enzyme were included in each plate. After 40 min at
37 °C, a developer mixture (50 µL) containing nicotinamide (2 mM) and trypsin (0.4 mg mL−1)
was added, and the mixtures incubated for 30 min at 22°C. The intensity of cleaved 7-amino4methylcoumarin (AMC) fluorescence was measured using Synergy H1 microplate reader
(Biotek, Winooski, VT) at 360 nm excitation and 450 nm emission wave lengths. Experiments for
determination of enzyme kinetic parameters were performed by incubation of test compounds or
BPS1 reference substrate at different concentrations with NAD+ and individual SIRT enzymes in
an assay buffer (100 µL final volume) at 37°C for different periods of time (5, 10, 20, 30, and 60
min), followed by in situ fluorophore cleavage by addition of a developer mixture (50 µL)
containing nicotinamide (2 mM) and trypsin (0.4 mg mL−1). Fluorescence was measured as
relative fluorescence units (RFU) at 22°C to determine the initial linear rate V0 (RFU min −1) for
each concentration. The data were analyzed using GraphPad Prism v6.02 (GraphPad, La Jolla,
CA) to afford km (µM) and Vmax (RFU min−1) values. The kcat values were calculated based on
the RFU vs AMC concentration standard curve and the enzyme purities and concentrations
provided by the manufacturer.
Fluorescent Staining: Perfused and fixed rat brains were sliced into 20 μm thick slices on
a microtome for staining. The slices were mounted onto slides and stained with fluorescently
conjugated primary SIRT1 antibody (Abcam) using 1:200 dilution. Following staining the slides
were cover slipped using Vecashield mounting medium with DAPI included by placing 25 μL
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drops of mounting media on each tissue slice. Images were taken using EVOS FL Auto Imaging
System microscope (Thermo Fisher Scientific).
MRI Procedure: Animals initially anesthetized with 5% isoflurane, and maintained
between 2-3% for the remainder of the experiment. During the procedure each animal was placed
on a heated re-circulating water platform in order to maintain body temperature. The animals were
held in position using a bite bar and a receive-only surface coil 2-element phased array for the rat
brain) was placed dorsal to the head. Scans were acquired using a 7T ClinScan system (Bruker,
UK) controlled by the Syngo software (Siemens, Knoxville, TN). A localizing scan was performed
and adjustments to head position were made accordingly. T2 images were obtained (repetition time
[TR] 3530 ms echo time, [TE] 38 ms, FOV 3.2 cm x 3.2 cm x 2.4 cm, resolution 125 µm x 125
µm x 1 mm). Images were processed using ImageJ software (Bethesda, MD).
PET Imaging Procedures in Animals: All studies performed under a protocol approved
by the Institutional Animal Care and Use Committee of Wayne State University. Sprague-Dawley
rats (200-250 g, N=3) were anesthetized with 3% isoflurane in oxygen and maintained at 2%
isoflurane in oxygen throughout the imaging studies. The body temperature was maintained using
electronically controlled heating pad (M2M Imaging, Cleveland, OH) set at 37oC. Anesthetized
rats placed in the microPET R4 scanner (Siemens, Knoxville, TN) in the supine position with the
long axis of the animal parallel to the long axis of the scanner with the brain positioned in the
center of the field of view. Each radiotracer (300-500 µCi/animal) was administered in saline via
the tail-vein injection in a total volume ≤1.25 ml. Dynamic PET images were obtained over 60
minutes, followed by 2 overlapping frames (5 min each) acquired to obtain a whole body images
of radiotracer biodistribution in other organs and tissues. After PET imaging, the positioning bed
with the affixed anesthetized animal was transferred to the Inveon SPECT/CT scanner (Siemens,
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Knoxville, TN) and CT images and 4 overlapping frames (2 min each) were acquired covering the
whole body using X-ray tube settings of 80 kV and 500 μA.
Image Analysis and Quantification: PET images were reconstructed using ordered subset
expectation–maximization (OSEM) method. PET image analysis was accomplished using the
AMIDE software. Digital Rat Brain Atlas was used for alignment and identification of specific
anatomical markers in the brain (Watson, 2006). GraphPad Prism 6 (Graph Pad Software La Jolla,
CA) and Excel 2010 (Microsoft, Redmond, WA) were used for image data analysis. Levels of
accumulation of individual radiotracers in tissues were expressed as standard uptake values (SUV)
that were calculated for the regions of interest (Ron S. Broide and Floyd E. Bloom) using the
AMIDE software. The SUV is defined as the ratio of the tissue radioactivity concentration C (e.g.
expressed as Bq/g tissue) at given time point post injection T, and the injected dose (e.g. in Bq,
decay-corrected to the same time T), and normalized by the body weight in grams. Calculations
for Logan plot analysis were performed as previously noted (Logan J, 1996).
Autoradiography: After PET imaging (or at certain time point after 300-500 µCi
radiotracer injection i.v.), the animals were sacrificed, the brain was rapidly extracted, frozen, and
embedded in the mounting medium M1 (Shandon-Lipshaw, Pittsburg, PA). Serial 20 µm thick
coronal sections of frozen brain tissue were obtained at -13°C using a cryo-microtome CM3050S
(Leica, Germany). Tissue sections were thaw-mounted on poly-A lysine coated glass slides and
heat-fixed for 5 min at 65°C on a slide warmer (Fischer Scientific, PA). Tissue sections, mounted
on slides, exposed to single-emulsion Carestream Kodak BioMax MR film (8”x10”, Sigma,
Milwaukee, WI), without exposure to light, in cassettes for 12 hours. After tissue exposure,
processing of the film used an automated system (Kodak X-Omat, Center for Molecular Medicine
and Genetics, Wayne State University).
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Chemical Synthesis:
Method 1: For new substrate analogues, we primarily modified the protecting group on α-nitrogen
and the acyl substituent on the ε-amino group. Benzyloxy carbonyl (Z, Cbz) was investigated as a
protecting group within the cap moiety. Compounds were prepared following previously published
methods (Heltweg et al., 2004; Heltweg et al., 2003) as shown in the synthetic Fig. 29-30 with
minor modifications. Compounds 17-27 were synthesized from commercially available Cbz-LysOH with formation of corresponding acetyl chloride following the published methods (Heltweg et
al., 2004) which upon reaction with AMC (19) in presence of POCl3 and pyridine provide desired
product in moderate to good yields.
Synthesis of compound 16: Cbz-Lys (1 equiv.) was dissolved in a mixture of THF (5 mL)
and water (5 mL). To this sodium bicarbonate (2 equiv.) and a solution of Boc2O (2.3 equiv.) in
THF (5 mL). After stirring at room temperature overnight, the THF was removed under reduced
pressure and the resulting aqueous solution was neutralized with 2N HCl. This was extracted with
ethyl acetate and the combined organic layers were washed with brine. The organic layer was dried
with sodium sulfate and concentrated to clear. The clear oil was used for further reaction without
any purification with 2 in presence of NMM/isobutyl chloroformate (Fig 2).
Benzyl

(6-acetamido-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino-1oxohexan-2-

yl)carbamate (17): Compound 17 was prepared following previously published method 1,
(Heltweg et al., 2004) as described in the synthetic Scheme 1 (Figure 1 and 2). Here we report MS
(EI) and HRMS of the compound. MS (EI): m/z 478.4 [M-H]. High-resolution MS: Calculated for
C26H29N3O6 (M+Na) 502.1954, found 502.1953.
Benzyl

(6-benzamido-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-oxohexan-2-

yl)carbamate (18): Compound 18 was synthesized by method 1 (Heltweg et al., 2004). The
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resulting product was chromatograph with 5% methanol in dichloromethane. Yield: 63%, 1H NMR
(CDCl3, 600 MHz): δ 9.38 (s, 1H), 7.76 (d, 2H, J = 7.8 Hz), 7.68 (s, 1H), 7.602-7.46 (m, 3H),
7.39-7.34 (m, 7H), 6.18 (s, 1H), 595 (d, 1H, J = 7.2 Hz), 5.11 (m, 2H), 4.41 (s, 1H), 3.49 (m, 1H),
2.40 (s, 3H), 2.07-2.05 (m, 1H), 1.88-1.80 (m, 1H), 1.70-1.64 (m, 2H), 1.56-1.50 (m, 2H).

13

C

NMR (CDCl3, 600 MHz): δ 171.00, 168.24, 161.26, 156.92, 154.07, 152.46, 141.47, 136.08,
134.25, 134.23, 131.61, 128.61 (2C), 128.25, 128.02, 126.92 (2C), 125.10, 116.04, 115.84, 11.31,
107.30, 67.28, 55.41, 38.73, 38.60, 31.24, 29.71, 28.75, 22.26, 18.56. MS (EI): m/z 542.6 [M+H].
High-resolution MS: Calculated for C31H31N3O6 (M+Na) 564.2111, found 564.2105.
Benzyl

(6-(2-fluorobenzamido)-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-

oxohexan-2-yl)carbamate (19). Compound 19 was synthesized by method 1 (Heltweg et al.,
2004). The resulting product was chromatograph with 3% methanol/dichloromethane and purified
by combiflash with 5% methanol/dichloromethane. Yield: 69%, 1H NMR (DMSO-d6, 600 MHz):
δ 10.51 (s, 1H), 8.29 (s, 1H), 7.77 (brs, 1H), 7.71 (d, 1H, J = 8.4 Hz), 7.65 (d, 1H, J = 7.8 Hz), 7.54
(t, 1H, J = 7.2 Hz), 7.50-7.47 (m, 2H), 7.38-7.31 (m, 4H), 7.24-7.17 (m, 2H), 6.27 (s, 1H), 5.03 (s,
2H), 4.16 (m, 1H), 3.24 (q, 2H, J = 6.6 Hz), 2.40 (s, 3H), 1.72-1.66 (m, 2H), 1.56-1.38 (m, 4H).
C NMR (DMSO-d6, 600 MHz): δ 172.49, 164.15, 160.59, 160.28, 158.63, 156.65, 154.09,

13

153.68, 142.67, 137.39, 132.66, 130.42, 128.84 (2C), 128.32 (2C), 126.41, 124.85, 116.55, 116.40,
115.77, 115.56, 112.75, 106.19, 65.98, 56.05, 39.33, 31.74, 29.04, 23.39, 18.45.19F (DMSO-d6,
300 MHz): δ -114.49. MS (EI): m/z 560.6 [M+H]. High-resolution MS: Calculated for
C31H30FN3O6 (M+Na) 582.2016, found 582.1989.
Benzyl

(6-(3-fluorobenzamido)-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-

oxohexan-2-yl)carbamate (20). Compound 20 was synthesized by method 1 (Heltweg et al.,
2004). The resulting product was chromatograph with 3% methanol in dichloromethane and
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purified by combiflash with 5% methanol/dichloromethane. Yield: 66%, 1H NMR (CDCl3): δ 9.19
(brs, 1H), 7.67 (s, 1H), 7.55-7.49 (m, 4H), 7.46-7.351 (m, 6H), 7.20 (t, 1H, J = 7.8 Hz), 6.56 (brs,
1H), 6.22 (s, 1H), 5.85 (brs, 1H), 5.14 (m, 2H), 4.40 (s, 1H), 3.51 (m, 2H), 2.43 (s, 3H), 2.07-2.06
(m, 1H), 1.88-1.80 (m, 1H), 1.72-1.60 (m, 2H), 1.56-1.52 (m, 2H). 13C NMR (CDCl3): δ 170.56,
166.86, 163.54, 161.18, 154.11, 152.21, 141.10, 136.00, 130.32, 128.59 (2C), 128.31, 128.06 (2C),
125.14, 122.43, 118.66, 118.52, 116.15, 115.80, 114.41, 114.27, 113.41, 107.31, 67.36, 55.34,
38.73, 30.95, 28.61, 22.16, 18.59. 19F (CDCl3, 300 MHz): δ -111.60. MS (EI): m/z 560.6 [M+H].
High-resolution MS: Calculated for C31H30FN3O6 (M+Na) 582.2016, found 582.1986.
Benzyl

(6-(4-fluorobenzamido)-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-

oxohexan-2-yl)carbamate (21). Compound 21 was synthesized by method 1 (Heltweg et al.,
2004). The resulting product was chromatograph with 5% methanol in dichloromethane and
purified by combiflash with 5% methanol/dichloromethane. Yield: 72%, 1H NMR (CDCl3): δ 9.38
(s, 1H), 7.78 (m, 2H), 7.66 (s, 1H), 7.51-7.45 (m, 2H), 7.39-7.33 (m, 5H), 6.99 (t, 2H, 6J), 6.65 (t,
1H, J = 6 Hz)), 6.15 (s, 1H), 6.02 (d, 1H, J = 8 Hz)), 5.11 (s, 2H), 4.45 (brs, 1H), 3.49-3.46 (m,
2H), 2.39 (s, 3H), 2.01-1.88 (m, 2H), 1.71-1.67 (m, 2H), 1.55-1.50 (m, 2H). 13C NMR (CDCl3): δ
170.91, 167.16, 165.59, 161.17, 154.1, 152.36, 141.37, 136.00, 130.38 (2C), 129.31 (2C), 129.25,
128.60 (2C), 128.32, 128.06, 125.13, 116.12, 115.80, 115.69, 115.54, 113.40, 107.30, 67.37,
55.38, 38.66, 30.93, 28.69, 22.17, 18.57. 19F (CDCl3, 300 MHz): δ -107.70. MS (EI): m/z 560.6
[M+H]. High-resolution MS: Calculated for C31H30FN3O6 (M+Na) 582.2016, found 582.1985.
Benzyl

(1-((4-methyl-2-oxo-2H-chromen-7-yl)amino-1-oxo-6-(2-

phenylacetamido)hexan-2-yl)carbamate (22). Compound 22 was prepared following previously
published method 1 (Heltweg et al., 2004) as described in the synthetic Scheme 1. The resulting
product was chromatograph with 3% methanol in dichloromethane and purified by combiflash
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with 5% methanol/dichloromethane. Yield: 59%, This is known compound, so here we report MS
(EI): m/z 554.6 [M-H]. High-resolution MS: Calculated for C32H33N3O6 (M+Na) 578.2267, found
578.2269.
Benzyl (6-(2-(2-fluorophenyl)acetamido)-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)1-oxohexan-2-yl)carbamate (23). Compound 23 was synthesized by method 1 (Heltweg et al.,
2004). The resulting product was chromatograph with 3% methanol in dichloromethane and
purified by combiflash with 5% methanol/dichloromethane. Yield: 57%, 1H NMR (DMSO-d6): δ
10.52 (s, 1H), 8.06 (t, 1H, J = 5.4 Hz), 7.78 (s, 1H),7.73-7.64 (m, 2H), 7.51 (s, 1H), 7.37-7.24 (m,
7H), 7.12-7.09 (m, 2H), 6.27 (s, 1H), 5.04 (s, 2H), 4.13 (m, 1H), 3.04 (m, 2H), 2.40 (s, 3H), 1.681.33 (m, 6H). 13C NMR (DMSO-d6): δ 172.10, 169.51, 167.22, 160.38, 156.18, 154.00, 153.68,
142.69, 137.39, 132.19, 129.14, 129.01 (2C), 128.96, 128.85 (2C), 126.45, 124.60, 122.62, 115.79,
115.57, 115.48, 112.76, 106.19, 65.99, 55.33, 38.98, 35.74, 31.17, 28.81, 22.85, 18.45.

19

F

(DMSO-d6, 300 MHz): δ -117.40. MS (EI): m/z 572.6 [M-H]. High-resolution MS: Calculated for
C32H32FN3O6 (M+Na) 596.2173, found 596.2180.
Benzyl (6-(2-(4-fluorophenyl)acetamido)-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)1-oxohexan-2-yl)carbamate (24). Compound 24 was synthesized by method 1 (Heltweg et al.,
2004). The resulting product was chromatograph with 3% methanol in dichloromethane and
purified by combiflash with 5% methanol/dichloromethane. Yield: 60%, 1H NMR (MeOD): δ 7.78
(s, 1H), 7.67 (d, 1H, J = 8.2 Hz), 7.46 (d, 1H, J = 2 Hz), 7.39-7.25 (m, 7H), 7.00-6.97 (m, 2H),
6.22 (s, 1H), 5.12-5.11 (m, 2H), 4.26 (t, 1H, J = 5.3 Hz), 3.45 (s, 2H), 3.19 (t, 2H, J = 6.6 Hz), 2.45
(s, 3H), 1.86-1.74 (m, 2H), 1.56-1.40 (m, 4H).

13

C NMR (MeOD): δ 172.44, 172.36, 162.70,

161.81, 161.08, 157.23, 153.91, 153.82, 141.94, 136.74, 131.58, 130.61, 130.40, 130.35, 128.09,
127.66, 127.48, 125.27, 115.82, 115.79, 114.81, 114.76, 112.22, 106.66, 66.40, 55.83, 42.37,
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38.79, 31.46, 28.58, 22.82, 17.12. 19F (MeOD, 300 MHz): δ -118.40. MS (EI): m/z 574.7 [M+H].
High-resolution MS: Calculated for C32H32FN3O6 (M+Na) 596.2173, found 596.2173.
Benzyl

(6-(4-iodobenzamido)-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-

oxohexan-2-yl)carbamate (25). Compound 25 was synthesized by method 1 (Heltweg et al.,
2004). The resulting product was chromatograph with 5% methanol in dichloromethane and
purified by combiflash with 5% methanol/dichloromethane. Yield: 60%, 1H NMR (CDCl3): δ
9.17 (s, 1H), 7.69-7.66 (m, 3H), 7.54-7.46 (m, 4H), 7.42-7.34 (m, 5H), 6.21 (s, 1H), 5.86 (brs, 1H),
5.12 (s, 2H), 4.38 (brs, 1H), 3.55-3.44 (m, 2H), 2.43 (s, 3H), 2.10-2.06 (m, 1H), 1.89-1.84 (m, 1H),
1.71-1.68 (m, 2H), 1.57-1.50 (m, 2H). 13C NMR (MeOD): δ 171.50, 166.21, 160.30, 155.42,
152.20, 135.86, 132.30 (2C), 126.97, 126.58 (2C), 126.15, 125.96, 123.76, 122.76, 120.18, 119.09,
118.70, 116.95, 114.96, 114.32, 110.82, 105.17, 96.01, 64.87, 54.25, 37.45, 29.90, 27.00, 21.10,
15.70. MS (EI): m/z 667.5 [M+]. High-resolution MS: Calculated for C31H30IN3O6 (M+Na)
690.1077, found 690.1075.
Benzyl (6-(2-(4-iodophenyl)acetamido)-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)1-oxohexan-2-yl)carbamate (26). Compound 26 was synthesized by method 1 (Heltweg et al.,
2004). The resulting product was chromatograph with 3% methanol in dichloromethane and
purified by combiflash with 5% methanol/dichloromethane. Yield: 72%, 1H NMR (MeOD): δ 8.11
(brs, 1H), 7.88 (d, 1H, J = 8.4 Hz), 7.82 (s, 1H), 7.76-7.73 (m, 2H), 7.67 (d, 1H, J = 8.4 Hz), 7.61
(d, 1H, J = 7.8 Hz), 7.54-7.48 (m, 2H), 7.40-7.31 (m, 2H), 7.09 (d, 1H, J = 7.8 Hz), 7.04 (d, 1H, J
= 8.4 Hz), 6.26 (s, 1H), 5.13 (m, 2H), 4.25 (m, 1H), 3.43 (s, 2H), 3.21 (m, 2H), 2.48 (s, 3H), 1.891.74 (m, 2H), 1.56-1.48 (m, 4H). 13C NMR (MeOD): δ 172.04, 171.92, 161.87, 154.00, 153.89,
137.31 (2C), 137.23, 135.45, 131.20, 130.80 (2C), 128.09, 127.67, 127.50, 126.50, 125.35, 115.91,
115.86, 112.26, 106.72, 91.30, 66.41, 55.80, 41.83, 38.53, 31.45, 28.53, 22.78, 17.15. MS (EI):
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m/z 680.4 [M-H]. High-resolution MS: Calculated for C32H32IN3O6 (M+Na) 704.1233, found
704.1231.
Benzyl

(6-(4-ethylbenzamido)-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-

oxohexan-2-yl)carbamate (27). Compound 27 was synthesized by method 1 (Heltweg et al.,
2004). The resulting product was chromatograph with 5% methanol in dichloromethane and
purified by combiflash with 5% methanol/dichloromethane. Yield: 77%, 1H NMR (CDCl3): δ 9.71
(s, 1H), 7.68 (m, 3H), 7.44-7.39 (m, 2H), 7.38-7.30 (m, 4H), 7.12 (d, 2H, J = 7.8 Hz), 6.87 (s, 1H),
6.26 (d, 1H, J = 7.8 Hz), 6.11 (s, 1H), 5.07 (s, 2H), 4.45 (brs, 1H), 3.42 (m, 2H), 2.62 (q, 2H, J =
7.2 Hz), 2.44 (s, 3H), 1.98-1.82 (m, 2H), 1.67-1.48 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz). 13C NMR
(CDCl3): δ 171.55, 168.20, 161.40, 156.88, 153.89, 152.75, 148.11, 141.63, 136.17, 131.90,
128.51 (2C), 128.13, 127.97 (2C), 127.89, 127.10 (3C), 125.05, 115.93, 115.84, 113.52, 107.21,
67.14, 55.65, 39.09, 31.78, 28.89, 28.70, 22.55, 18.51, 15.27. MS (EI): m/z 570.7 [M+H]. Highresolution MS: Calculated for C33H35N3O6 (M+Na) 592.2424, found 592.2433.
Synthesis of 4-fluoro-phenylhexanoicanilide (28): 0.64 mmol of 4-fluorophenylacetic acid
(purchased from Alfa-Aesar) was dissolved in ACN and 1 equivalent of DMAP was added with a
catalyst amount of DCC. The mixture was stirred under argon for 10 minutes. Subsequently the
amine, compound R1, (0.48 mmol) was dissolved in ACN and added to the mixture dropwise. The
reaction was stirred under argon, at room temperature, overnight. The compound was purified
using flash chromatography on a silica column and eluted with 3% MeOH in DCM. The compound
was dried as white crystals in a yield of 77%. 1H NMR (499 MHz, CDCl3) δ 8.19(s, 1H), 8.12 (d,
J = 7.9 Hz, 1H), 7.90 (t, J = 7.9 Hz, 1H), 7.85 (dd, J = 8.5, 5.4 Hz, 2H), 7.79 (dd, J = 8.4, 5.4 Hz,
1H), 7.69 (t, J = 7.3 Hz, 1H), 7.59 (t, J = 8.7 Hz, 3H), 6.27 (s, 1H), 4.20 (s,3H), 4.10 (s, 1H), 3.99
(t,2H, J = ), 3.82 (dd, J = 13.2, 6.8 Hz, 1H), 2.92 (t, J = 7.3 Hz, 1H), 2.50 (dd, J = 12.6, 3.2 Hz,
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3H), 2.36 – 2.24 (m, 4H), 2.11 – 2.01 (m, 2H), 1.90 (d, J = 12.5, 8.9 Hz, 4H), 1.77 – 1.66 (m, 4H).
C NMR (126 MHz, CDCl3) δ 175.42, 171.36, 130.95, 128.95, 124.19, 119.80, 115.83 (d, J =
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21.3 Hz), 115.36 (d, J = 21.5 Hz), 77.27, 77.02, 76.76, 49.38, 42.80, 40.45, 39.29, 37.17, 33.70,
28.87, 25.96, 25.51, 24.84, 24.68. 19F NMR (376 MHz, CDCl3) δ -115.86 (m).
Radiosynthesis of 4-18F-phenylhexanoicanilide (28a): A solution of kryptofix/ K[18F] was
received from the cyclotron and transferred into a crimped V-vial for drying. Acetonitrile (0.4
mL) was added to the mixture and it was dried under a stream of argon at 80°C. 4 mg of 4-nitro
benzaldehyde in 0.4mL of DMF was added and stirred for 20 min at 120°C under Argon. 0.2mL
of CHCl3 was then added to the mixture with 0.2mL of KOH/MeOH and stirred at -78°C for 10
min. The reaction mixture was evaporated under argon at room temperature to the DMF base.
The resulting mixture was eluted through a cartridge with 10% MeOH/DCM and evaporated to
dryness. Subsequently, 0.4mL of t-Bu-OH was added with concentrated, 5M, NaOH and stirred
for 5 min at room temperature. Borohydride (10mg) was added to the reaction mixture and stirred
for 10 minutes at 50°C. The resulting mixture was filtered and injected into semi-prep HPLC and
purified with 35% ACN in H2O. The eluted mixture was coupled with compound 1 (10mg) using
DCC and DMAP. This was then purified for a yield of 180 uCi of pure compound (0.2% yield not
decay corrected).
2-Nitro-ethylbenzoate (29): Purchased from Alfa Aesar and used without further
purification.
2-F-ethylbenzoate (30a): Purchased from Alfa Aesar and used without further purification.
2-18F-ethylbenzoate (30b): The F-18 was obtained in kryptofix/K[18F] complex in
acetonitrile/water (1 mL) from the PET/Cyclotron Facility, Wayne State University (Detroit, MI)
and transferred into a crimped 2 mL V-vial for azeotropic drying. Acetonitrile (0.4 mL) was added
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to the mixture, which was dried under a stream of argon at 90-100°C. A solution of 29 (~2 mg) in
dry DMSO (0.4 mL) was added to the dried kryptofix/ K[18F] and heated to 120°C under argon
with stirring for 15 minutes. After cooling, the reaction mixture was passed through a 900 mg
Altech silica gel cartridge (Fisher Scientific, Waltham, MA) and eluted with 2 mL of 10%
methanol in dichloromethane (DCM). The solvent was evaporated under a stream of argon to
remove DCM and to reduce the volume to 0.5 mL. 31 was purified by semipreparative HPLC
(50% ACN in water) by collecting the peak at 15 min. The decay corrected radiochemical yield
was 25% and the compound purity was >95%, as assessed by analytical HPLC and co-elution with
the non-radiolabeled reference standard 32.
2-18F-benzoic acid (31): Compound 30 was treated with 0.5mL of 1M NaOH at 80°C for 10
minutes for hydrolysis of the ester group and form 31. Completion of the reaction was assessed by
analytical HPLC. Subsequently, the solution was neutralized to pH of 7.5 with 0.5 mL of 1M HCl
and the mixture was evaporated to dryness under a stream of argon. Compound 31 was redissolved
in saline and prepared for animal injection.
2-Nitro-benzaldehyde (32): Purchased from Alfa Aesar and used without further
purification.
2-Fluoro-benzaldehyde (33): Purchased from Sigma and used without further purification.
2-18F-benzaldehyde (34): The F-18 was obtained in kryptofix/K[18F] complex in
acetonitrile/water (1 mL) from the PET/Cyclotron Facility, Wayne State University (Detroit, MI)
and transferred into a crimped 2 mL V-vial for azeotropic drying. Acetonitrile (0.4 mL) was added
to the mixture, which was dried under a stream of argon at 90-100°C. A solution of 32 (~2 mg) in
dry DMSO (0.4 mL) was added to the dried kryptofix/ K[18F] and heated to 130-140°C under
argon with stirring for 12 minutes. After cooling, the reaction mixture was passed through a 900
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mg Altech silica gel cartridge (Fisher Scientific, Waltham, MA) and eluted with 2 mL of 10%
methanol in dichloromethane (DCM). The solvent was evaporated under a stream of argon to
remove DCM and to reduce the volume to 0.5 mL. 34 was purified by semipreparative HPLC
(50% ACN in water) by collecting the peak at 15 min. The decay corrected radiochemical yield
was 15% and the compound purity was >95%, as assessed by analytical HPLC and co-elution with
the non-radiolabeled reference standard 33.
2-fluoro-phenylhexanoicanilide, 2-FPhAHA (35): Compound 1 (0.240g, 1.163 mmol) was
dissolved in 5mL of dichloromethane and 0.5mL triethylamine. The 2-fluoro benzoylchloride (0.2
mL, 1.696 mmol) was added dropwise at 0°C. The reaction was stirred at 0°C for 30 minutes then
gradually warmed to RT and stirred under argon for 3 hours. The mixture was washed with
ethylacetate and 4N HCl solution. The organic layer was dried over magnesium sulfate and then
evaporated to dryness.

The resulting crude mixture was re-crystallized with diethyl-ether

overnight and then filtered with vacuum filtration before being dried under high-vacuum. Product
35 (110mg) was made as a white solid in 28% yield. 1H NMR (400 MHz, cdcl3) δ 8.13 – 7.97 (m,
1H), 7.81 (s, 1H), 7.53 (d, J = 7.8 Hz, 2H), 7.45 – 7.41 (m, 1H), 7.35 – 7.16 (m, 3H), 7.16 – 6.99
(m, 2H), 6.80 (s, 1H), 3.46 (d, J = 5.9 Hz, 2H), 2.35 (t, J = 7.3 Hz, 2H), 1.82 – 1.69 (m, 2H), 1.69
– 1.58 (m, 2H), 1.44 (d, J = 6.5 Hz, 2H). 13C NMR (101 MHz, cdcl3) δ 171.33, 163.47, 161.73,
159.28, 138.18, 133.15 (d, J = 9.3 Hz), 131.82, 128.86, 124.75 (d, J = 3.1 Hz), 124.00, 121.21 (d,
J = 11.3 Hz), 119.82, 115.98 (d, J = 24.8 Hz), 77.35, 77.03, 76.71, 39.74, 37.32, 29.17, 26.36,
25.02. M/Z calculated: 329.1665; M/Z found : 329.1654
2-Nitro-N-(6-oxo-6-(phenylamino)hexyl)benzamide: The solution of 2-nitrobenzoyl
chloride (0.12 g, 0.62 mmol) in 0.5 mL of DCM was added dropwise to the mixture of
phenylhexanamide (0.10 g, 0.48 mmol) and Hunig's base (0.13 mL, 0.73 mmol) in DMF (5 mL)
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at 0°C and then left to stir at room temperature for 12 h. The solvent was then evaporated under
reduced pressure; the crude was dissolved in EtOAc and washed with water. The organic layer
was dried over sodium sulfate. Evaporation and purification with column chromatography
(eluent - EtOAc) gave the desired precursor in 70-72% yield. 1H NMR (600 MHz, DMSO-d6) δ
9.87 (s, 1H), 8.66 (t, J = 5.5 Hz, 1H), 8.02 (d, J = 8.1 Hz, 1H), 7.75 (t, J = 7.5 Hz, 1H), 7.67 (t, J
= 7.8 Hz, 1H), 7.60 (d, J = 8.2 Hz, 2H), 7.57 (d, J = 7.5 Hz, 1H), 7.28 (t, J = 7.8 Hz, 2H), 7.01 (t,
J = 7.3 Hz, 1H), 3.22 (dd, J = 12.9, 6.6 Hz, 2H), 2.32 (t, J = 7.4 Hz, 2H), 1.67 – 1.59 (m, 2H),
1.58 – 1.50 (m, 2H), 1.42 – 1.33 (m, 2H). 13C NMR (151 MHz, DMSO-d6) δ 171.2, 165.3, 147.0,
139.4, 133.5, 132.8, 130.5, 129.0, 128.6, 124.0, 122.9, 119.0, 39.0, 36.4, 28.6, 26.1, 24.8. HRMS
(+ESI-TOF) m/z for C19H21N3O4 [M+Na]+ 356.1600; M/Z found : 356.1598
Radiosynthesis of 2-18F-phenylhexanoicanilide 2-[18F]PhAHA (37): The F-18 was
obtained in kryptofix/K[18F] complex in acetonitrile/water (1 mL) from the PET/Cyclotron
Facility, Wayne State University (Detroit, MI) and transferred into a crimped 2 mL V-vial for
azeotropic drying. Acetonitrile (0.4 mL) was added to the mixture, which was dried under a stream
of argon at 90-100°C. A solution of 36 (~2 mg) in dry DMSO (0.4 mL) was added to the dried
kryptofix/ K[18F] and heated to 130-140°C under argon with stirring for 12 minutes. After cooling,
the reaction mixture was passed through a 900 mg Altech silica gel cartridge (Fisher Scientific,
Waltham, MA) and eluted with 2 mL of 10% methanol in dichloromethane (DCM). The solvent
was evaporated under a stream of argon to remove DCM and to reduce the volume to 0.5 mL. 37
was purified by semi-preparative HPLC (65% ACN in water) by collecting the peak at 6 min. The
decay corrected radiochemical yield was 10% and the compound purity was >95%, as assessed by
analytical HPLC and co-elution with the non-radiolabeled reference standard 35.
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5b. Continuing work
The most aggressive and common form of brain cancer, gliomas, can originate from any
glial cell within the brain but most commonly derive from astrocytes (astrocytoma, 70% of the
cases) or oligodendrocytes (oligodendroglioma, 20-25% of the cases), while the remaining tumor
types are formed from a mixture of astrocytes, oligodendrocytes and ependymal cells (Lino and
Merlo, 2009). Glioblastomas or glioblastoma multiforme (GBM) tumors are generally termed as
grade IV astrocytomas, based on the World Health Organization (WHO) classification scale.
Glioblastomas are the most common, making up 50% of functional brain tissue tumors and 20%
of intracranial tumors, as well as the most aggressive brain tumor type (median survival is 14.6
months, 30% 2 year survival). While substantial progress has been made towards improving
diagnosis of this disease, very little progress has been made in regards to treatment over the last
decade.
Currently, GBM is treated primarily with surgery, when possible, followed by radiation
and temozolomide (TMZ) treatment (Dubrow et al., 2013). Approval and increased usage of TMZ
during the last decade has improved patient survival but there continues to be an unmet need for
effective treatments of GBM. The standard of care therapy, even when successful, leaves patients
with an average of only 6.9 months before recurrence (Stupp et al., 2005). Therefore, extensive
research into biological mechanisms behind glioma tumor formation has been a primary area of
focus for many researchers. Subsequently, the field of epigenetics and epigenetic regulators, have
arisen as promising possible treatment targets for of this deadly disease. Epigenetic modifiers, such
as HDAC enzymes, are responsible for manipulating gene transcription and may play a pivotal
role in changing cellular phenotype from benign to malignant. In particular, SIRT1 (class III
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HDAC) has emerged from the group of HDACs as a promising target within epigenetics for cancer
therapy.
SIRT1, as previously mentioned, plays a large role in metabolic regulation and oxidative
stress. One primary complication for SIRT1 targeted therapy, is the pleiotropic role of SIRT1 in
pathologic states and the role of SIRT1 as a strict tumor suppressor or promoter has yet to be fully
uncovered and remains unclear at this time. For example, SIRT1 upregulation is correlated with
disease progression and poor prognosis in breast and pancreatic cancers however the opposite has
been observed in bladder and ovarian cancers (Mvunta et al., 2016; Sanchez-Carbayo et al., 2006).
SIRT1-targeted small molecule activators (i.e. Resveratrol and SRT501) are currently in use in
clinical trials for treatment of colon cancer and hepatocellular carcinoma (NCT00256334,
NCT00920803), in these varieties of cancer, SIRT1 upregulation has been demonstrated to be
beneficial. However, SIRT1 expression within one cancer type at different stages does not remain
constant, implicating SIRT1 as a possible regulator of cancer prognosis.
One possible innovation for GBM that has been identified are SIRT1-targeted therapies
due to its role in apoptotic pathways. Knockdown of SIRT1 in glioma cell lines demonstrated
growth inhibition and increased apoptosis as compared to the wild type cancer cells, indicating
that SIRT1 may play a role in the progression of GBM via PTEN/PI3K/AKT pathway (Qu et al.,
2012); a pathway which is commonly over-activated in GBM (Narayan et al., 2013). Additional
indications of SIRT1 in GBM pathology include glioblastoma cell lines with further adaptation to
glucose dependence (Warburg effect) had increased levels NAD+ and SIRT1 expression .
Due to the key regulatory role of SIRT1 in stress, apoptotic and metabolic responses within
cells, SIRT1-directed therapies may provide a new route for treatment of gliomas. However, much
is still unknown about the exact role of SIRT1 within cancers and especially gliomas. This work
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should provide more evidence for treatment of glioma with SIRT1-directed therapies based on in
vivo, non-invasive imaging studies with a SIRT1-selective imaging agent.
To establish overexpression of SIRT1 in specific glioma cell lines, in vitro cellular uptake
studies were performed using SRIT1-selective PET imaging agent termed 2-[18F]PhAHA. This
study demonstrated increased radio-metabolite accumulation in U87 and C6 cells, expressing
relatively higher expression of SIRT1, and decreased radio-metabolite accumulation in cells with
relatively lower levels of expression of SIRT1 (i.e. MiaPaCa, MD-MB-231, MCF10DCIS). This
work translated into in vivo imaging where glioma and gliosarcoma rat models were developed by
intracranial injection of both U87 and 9L glioma cells. It should be noted that 9L and C6 cell lines
represent a subset of grade IV astrocytomas, known as gliosarcomas, and are rat-derived tumor
lines (Han et al., 2010). Many similarities between human glioma and rat derived gliosarcoma
tumor types exist but there are also differences in the pathogenicity of the cells (Barth and Kaur,
2009). Imaging both U87 as well as 9L derived tumors in vivo with 2-[18F]PhAHA will provide a
better understanding and comparisons for the expression-activity of SIRT1 in two types of tumor.
Using 2-[18F]PhAHA for PET imaging it is possible to quantify and visualize changes in
SIRT1 expression-activity as well as regional localization over time and tumor growth. For
adequate tumor-co-registration and identification of brain regions, the PET/CT images were coaligned with T2 weighted MRI. Quantification of images was performed using Logan analysis for
further understanding of changes in radiotracer accumulation in the tumor and other areas of the
brain with high SIRT1 activity. For further proof that 2-[18F]PhAHA is SIRT1-selective in tumor
models, imaging studies using known SIRT1 inhibitor, EX-527, were performed. As expected, the
accumulation of 2-[18F]PhAHA-derived radioactivity in the tumor and other areas of the brain with
high SIRT1 expression was markedly decreased after administration of inhibitor.
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These preliminary studies provide evidence that SIRT1 may play a role in progression of
GBM and may be a possible undiscovered target for therapy. Furthermore, this new technology
provides a route for non-invasive monitoring of therapy as well as designing individualized
treatments based on enzyme expression levels within the tumor, which may vary patient to patient
and even within a tumor of one patient.
Results and Discussion:
Towards improving treatments and diagnosis for patients with GBM, characterization of
SIRT1-selective radiotracer, 2-[18F]PhAHA, was performed both in vitro and in vivo glioma and
gliosarcoma tumor models. Development of PET imaging with 2-[18F]PhAHA in an animal glioma
model is aimed at laying the foundation for future work to monitor the effects of SIRT1-targeted
pharmacomodulation on tumor growth and progression. These studies demonstrate significant
differences in SIRT1 expression-activity in tumor vs. normal brain tissue based on increased
radioactive accumulation of 2-[18F]PhAHA-derived products.
For this study, two different types of glioma models, human-derived glioblastoma and ratderived gliosarcoma, were developed in two types of rats, nude and Sprague Dawley (SD). Using
the U87 lineage, a human-derived glioblastoma cell line in nude rats (Pontén, 1975), allowed for
characterization in a more clinically relevant tumor as glioblastomas make up the majority of brain
tumors. However, to better understand the fundamental role of SIRT1 in brain tumors, a Fischer
rat-derived gliosarcoma SD rat model was also developed using 9L cell lines (Benda et al., 1971).
Though gliosarcoma tumors make up a smaller percentage of clinically seen brain tumors, they
represent a very severe and poorly understood group (Han et al., 2010). The 9L gliosarcoma is a
well-established and widely used model for understanding tumor growth and biology (Stojiljkovic
et al.). This model is especially appealing due to its immunogenicity in syngeneic hosts, such as
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Fischer or SD rats, increasing success rates for tumor cell acceptance, post-injection. Additionally,
the 9L cell line is a rapidly growing and more severe form of cancer than the U87 (Barth and
Kaur, 2009).
The noted increase in 9L tumor severity of may be due in part to a missense mutation in
the DNA binding region of a key tumor suppressor protein, p53 (Asai et al., 1994). This mutation
may disrupt the p53 interaction s-Myc and cause further progression of cell pathology (Asai et al.,
1994). However, the U87 cell line expresses wildtype p53 protein, but instead contains a
pathogenic mutation in PTEN tumor suppressor gene (Haas-Kogan et al., 1998). These mutated
proteins contribute significantly to the
4
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Figure 57. Of the cell lines tested, U87 and C6
glioma lines demonstrate the highest uptake of
SIRT1-selective radiotracer 2-[18F]PhAHA
derived radioactivity (P>0.05, One Way
ANOVA).

and MCF10DCIS) (Fig. 57). This correlates well with previous literature demonstrating an
increase in levels of SIRT1 protein in glioma tissue using immunohistochemistry (IHC) with a
staining intensity index for quantification (http://www.proteinatlas.org/ENSG0000009671SIRT1/cancer/tissue/glioma). An example of literature SIRT1 IHC results in glioma tissue is
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displayed in Fig. 55 (Ma et al.,
2013). These panels indicate an
increase

in

SIRT1

staining

intensity in glioma tumor tissue
as compared to normal brain
tissue.
Following

in

vitro

characterization, tumors were
grown in rats from i.c. injections
of either 9L or U87 cell
suspensions. For verification of
tumor growth and location, T2-

Figure 58: IHC results for SIRT1 staining in different types
of medulloblastoma cells. (Ma et al., 2013).

weighted MR images of each animal were acquired between 10 and 14 days post i.c. tumor cell
implantation. The SD rats developed 9L tumors successfully and underwent PET/CT and MR
imaging sessions. The U87 cells, transfected with GFP,
tumors were grown in nude rats and bioluminescence
imaging was performed in addition to PET/CT and MRI.
PET/CT imaging with 2-[18F]PhAHA were acquired
shortly after the MR images to allow for accurate coregistration and overlays of these images. From the
dynamic PET/CT images, peak times for differential
washout between areas of high levels and relatively lower

Figure 59. H&E staining of axial
section from brain of 9L tumor
bearing
rat
aligned
with
corresponding PET/CT image at 30
min post administration of 2[18F]PhAHA. Arrow indicates bregma
(site of injection).
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levels of SIRT1 expression-activity within the brain, remained about 20 minutes as was the case
in normal animals.
Within some tumors, excellent co-registration exists between tumor and 2-[18F]PhAHAderived radioactivity accumulation, however, in others the areas of highest accumulation are in
surrounding tumor tissue rather than centered within of the tumor itself. Fig. 59-60 displays a 9L
tumor bearing rat with increased levels of 2-[18F]PhAHA-derived radioactivity accumulation in
the tumor tissue. However, Fig. 61 displays PET/CT imaging using 2-[18F]PhAHA in a U87 tumorbearing rat and there is greater per-tumoral accumulation than central tumor accumulation. Yet,
even in this animal, there are certain lesions with increased accumulation in the tumor. Both tumor
types, 9L and U87, display great heterogeneity within the tumor tissue. Sample images of 2[18F]PhAHA-derived radioactivity accumulation in both 9L and U87 tumor bearing rats are
displayed centered on the injection site at bregma (Fig. 59-60).
To assess the effectiveness and growth localization of tumor tissue within the brain as well
as confirmation that
the cells are being
expressed properly,
bioluminescence
imaging

was

performed

with

animals bearing U87
tumors. This is only
Figure 60. Coronal slices from dynamic PET/CT/MRI images of 9L
tumor bearing rat at 30 min post 2-[18F]PhAHA administration centered
at bregma. Top: MRI only; Middle: MRI/PET overlay; Bottom:
PET/CT

possible

with

the
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U87 cell line, as it has been transfected with luciferase (Fig. 62).
Following characterization of 2-[18F]PhAHA in both tumor models, U87 and 9L, it was
interesting to compare the expression-activity of SIRT1 with HDACs class IIA, using 18F-TFAHA
as a radiotracer for PET
imaging. Figures 63-64
display

each

tracer

separately as well as the
two overlaid in panels for
U87

and

models
the

9L

tumor

demonstrating

similarities

differences
HDAC

and

and

between
SIRT1

Figure 61. Coronal and axial slices from dynamic PET/CT/MRI
images of U87 tumor bearing rat at 30 min post 2-[18F]PhAHA
administration centered at bregma. Top: MRI only; Middle:
MRI/PET overlay; Bottom: PET/CT

expression within one animal, 24 hours apart.

These overlays effectively demonstrate the

localization and differences in activity between
HDACs class IIa and SIRT1 within regions of tumor
and brain tissue.

Figure 62: Bioluminescence imaging of
U87TdRLuc tumor in a rat demonstrating
tumor localization within the brain.
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Heterogeneity within the 9L tumors is clearly defined by differences in 2-[18F]PhAHA and
18

F-TFAHA accumulation. For example, tissue surrounding the needle track and infiltration in this

area demonstrates increased accumulation of 2-[18F]PhAHA but not of

18

F-TFAHA-derived

radioactivity. Additionally, different lesions within this tumor have different levels of HDACs
class IIa and SIRT1 expression-activity.
In U87 animals, one of the most striking differences is in the cerebellar lesion of the tumor
at -4.0mm. This lesion demonstrates increased 18F-TFAHA-derived radioactivity accumulation as
opposed to this same lesion imaged with 2-[18F]PhAHA, which demonstrates very little

Figure 63. Coronal slices through bregma, injection site (0.0) and 1 mm steps to either side,
for both tracers in the same 9L bearing tumor rat, 24 hours apart. Top, in red, are PET/CT
images using 2-[18F]PhAHA at 20 min post i.v. administration. In green, are PET/CT images
using 18F-TFAHA also at 20 min post i.v. administration of the tracer. The following line
demonstrates overlay of the two tracers on CT followed by the tracer overlay on MRI. Lastly,
MRI alone on bottom.
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accumulation in this lesion (Fig. 64). In slices at -1.0 and -2.0 the accumulation of 2-[18F]PhAHAderived radioactivity is much more peripheral than that of 18F-TFAHA, located more centrally. In
certain areas of the brain, the two classes of HDACs appear to complement each other in their
activity levels. These observations will be further confirmed by IHC staining.
Looking at the similarities and differences between 2-[18F]PhAHA – derived radioactivity
accumulation within the two tumor models, it may be possible to conclude that there is higher
SIRT1 expression-activity within the 9L tumor tissue (N = 6 animals) than the U87 tumor tissue
(N = 3 animals) (Fig. 63). While, this is not conclusive, or statistically significant due to unequal
numbers of animals, certainly more studies are needed to understand if this is a robust observation,
or not. And if so, determining the mechanism causing these differences in SIRT1 expression levels
will also be important. This difference is quantified by the differences in slopes between 9L
(m=2.2) and U87 (m = 1.6) Logan plots when the brainstem is used as reference tissue, where the

Fig. 64: Coronal slices through bregma, injection site (0.0) and 1 mm steps to either side, for
both tracers in the same U87 bearing tumor rat, 24 hours apart. Top, in red, are PET/CT images
using 2-[18F]PhAHA at 20 min post i.v. administration. In green, are PET/CT images using
18
F-TFAHA also at 20 min post i.v. administration of the tracer. The following line
demonstrates overlay of the two tracers on CT followed by the tracer overlay on MRI. Lastly,
MRI alone on bottom.
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dotted lines represent 95% confidence intervals about the lines of best fit. The increase in slope in
9L tumor animals demonstrates a higher distribution volume for the tracer in the tumor tissue
relative to the U87 tumor animals. Therefore, 2-[18F]PhAHA is accumulating more effectively in
9L tumors than U87 tumors (based on N = 6 for each group). Though, these results are still
preliminary, as more studies are needed for full characterization of this finding. However, one
possible reason for this may be due to afore mentioned p53 mutation within 9L gliosarcoma cell
lines causing changes to SIRT1-p53 interactions (Asai et al., 1994). According to the current
understanding, SIRT1 deacetylates p53 to promote cellular senescence and act as a co-tumor
suppressor in many cases, however, this is complicated because SIRT1 does not fit the model of a
true tumor suppressor (Brooks and Gu, 2011). Therefore, decreasing the effectiveness of p53 due
to a mutation may or may not affect SIRT1 expression and activity within the cell.
Quantification of the animals bearing 9L gliosarcoma and U87 glioma tumors demonstrate
rapid accumulation and increase in 2-[18F]PhAHA-derived accumulation within the tumor almost

Figure. 65: Quantification of 2-[18F]PhAHA-derived accumulation in tumor tissue in both U87
and 9L glioma models with brainstem as reference tissue for the Logan plot analysis. Dotted
lines represent 95% confidence interval.
immediately post administration of the tracer. Additional Logan plot analysis for 9L tumor bearing
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rats was performed using other areas of the brain including cortex, caudate putamen, n.
accumbens, and hippocampus (Fig. 66) and the brainstem as reference tissue. Based on Logan
analysis of the data, equilibrium was reached almost instantaneously as the y-intercept for each
line (area of the brain, including tumor) was about zero. This is an important point for establishing
and understanding the bio-availability of the radiotracer within the body. The Logan analysis also
demonstrated significant differences, based on slopes of best-fit lines, for tumor tissue as compared
to non-cancerous cortical tissue within the brain when normalized by the brainstem as a reference
tissue (Fig. 65-66). Additionally, a significant difference in 2-[18F]PhAHA-derived accumulation
between ipsilateral and contralateral regions of the brain, particularly in n. accumbens (Fig. 66).
Interestingly, this is not true for all areas of the brain with high radio-metabolite accumulation, i.e.
hippocampus, caudate putamen, as these regions display little differences between ipsi-and
contralateral sides for N = 6 animals, based on 95% confidence intervals (Fig. 66). To understand
completely if this is true difference in n. accumbens SIRT1 activity, more studies, including ex-

141

vivo studies, are needed. It is possible that this an artifact due to partial volume effect as it is near
the highly radioactive tumor tissue.
Furthermore, due to the non-invasive method of imaging, this technology can be used for
longitudinal studies and evaluation of SIRT1-targeted pharmacomodulation on tumor progression.
Use of 2-[18F]PhAHA as a PET imaging agent has been successful for imaging the increase in
SIRT1 expression-activity during progression of gliosarcoma (9L) tumor growth (Fig. 67). In this
case, increases in 2-[18F]PhAHA-derived radioactivity correlate with tumor growth as displayed
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Figure 66. Logan plot quantification for areas of the brain with high SIRT1 expression-activity,
including tumor lesions for animals bearing 9L tumors. All calculations were done using brainstem
as reference tissue. Regression analysis was performed and demonstrated a significant difference
between tumor and cortex tissue as well as a small significant difference for n. accumbens, i.l vs c.l.
sides.
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by MRI. The ability to track tumor progression in vivo using 2-[18F]PhAHA with PET/CT imaging
may become an integral part of diagnosis and treatment for cancers of the brain.
For further validation that 2-[18F]PhAHA-derived accumulation is accurately displaying
increases in SIRT1 expression-activity, an in vivo blocking study with SIRT1-selective inhibitor,
EX-527 was performed. The results of the study in rats bearing a 9L gliosarcoma tumor displayed
significantly decreased activity within areas of 2-[18F]PhAHA-derived accumulation following
intraperitoneal administration of SIRT1-selective inhibitor, EX-527 (5mg/kg 30 minutes prior to

Day 7

Day 15
Post i.c.
tumor
injection
Day 7

Day 15
Post i.c.
tumor
injectio
n

Figure 67. Coronal and axial sections in 1 mm steps through tumor of an animal at two different
time points (7d and 15d) post i.c. 9L tumor cell injection. Using non-invasive SIRT1-targeted
molecular imaging with 2-[18F]PhAHA we are able to track the changes in tumor growth and enzyme
expression over time.

143

administration of 2-[18F]PhAHA) (Fig. 68) This is demonstrated both qualitatively (Fig. 68A) and
quantitatively (Fig. 68B).

Figure 68. A) PET/CT images of a rat bearing a 9L tumor acquired at 20 minutes post i.v.
administration of 2-[18F]PhAHA scaled to the SUV values shown on the right. B) PET/CT images
acquired at 20 minutes post i.v. administration of 2-[18F]PhAHA and 50 minutes post i.p
administration of 5 mg/kg EX-527 (SIRT1-selective inhibitor) scaled to the same SUV values as
figure A. C) The SUV curves for the tumor with and without blocking by EX-527 as determined by
ROI drawn around the tumor based on PET/MRI images. Brainstem is shown for reference tissue,
with relatively lower SIRT1 expression-activity and therefore lower uptake of 2-[18F]PhAHA. D)
A quantitative representation for ROI’s derived from PET images with 2-[18F]PhAHA before
(black) and after blocking with inhibitor (gray) for the tumor and other areas of high SIRT1
expression-activity (i.e. N. Accumbens, Hippocampus, Caudate Putamen).
Conclusions:
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While further validation of SIRT1 localization is needed through immunohistochemistry,
these results are promising indicators for use of 2-[18F]PhAHA with PET imaging in furthering the
efficacy of diagnostics and therapies for GBM. In this work, it has been demonstrated that SIRT1selective radiotracer, 2-[18F]PhAHA, can be used for imaging SIRT1-expression-activity in two
types of glioma models both at one time point and longitudinally. Furthermore, the imaging can
be quantified to demonstrate significant differences of tracer accumulation in tissues. Most
notably, this tracer can be used in complement with

18

F-TFAHA to demonstrate differences in

HDACs class IIa expression-activity and SIRT1 expression activity in glioma models.
Methods:
Cell cultures and in vitro Radiotracer Uptake Studies: The U87MG, MiaPaca, and
MDA-MB-231, 9L, and C6 cell lines were obtained from the American Type Tissue Culture
Collection (ATCC); the MCF10A cell line was obtained from the cell culture repository of the
Karmanos Cancer Institute (Detroit, MI). Tumor cells were propagated in DMEM supplemented
with 10% fetal calf serum (FCS), penicillin and streptomycin, at 37°C in a humidified atmosphere
with 5% CO2. In vitro radiotracer uptake studies were performed as previously described (Yeh et
al., 2013c). Briefly, prior to in vitro radiotracer uptake experiment, the cells were inspected for
confluency and viability. Each of the four cell plates for a given cell line had the media removed
by pipette aspiration, and fresh media (15 mL) containing the radiotracer (1-2 uCi/mL) was added
to cells in the culture plates. The tumor cell monolayers were incubated with the radioactivitycontaining medium for 30 minutes. The cells were then harvested by gentle unidirectional scraping
and the suspensions of cells in the media were transferred into 15mL conical centrifuge tubes and
pelleted by centrifugation (3000 rpm for 2 min). 50uL samples of supernatant and cell pellets flashfrozen on dry ice were placed in pre-weighed scintillation vials, weighed, and the radioactivity
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was measured using Pakard 5500 gamma counter (Perkin Elmer, CA). The background-corrected
and decay-corrected radioactivity concentrations in individual cell pellets (cpm/g) was divided by
corresponding cell culture media samples (cpm/g) to determine the fold increase of radiotracer
accumulation in cells versus the cell culture media.
Bioluminescence Images: Animals were anesthetized using 2-3% isofluorane mixed with
air and imaging was performed while animals were under anesthesia. Bioluminescence images
(BLI) of gliomas were obtained after administration of luciferin (10 µl/g i.p.) using an InVivo
Xtreme system (Bruker, UK) at 10 to 14 days post U87 cell implantation.
MR Imaging: Animals initially anesthetized with 5% isoflurane, and maintained between
2-3% for the remainder of the experiment. During the procedure each animal was placed on a
heated re-circulating water platform in order to maintain body temperature. The animals were held
in position using a bite bar and a receive-only surface coil 2-element phased array for the rat brain)
was placed dorsal to the head. Scans were acquired using a 7T ClinScan system (Bruker, UK)
controlled by the Syngo software (Siemens, Knoxville, TN). A localizing scan was performed and
adjustments to head position were made accordingly. T2 images were obtained (repetition time
[TR] 3530 ms echo time, [TE] 38 ms, FOV 3.2 cm x 3.2 cm x 2.4 cm, resolution 125 µm x 125
µm x 1 mm). Images were processed using ImageJ software (Bethesda, MD).
Cell Suspension: (Maxwell Laws): The U87MG or 9L were obtained from ATCC,
subsequently the U87 cells were transfected with luciferase lentiviral particles at MD Andersen
Cancer Center and characterized at this location. The 9L cells were dislodged using Hank’s
Balanced Salt solution (HBSS, 5 mL) for 1-2 minutes, centrifuged to obtain the cellular pellet, and
resuspended in growth media sufficient enough to achieve 1x107 cells/mL or 1x104 cells/µL.
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Injection Procedure: (Maxwell Laws): Rats were anesthetized via inhalation of
isoflurane (3-5% in oxygen for induction, 1-3% for maintenance via nose cone). The rat was placed
into a stereotaxic apparatus. An anterior/posterior incision was made to identify bregma, at which
point a short-beveled 30-ga needle loaded with the cell suspension was placed relative to bregma;
AP: -1.5, LAT: -4, DV: -6. A 5 µL tumor cell suspension was then injected slowly over 10 minutes,
then the needle was slowly withdrawn 2 mM and the remaining 5 µL was injected slowly over 10
minutes for a total of 1x105 cells in 10 µL.
Nude rats were implanted via intracerebral injection (i.c.) with U87 glioma cells (1x105
cells in 10 µL), that had been transfected to express a GFP-luciferase fusion reporter gene.
Sprague-Dawley rats were given injected via i.c. injection with 9L gliosarcoma cells (1x105 cells
in 10 µL) and grown for 7-14 days before the brains were harvested for ex-vivo studies.
Radiosynthesis for 2-[18F]PhAHA : See previous chapter.

Ongoing work:
Currently, this study is undergoing completion through additional imaging of U87 and 9L
tumor models as well as autoradiographical studies to complement the PET/CT imaging.
Additional studies with EX-527 and 2-[18F]PhAHA will also be performed to increase statistical
significance for the EX-527-dependent inhibition of SIRT1 as visualized by differences in 2[18F]PhAHA-derived accumulation. Lastly, IHC staining of brain slices will be performed using
antibodies against both SIRT1 and phospho-SIRT1 to determine the exact localization of SIRT1
and activated SIRT1 within the brain. With the addition of these studies, these results will provide
valuable knowledge regarding the role of SIRT1 within glioma and gliosarcoma tumors. This data
may then be applied to monitor the effects of SIRT1-targeted pharmacomodulation on tumor
growth and progression.
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CHAPTER 6 CONCLUSIONS AND FUTURE DIRECTIONS
HDAC enzymes and epigenetic regulation demonstrate great potential for treatment of
disease. Treating difficult diseases such as Alzheimer’s, cancer, and stress-related disorders may
be aided greatly by the development of HDAC selective imaging substrates. The aim of this work
was to develop isoform- and class-selective imaging agents for HDACs to gain understanding and
visualization of HDAC expression-activity product. The use of radiolabeled substrates in PET
imaging allows for non-invasive visualization and quantification of spatial and temporal dynamics
of the HDACs in different organs and tissues. Through this work, selective, radiolabeled, imaging
agents for HDAC class IIa, SIRT1, and SIRT2 have been established in vitro and in vivo.
Furthermore, HDAC class IIa and SIRT1 imaging agents have been evaluated in a disease model,
demonstrating effectiveness for imaging enzyme-mediated epigenetic regulation changes in
cancer. These imaging agents can be applied to non-invasive monitoring of treatment and disease
progression via PET imaging for many difficult diseases. The ability to use two complementary
tracers for cancer imaging is especially important to identify areas of target responder vs nonresponder in a patient. Additionally, through the development of these tracers, many of the
radiochemical syntheses developed in this work follow unprecedented steps and lay a strong
foundation for future radiochemical synthesis of novel fluorinated compounds.
The future work will be aimed at finishing in vitro characterization of these compounds and
proceeding with in vivo studies for norm and disease. Studying the roles of the SIRTs and HDAC
class IIa enzymes in stress related disorders and cancer could provide information for novel
treatments and monitoring of disease. These studies are the first of their kind to demonstrate
selective radiolabeled substrates for HDAC class IIa, SIRT1 and SIRT2. The synthesis of focused
substrate libraries provides unprecedented information about the structure activity relationship for
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these enzymes activity both in vitro and in vivo. This information may be instrumental in the
development of future class- or isoform-selective activators or inhibitors for treatment of disease.
The ability to non-invasively visualize HDAC enzyme expression-activity product in vivo
through non-invasive imaging holds incredible promise for developing new treatments for disease.
These imaging agents will enable non-invasive monitoring of pharmacodynamics of HDACs
inhibitors on the target level. By opening the door to new methods of diagnosis and treatment for
diseases such as cancer and stress-related disorders this research may lead to effective clinical
trials and drug development. While more work is necessary to establish these compounds as
imaging agents in vivo and in disease models, the work done and proposed lay the start to an
exciting path of discovery for understanding the role of epigenetic regulation in the body.
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ABSTRACT
DEVELOPMENT OF NOVEL RADIOTRACERS FOR PET IMAGING OF HDACMEDIATED EPIGENETIC REGULATION
by
ROBIN E. BONOMI
August 2016
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Over the past two decades, epigenetic regulation has become a rapidly growing, highly
innovative and influential field of biology and medicine. Protein acetylation and deacetylation,
two key epigenetic regulatory mechanisms, are mediated by histone acetylase transferases (HATs)
and histone deacetylases (HDACs), respectively. To date, the vast majority of studies on epigenetic
regulation have been conducted in cell cultures and tissue samples using conventional
methodologies of molecular and cellular biology, which contain inherent limitations for
monitoring therapy and disease. Therefore, there is a growing need for novel, advanced
methodologies that allow for non-invasive detection and monitoring of HDAC–mediated
epigenetic regulatory processes in different organs and tissues. One such methodology is molecular
imaging with positron emission tomography (PET), which allows for non-invasive visualization
and quantification of spatial and temporal dynamics of expression-activity of various receptors
and enzymes in different organs and tissues in norm and disease. The availability of selective
substrates to various classes and isoforms of HDACs would enable the development of
radiolabeled imaging agents for non-invasive in vivo PET imaging. Therefore, the aim of this work
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is to develop class- and/or isoform-selective radiolabeled substrates of HDACs, with particular
emphasis on class III (sirtuins, SIRTs).
Herein, HDAC class IIa, SIRT1 and SIRT2-selective radiotracers have been developed and
validated through in vitro and in vivo characterization. Two of these tracers,

18

F-TFAHA for

HDAC class IIa and and 2-[18F]PhAHA for SIRT1, have also been validated in a disease model
demonstrating their utility in understanding epigenetic regulation in an aggressive form of brain
cancer. The development of these targeted imaging agents may help develop new therapies for
disease as well as methodologies for monitoring treatment effectiveness and disease progression.
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